Developing new models to predict treatment outcome in patients with chronic hepatitis C infection by Cunningham, Morven Elizabeth
Developing new models to predict treatment outcome in patients with
chronic hepatitis C infection
Cunningham, Morven Elizabeth
 
 
 
 
 
The copyright of this thesis rests with the author and no quotation from it or information
derived from it may be published without the prior written consent of the author
 
 
For additional information about this publication click this link.
http://qmro.qmul.ac.uk/xmlui/handle/123456789/12753
 
 
 
Information about this research object was correct at the time of download; we occasionally
make corrections to records, please therefore check the published record when citing. For
more information contact scholarlycommunications@qmul.ac.uk
1 
Developing new models to predict treatment outcome in patients with 
chronic hepatitis C infection 
Morven Elizabeth Cunningham 
A thesis submitted to Queen Mary, University of London in partial fulfilment of 
the requirements for the degree of Doctor of Philosophy 
2 
Abstract 
Chronic infection with hepatitis C virus (HCV) is a significant global health 
problem, with approximately 170 million individuals infected worldwide. 
Treatment is rapidly evolving to combinations of highly potent direct-acting 
antiviral drugs, although optimal combinations for individual patient groups are 
not yet clear. Treatment failure still occurs, and relapse may occur in as many as 
10% of treated individuals.   
 
Whilst HCV replicates primarily in the liver, HCV RNA has been identified in 
extrahepatic sites, including monocytes, although extrahepatic replication is 
controversial. Our group recently developed a novel assay to study replication of 
patient-derived HCV by fusion of patient monocytes with cultured hepatoma cells. 
In this study, we extended the utility of this fusion model, by using cell culture 
monocytes to ‘capture’ HCV from patient serum prior to fusion with hepatoma 
cells. We studied whether this ‘capture-fusion’ model could be used to screen 
individual patient drug response and the mechanisms permitting viral replication 
in the hybrid cells.  
 
Using the capture-fusion assay, patient-derived HCV of all viral genotypes 
replicated to levels detectable by a sensitive PCR assay and could be inhibited 
by antiviral drugs in a genotype-specific manner. Isolates with genotypic and 
phenotypic drug resistance could be identified, and, in a blinded study, drug 
sensitivity in the assay correlated with clinical treatment response. Relapse after 
interferon and ribavirin treatment was associated with poor pre-treatment ribavirin 
sensitivity and also with viable HCV in patient-derived monocytes at the end of 
therapy. Uptake of HCV into monocytes appeared independent of classical HCV 
entry receptors, and our work implicated CD64 in HCV monocyte entry. Cell 
fusion appeared to permit transfer of HCV RNA to hepatocytes without triggering 
an intracellular antiviral innate immune response.  
 
Our data suggest that this novel ‘capture-fusion’ model represents a promising 
new technique which may help identify appropriate treatment strategies for 
patients with chronic HCV infection. 
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1.0 Introduction 
1.1  Clinical impact of HCV infection 
Hepatitis C virus (HCV) infection represents a significant global health problem, 
with 170 million individuals estimated to be chronically infected worldwide [1]. 
Only a minority of those exposed to the virus clear it spontaneously, with chronic 
HCV developing in around 80% of those infected. Chronic HCV infection 
frequently leads to development of liver fibrosis, progressing to cirrhosis in 20-
30% of those infected for 20 years [2]. Acute infection is usually asymptomatic 
and chronically infected individuals often remain unaware of the diagnosis until 
advanced liver disease has developed. Once cirrhosis is established, there is a 
risk of hepatocellular carcinoma (HCC) of approximately 4% per annum, and of 
decompensation, death or need for liver transplantation of around 6% per annum 
[3]. In the UK, deaths due to HCV related liver disease continue to rise, and based 
on current levels of diagnosis and treatment, are predicted to continue to do so 
until at least 2020 [4]. Successful treatment with eradication of the virus can halt 
the progression of liver fibrosis and significantly reduce development of 
complications in patients with cirrhosis [5]. 
 
1.1.1 Genotypic distribution of HCV 
HCV is subdivided into seven major genotypes, which vary by up to 30% at the 
nucleotide level, and numerous subtypes which vary by at least 15% [6, 7]. Viral 
genotypes reflect global diversity and evolution of the virus, and therefore show 
a geographical distribution. Genotype (G)1 is most commonly found in Western 
Europe, North America and Japan. G2 is common in Europe, whilst G3 
predominates in South East Asia. G4 infection is seen predominantly in North 
19 
Africa, G5 in South Africa, G6 in the Far East, particularly Vietnam, and G7 has 
been isolated from a single emigrant from the Congo [7]. In the UK, the genotypic 
burden of HCV infection is 45% G1, 44% G3, 7% G2 and 3% G4, with the 
remainder comprising G5 or 6, or unclassifiable strains [8]. Knowledge of the 
infecting genotype is important as it influences treatment response. Whether it 
affects disease progression has been controversial, but there is some evidence 
to suggest that G3 infection is associated with faster progression of fibrosis than 
other viral genotypes [9].  
 
1.2  The hepatitis C virus 
1.2.1 Taxonomy and genome organisation 
HCV is the sole member of the Hepacivirus genus of the Flaviviridae family, which 
also includes dengue virus and yellow fever (Flavivirus genus). Its 9.6kb positive-
strand RNA genome comprises a highly conserved 5’ untranslated region 
containing the internal ribosomal entry site, an open reading frame which 
encodes ten viral structural and non-structural proteins, and a 3’ non-coding 
region (Figure 1-1). The structural proteins consist of the envelope proteins (E1 
and E2) and the core protein. The non-structural proteins comprise the p7 ion 
channel, NS2-3 protease, NS3 serine protease and RNA helicase, the NS4A 
polypeptide, NS4B, NS5A which forms a critical component of the viral replication 
complex, and NS5B which is the viral RNA-dependent RNA polymerase (RdRp).  
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Figure 1-1. Organisation of the HCV genome. Adapted from Lange and Sarrazin (2014) [10]. 
 
1.2.2 HCV cell entry 
HCV cell entry is a complex, multi-step process which remains incompletely 
understood. A number of the receptors and co-factors implicated in the process 
have recently been identified, and much of the current understanding of HCV cell 
entry is summarised in Figure 1-2. 
 
The hepatocyte tropism of HCV may be at least partially determined by entry 
receptor expression. All of the proteins implicated in HCV cell entry are expressed 
on hepatocyes; these include the tetraspanin CD81, scavenger receptor B1 (SR-
B1), the tight junction proteins claudin-1 (CLDN1) and occludin and the low 
density lipoprotein receptor (LDLR). Other receptors or co-factors may also play 
a role, including glycosaminoglycans (GAGs), the epidermal growth factor 
receptor (EGFR) and the cholesterol receptor NPC1L1. 
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Glycosaminoglycans have been implicated in early non-specific attachment of 
HCV particles, and may serve to concentrate virions on the surface of the host 
cell to facilitate downstream interaction with specific receptors [11, 12]. HCV 
circulates in the blood in a number of forms, which can be separated according 
to buoyant density. The virions with high buoyant density appear to be associated 
with immunoglobulin [13], whilst those in the low density fraction are associated 
with low-density and very low-density lipoproteins [14, 15]. Virions found in the 
lower buoyant density fraction of plasma are more infectious than those with 
higher buoyant density [16], implying that association with low density lipoprotein 
may enhance infectivity [17]. The low density lipoprotein receptor (LDLR) has 
been implicated as a candidate HCV receptor. Endocytosis of HCV from patient 
serum into immortalised B cells or hepatoma cells was increased by upregulation 
of the LDLR, and decreased in a dose-dependent manner by inhibition with an 
anti-LDLR antibody [18]. Subsequent studies have supported a role for LDLR in 
entry of serum-derived HCV into primary human hepatocytes [19], and suggested 
an interaction between LDLR and apolipoprotein E present in the lipoviral particle 
[20]. However a recent report suggests that the LDLR entry pathway may not lead 
to productive infection, but rather a functional LDLR may be required for viral 
replication [21]. Thus while the LDLR certainly appears to be important in the 
HCV life cycle, its precise role remains to be fully elucidated. 
 
SR-B1 is an integral membrane protein found mainly in the liver, adrenal and 
intestine. In the liver, it facilitates uptake of cholesterol esters from high density 
lipoprotein (HDL) as part of cholesterol homeostasis. SR-B1 overexpression 
increases HCV infection, whilst blocking antibodies against SR-B1 reduce 
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infectivity of human hepatoma cells [22]. However, it has also been observed that 
HDL increases, whilst oxidised LDL inhibits HCV infectivity and these effects are 
dependent on SR-B1 [23]. This suggests that the interaction between SR-BI and 
HCV is more complex than simple virus-receptor binding. A number of reports 
suggest that in addition to its role in lipid homeostasis SR-B1 can modulate 
plasma membrane composition [24]. Although the exact role of SR-B1 in HCV 
cell entry has yet to be described, an early HCV interaction with SR-B1 may 
facilitate removal of lipid from the viral particle or induce conformational change 
in the HCV glycoproteins which primes subsequent receptor binding. 
Alternatively, the HCV - SR-B1 interaction may trigger conformational changes in 
the plasma membrane which bring the virus into close proximity with additional 
entry receptors [25]. 
CD81 is a ubiquitously expressed transmembrane protein which interacts with 
HCV E2 via a long extracellular loop [26]. A number of lines of evidence indicate 
that CD81 is a critical entry factor for HCV. Anti-CD81 blocking antibodies can 
neutralise HCV infection, which is also abolished by small interfering RNA 
(siRNA)-mediated knockdown of CD81 expression [26-29]. Ectopic expression of 
CD81 in HepG2 cells, a liver cell line which does not normally express CD81 and 
is not permissive to HCV infection, permitted infection of these cells [26, 29, 30]. 
However, expression of CD81 alone is not sufficient for HCV entry [26]. 
Increasingly, it appears that CD81 interacts with claudin-1 (CLDN1) to permit 
HCV entry. CLND1 is a member of the claudin family of tight junction proteins 
which is highly expressed in the liver, but also in other epithelial tissues. CLDN1 
appears necessary for infection of human hepatoma cells, and ectopic 
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expression of CLDN-1 renders non-hepatic cells permissive to HCV infection [31-
33]. It appears to play a role relatively late in viral entry, probably after viral 
interaction with CD81 [32]. Anti-CLDN1 antibodies which inhibit viral entry appear 
to act by inhibiting the interaction between CLDN1 and CD81 [34]. The natural 
occurrence of CLDN1-CD81 complexes in a variety of cell types has been 
demonstrated, and disruption of these complexes inhibits HCV entry [35, 36]. 
Although SR-B1, CD81 and CLDN1 are all essential for HCV entry into 
hepatocytes, the expression of these proteins is not sufficient to allow infection of 
non-permissive cells [32]. Occludin, a transmembrane protein present in the tight 
junction complex of polarised epithelial cells which is highly expressed in the liver, 
was recently identified as a fourth host cell protein required for HCV cell entry 
[37]. Expression of human SR-B1, CD81, CLDN1 and occludin, but not single, 
double or triple combinations of these receptors, renders normally non-
permissive murine cells susceptible to HCV infection [37, 38]. Its precise role in 
HCV entry remains to be described.  
Most recently, other proteins have been postulated to act as co-factors for HCV 
entry. The Niemann-Pick C1-like cholesterol receptor (NPC1L1) has been 
implicated as a co-factor acting late in the sequence of binding and internalisation 
[39]. Other host factors, particularly cytokines and growth factors, have been 
implicated in HCV cell entry. For example, stimulation of the ephrin receptor 
(EphAR) or epidermal growth factor receptor (EGFR) enhances HCV entry, whilst 
silencing or inhibition reduces entry. A role for these receptor tyrosine kinases in 
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the association between CD81 and CLDN1 and in membrane fusion has been 
suggested [40].  
 
The current model for HCV entry into hepatocytes, summarised in Figure 1-2, 
suggests an initial interaction of the virus with GAGs and LDLR prior to interaction 
with CD-81/CLDN1 complexes. This interaction may trigger translocation of the 
virus-receptor complex to the intercellular tight junctions, where it interacts with 
occludin prior to internalisation via clathrin-mediated endocytosis [41, 42]. This is 
followed by pH-dependent membrane fusion within early endosomes and release 
of the viral genome into the cytoplasm [43]. 
 
 
 
Figure 1-2. Schematic representation of current understanding of HCV entry into hepatocytes. 
LVPs, lipo-viral particles; LDL-R, low density lipoprotein receptor; GAG, glycosaminoglycans; 
SR-B1, scavenger receptor B1; CLDN1, claudin 1; OCLN, occludin. Adapted from Ploss and 
Dubuisson (2012) [44]. 
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1.2.3 HCV replication cycle 
To date, the events governing viral RNA translation, replication, and genome 
packaging for cell exit are poorly characterised. The current understanding of the 
HCV life cycle is summarised in Figure 1.3. 
 
The 5’ terminus of the HCV genome contains the internal ribosomal entry site 
(IRES) which is involved in ribosome binding and initiation of translation of the 
genome [45]. Translation yields a polyprotein precursor of approximately 3000 
amino acids. This polyprotein is co- and post-translationally cleaved by both 
cellular and viral proteases to yield the mature structural and non-structural 
proteins [46]. The current understanding of the functions of the viral proteins is 
summarised in Table 1-1.  
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HCV Protein Function 
Core 
Capsid forming protein; regulatory role in 
translation, RNA replication and particle 
assembly 
 
Envelope glycoprotein 1 (E1) 
Adsorption, receptor-mediated 
endocytosis 
 
Envelope glycoprotein 2 (E2) 
Adsorption, receptor-mediated 
endocytosis 
 
P7 
Forms an ion channel in the endoplasmic 
reticulum. Essential for formation of 
infectious virions 
 
NS2 
Component of the NS2-3 protease, 
which cleaves the viral polyprotein 
between NS2 and NS3. Role in HCV 
assembly. 
 
NS3 
NS2-3 protease, cleavage of 
downstream HCV proteins. 
ATPase/helicase activity, unwinding of 
viral RNA. Interference in innate immune 
sensing of HCV infection (via the NS3-4A 
protease, see text). 
 
NS4A Component of NS3-4A protease.  
NS4B 
Induces membranous web at the 
endoplasmic reticulum during HCV RNA 
replication. 
 
NS5A 
Multi-functional phosphoprotein 
implicated in formation of the HCV 
replication complex, virion assembly and 
manipulation of the host-cell 
environment. Contains interferon-
sensitivity determining region. 
 
NS5B Viral RNA-dependent RNA polymerase 
Table 1-1. Current understanding of the functions of the HCV proteins. Adapted from 
Kupfer (2012) [47] and Ross-Thriepland and Harris (2015) [48]. 
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In common with other positive strand RNA viruses, replication of the viral genome 
appears to occur within a membrane-associated replication complex [49]. The 
viral NS4B protein induces formation of a “membranous web” consisting of 
vesicles in a membranous matrix, derived primarily from the endoplasmic 
reticulum [50]. Domain I of the non-structural protein NS5A is also implicated in 
formation of the membranous web [51], and biogenesis of the membranous web 
is blocked by NS5A inhibitors [52, 53]. All components of the HCV polyprotein 
associated with this membranous web when visualised by electron microscopy 
[49], and it was identified as the site of HCV RNA synthesis in hepatoma cell lines 
[54]. The reasons for assembly of the membranous web for viral replication are 
mainly speculative, and may include protection viral RNA/dsRNA from cellular 
innate immune sensing machinery or RNA interference, physical support for both 
the organisation of the viral replication complex and also tethering of unwinding 
viral RNA, and compartmentalisation of both viral and host factors required for 
replication [46]. 
  
As with cell entry events, additional host factors are increasingly recognised to 
play a role in viral replication. Recently, the liver-specific microRNA miR-122 has 
been found to interact with the 5’UTR to enhance HCV replication [55], perhaps 
by protecting the HCV RNA from degradation by the host cell [56], or by 
enhancing the interaction between the IRES and ribosome [57]. Furthermore, 
proteins of the cyclophilin family appear critical for HCV replication. 
Pharmacological inhibition of cyclophilin A potently inhibits HCV replication in 
vitro [58].  The exact role of cyclophilin proteins in HCV replication is not yet clear, 
although an interaction with NS5A has been postulated [59, 60], and more recent 
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data suggests that interaction with cyclophilin A increases NS5A-RNA binding 
capacity, which is reduced by cyclophilin inhibitors [61]. Interestingly, the role of 
NS5A in formation of the membranous web also appears to require cyclophilin 
activity [53, 62]. Finally, another more recently identified cellular factor necessary 
for HCV replication is phosphatidylinositol 4-kinase type III-α (PI4KIII-α). Again, 
this enzyme appears to interact with the viral NS5A and may be required for 
structural integrity of the replication complex [63, 64]. 
 
Conversely, viral proteins also interfere with host cell signalling, in particular 
activation of the innate immune system. Binding of viral dsRNA with toll-like 
receptor 3 (TLR3) or the cytosolic RNA helicase retinoic acid inducible gene-1 
(RIG-I) triggers induction of type-1 interferons through separate signalling 
pathways. The NS3/4A complex can interfere with induction of type-1 interferons 
in response to dsRNA sensing through both pathways, by degradation of the 
TLR3 adaptor protein TRIF and the RIG-1 adaptor protein Cardif [65, 66]. This 
interference likely contributes to viral immune evasion, and both the 
establishment and maintenance of chronic viral infection.  
 
The events governing virus particle assembly and release are incompletely 
characterised. Assembly appears to be a complex, multistep process involving a 
number of cellular factors as well as most of the viral components. Following its 
cleavage from E1 by signal peptide peptidase, the core protein moves from the 
endoplasmic reticulum membrane to associate with cytosolic lipid droplets [67]. 
Assembly may be initiated on these lipid droplets, or on the ER membrane in 
close proximity with core-associated lipid droplets [68]. NS5A appears critical to 
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viral assembly, and this role is mediated by domain III of the non-structural protein 
[69]. Recruitment of NS5A to low density membrane fractions around cytosolic 
lipid droplets is promoted by CK1-dependent NS5A hyperphosphorylation, 
facilitating interaction with core and nucleocapsid assembly [70].  The maturation 
and release of viral particles is tightly linked to the VLDL pathway. Infectious 
virions produced in vivo or in cell culture differ in their buoyant density and lipid 
association profiles, supporting the notion that exploitation of cellular lipid 
pathways by HCV for assembly and release results in the production of lipo-viral 
particles [68]. The precise mechanism by which this occurs, however, remains to 
be described. 
 
 
Figure 1-3. Schematic representation of current understanding of the HCV replication cycle. 
Entry in to the cell (a) is followed by cytoplasmic release and uncoating (b). Initiation of 
translation and polyprotein processing (c) and RNA replication (d) precede virus packaging and 
assembly (e) and finally release (f). From Moradpour et al (2007) [46].  
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1.3 HCV quasispecies diversity 
Importantly, the viral NS5B RNA-dependent RNA polymerase (RdRp) has no 
proof reading capacity. Combined with the high replication rate of HCV (an 
estimated 1012 virions are produced in an infected individual per day [71], this 
results in a high rate of viral variation. Consequently, within an infected 
individual HCV exists as a closely related viral quasispecies, usually centred 
round a dominant sequence. The genetic variation of the quasipecies swarm 
may be up to 10% [72]. Sequence variation is distributed equally throughout the 
genome, with the exception of the 5’UTR and core regions which are relatively 
well conserved, and a region within the E2, the highly variable region (HVR), 
where greater than average genetic diversity is observed [72]. The viability of 
many of these mutated viruses is not clear. The need to establish a consensus 
sequence, which led to the successful development of the two existing HCV 
replication models (the replicon system and JFH-1 cell culture system), 
suggests that many individual sequence variants may be non-viable [28, 73]. 
 
It is widely hypothesised that the evolution of viral quasispecies is driven by 
continued selective pressure from the host immune system, in a constant 
process of immune escape. A dynamic viral quasispecies appears important in 
both establishment of chronicity in acute HCV infection [74, 75] and also in 
continued escape from antibody and T cell responses in chronic HCV infection 
[76, 77].  
 
The existence of viral quasispecies, lack of proof reading capacity of the HCV 
RdRp and rapid viral turnover also becomes important in the context of new 
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antiviral therapies directly targeting viral non-structural proteins (direct-acting 
antivirals, DAAs). It is possible for isolates with pre-existing mutations conferring 
resistance to DAAs to be present within the viral quasispecies population of an 
infected individual, although to-date the clinical significance of these pre-
existing resistance-conferring variants (RAVs) is uncertain (see for example [78-
81]. This effectively precludes monotherapy with DAAs, due to the high risk of 
emergence and selection of RAVs during single agent therapy, leading to 
treatment failure [82, 83] (discussed in more detail below). 
  
1.4 Tools to study HCV replication 
For many years, study of the HCV lifecycle has been hampered by its poor growth 
in culture and lack of a small animal model of infection. Early in vitro models 
involved generation of virus-like particles expressing HCV envelope proteins in 
insect cells [84]. These were valuable for early studies of cell entry and 
investigation of host immune responses to HCV infection [12, 85-87] however 
they were not replication competent and so could not be used to study other 
aspects of the life cycle. Furthermore, generation in non-eukaryotic cells raised 
concerns regarding relevance of glycoprotein expression to HCV infection of 
humans. Significant steps forward came with generation of HCV pseudoparticles 
(HCVpp) in mammalian cells, and then with the development of the HCV replicon 
and the discovery of the JFH-1 strain, a unique HCV strain which replicates and 
produces infectious virions in tissue culture. 
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1.4.1 HCV pseudoparticles 
HCV pseudoparticles (HCVpp) comprise HCV envelope proteins expressed on a 
lentiviral core [88]. They differ from the early virus-like particles in that they are 
generated within mammalian cells, 298T cells, and so may more closely replicate 
HCV virions generated in human infection. HCVpp have been enormously useful 
in identification of HCV entry factors, as well as some seminal studies describing 
host antibody responses to HCV infection [75, 89]. However, as they do not 
contain HCV replicative machinery, they cannot be used to investigate viral life 
cycle beyond cell entry. 
 
1.4.2 HCV replicon 
The HCV replicon system is based on autonomous replication of subgenomic 
particles derived from a genotype 1b strain. The replicons comprise the HCV 
5’UTR, a neomycin selection marker, a heterologous IRES allowing efficient 
expression of viral proteins NS3 to NS5B, and the HCV 3’UTR. Transfection of 
these replicon RNA molecules into Huh 7 cells permits selection of a cell line 
expressing high levels of HCV RNA and viral proteins, although infectious virions 
are not produced [73]. Replication in this system is critically dependent on host 
cell permissiveness and acquisition of cell culture adaptive mutations [90-92]. 
The latter in particular may limit applicability to HCV infection in vivo. Attempts to 
create replicons of viral genotypes other than 1 and 2 proved technically 
challenging, requiring considerable tissue adaptation or incorporation of elements 
of the G1b structure [93-95]. More recently, G3a and G4a replicons have been 
described [96-98], extending the range of genotypes which can be studied. 
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1.4.3 Cell culture produced HCV 
To-date, only one HCV strain has been identified which will replicate to significant 
levels in vitro. Japanese fulminant hepatitis-1 (JFH-1) is a G2b HCV strain  which 
replicates in tissue culture, without the need for adaptive mutations, producing 
virions which are infectious to Huh 7 cells (cell culture produced HCV, or HCVcc) 
[28, 99]. This unique strain was derived from virus taken from a Japanese patient 
with fulminant hepatitis, a highly atypical clinical presentation of acute HCV 
infection. Recombinant strains based on the JFH-1 G2b structure but expressing 
NS3 and NS4A proteins from other viral genotypes have been engineered. 
However, it has not proved possible to generate infectious recombinant viruses 
expressing NS3/4A from all genotypes/subtypes, and many of these 
recombinants require acquisition of further adaptive mutations in order to 
replicate robustly in culture [100, 101]. 
 
1.4.4 Limitations of current replication models 
The replicon, HCVpp and HCVcc systems have allowed huge advances in 
understanding of the HCV lifecycle and anti-HCV drug development. However, 
their applicability to HCV in infected individuals has some critical limitations. 
Replication is limited to the human hepatoma cell line Huh7 and its subclones 
which differ from primary human hepatocytes (PHH) in a number of ways, 
including poor differentiation, a lack of polarisation and aberrant lipoprotein 
production compared to PHH [102]. Development of G3a and G4a replicons 
extended the range of viral genotypes that could be studied [97, 98, 103], and 
chimeric variants have been extensively used in the analysis of resistance to 
novel antiviral agents. However, these systems are of limited value in the analysis 
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of replication and drug sensitivity of an individual patient’s virus. For example, to 
define the drug sensitivity of a single viral isolate requires subcloning of the gene 
for each direct acting antiviral agents’ (DAA) target and insertion into a 
subgenomic replicon [104]. Since it is difficult to generate replicons with more 
than one modified locus, studies of multi-drug combinations are difficult.  
 
A number of alternate model systems have been investigated to better replicate 
primary infection but these do not have widespread applicability, mainly due to 
costs, technical difficulty or limited availability of materials. Immunodeficient mice 
engrafted with human hepatocytes can support HCV infection but are expensive 
and technically challenging to maintain [105]. Human induced pluripotent stem 
cells (hiPSC) and human embryonic stem cells (hESC) can be induced to 
differentiate into hepatic-like cells (HLCs), which support replication of the HCV 
replicon, HCVcc and a limited number of primary patient-derived strains. As the 
nomenclature suggests, HLCs exhibit some differences to mature primary human 
hepatocytes and these have been compounded by differences in source cell type 
and differentiation protocol used (reviewed in [106]). Direct infection of PHH by 
HCV-infected sera has recently been described, although only a minority of sera 
replicated sufficiently in this model for use in experimental protocols and the 
technique is difficult to reproduce due to limited availability of cells [107].  A 
reliable, high throughput model to study replication and drug sensitivity of patient-
derived HCV remains lacking. 
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1.5 Extrahepatic HCV replication 
Whilst the liver is the primary site of HCV replication, HCV RNA has been 
detected in non-hepatic cell types including CNS, bone marrow and peripheral 
blood mononuclear cells (PBMCs) [108]. The presence of HCV genomes alone 
does not confirm viral replication and determining whether HCV can replicate in 
extrahepatic sites has proved challenging. Demonstration of HCV replication has 
relied mainly on detection of HCV negative strand RNA by PCR or in situ 
hybridisation (ISH) or visualisation of HCV non-structural proteins by 
immunofluorescence or immunohistochemistry. As the RNA negative strand is a 
replicative intermediate and the non-structural proteins are not present in the 
mature virion, presence of either, or ideally both, is indicative of viral replication 
in the cell.  The challenges faced by investigators using these techniques have 
been several fold. Firstly, HCV RNA is present within cells at very low levels and 
negative strand RNA degrades rapidly after tissue sampling [109]. When 
detected, negative strand HCV RNA is present at levels 10 – 1000-fold lower than 
positive strand RNA, challenging the detection capability of even the most 
sensitive PCR assays [108]. The technique of amplifying the RNA negative strand 
has itself been widely criticised, in particular due to the risk of false positive results 
due to self-priming by the RNA or priming by fragments of RNA or DNA present 
in the reaction [110]. In response to these concerns recombinant Tth polymerase 
(derived from Thermus thermophilus) was adopted in more recent studies as its 
catalytic activity remains intact at higher temperatures than standard Taq 
polymerase, reducing the rate of false priming events [111]. ISH is less sensitive 
for RNA detection than PCR, and its sensitivity can be further reduced if the 
number of single stranded RNA molecules is reduced by binding of positive and 
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negative strands [108]. Detection of NS proteins may also be problematic, as they 
are present in low concentration within cells. An antibody of high sensitivity is 
required to avoid false negative results.  
 
Given these challenges and limitations, the question of whether HCV can 
replicate in extra-hepatic sites has remained controversial. However, a 
considerable number of investigators using a range of these techniques have 
demonstrated negative strand RNA and NS proteins in extra-hepatic sites. Added 
to this, compartmentalisation of HCV variants has been described, suggesting 
adaptive sequence mutations to facilitate persistence in non-hepatic cells (see 
below). Taken together, this evidence is suggestive of low-level extra-hepatic 
HCV replication. 
 
1.5.1 Detection of HCV in PBMCs 
The presence of replicating HCV in PBMCs taken from patients with chronic HCV 
infection (demonstrated by negative strand RNA, viral protein detection or both) 
has been reported by several investigators [112-116]. HCV replication has also 
been described in PBMCs of patients who have cleared the virus from serum 
following treatment [116-120] although others have failed to confirm this finding 
[115]. Whilst HCV replicative forms have been demonstrated in B and T 
lymphocytes, monocytes/macrophages and dendritic cells, HCV appears to be 
detected most frequently in B cells and monocytes/macrophages [116, 119]. 
Replicative forms of the virus were generally detected in cells from some but not 
all participants. Whether this reflects insufficient assay sensitivity to detect very 
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low level viral replication, or patient- or virus-specific factors governing entry and 
replication in these cells, is unknown. 
 
1.5.2 Infection of PBMCs in vitro 
As the primary site of HCV replication is the liver, studies on cell entry have 
focused on receptors and co-factors mediating entry into hepatocytes. These 
receptors may be present on other cell types; for example, neuroendothelial cell 
lines have recently been reported to express CD81, SR-B1, claudin and occludin, 
and to be permissive to HCV replication in vitro. These receptors have also been 
demonstrated on neuroendothelial cells in vivo, and may represent the means by 
which HCV gains entry into the CNS [121]. Alternatively, HCV may utilise 
alternate receptors to gain entry into non-hepatic cells.  
 
Monocytes/macrophages and B cells express CD81 and SR-B1. As these cells 
do not form tight junctions, they do not express claudin-1 or occludin [122]. Given 
its function in binding of antibody-antigen complexes, the Fc receptor (FcR) is an 
attractive candidate receptor for HCV entry into PBMCs. Upregulation of FcR 
expression by monocytic cell lines enhances HCV uptake which can be 
abrogated by FcR blocking, implicating the FcR as a route of HCV entry into these 
cells, although the effect of cytokine stimulation on other HCV entry receptors 
was not described [123]. Furthermore, CD5 has recently been implicated in HCV 
cell entry into primary and immortalised T cells [124].  
 
Primary or immortalised B cells, T cells and monocytes/macrophages can be 
infected with patient-derived HCV in vitro, and appear to permit low-level 
38 
replication, as evidenced by detection of HCV negative strands, demonstration of 
nonstructural proteins within the PBMCs by immunofluorescence, or an increase 
in HCV RNA during the period of incubation [125-129]. Thus far, efforts to infect 
B lymphocytes, T cell or monocytes/macrophages in vitro with HCV produced in 
cell culture (HCVcc), which is infectious to hepatoma cell lines, have proved 
unsuccessful [122, 124, 130]. This highlights the critical differences between 
patient-derived HCV and HCVcc which may mean that cell culture-produced 
strains cannot be used for studies of extrahepatic cell entry and replication, and 
will make investigation of this area of HCV biology more challenging. It also 
supports the concept that HCV may enter non-hepatic cells using alternate 
mechanisms to those used for hepatocyte entry. It is interesting to note that the 
HCVcc strain JFH-1 is derived from a viral isolate which caused a fulminant 
hepatitis, an extremely unusual presentation of acute HCV infection [131]. In this 
context, it is tempting to speculate that infection of monocytes, or other PBMCs, 
may mitigate the clinical impact of acute HCV infection. 
 
1.5.3 Compartmentalisation of HCV variants 
Compartmentalisation of HCV, whereby genetically distinct viral variants are 
found in non-hepatic cells and in plasma, has been cited as evidence for viral 
replication in these cells [132, 133]. The quasispecies detected in PBMCs appear 
distinct from those associated with immunoglobulin, making it less likely that the 
variation simply reflects differences in immunoglobulin-bound virus endocytosed 
into cells [132]. The possibility that compartmentalisation may be due to selective 
adsorption of a minor variant in the quasispecies onto the surface of cells rather 
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than infection of the cells, has been effectively excluded through adsorption 
studies [134].  
 
Compartmentalisation occurs systematically within the E2 highly variable region, 
and these variants are stable over time [132, 133]. However, as this region is 
implicated in interaction with entry receptors, it remains possible that distinct 
sequences reflect a restriction on cell entry rather than replication and acquisition 
of adaptive mutations. The discovery of distinct mutations within the 5’UTR 
internal ribosomal entry site (IRES) of virus strains isolated from non-hepatic cells 
is more suggestive of adaption to this environment. 
 
Given its critical role in ribosomal binding to initiate translation of the viral 
genome, the IRES, located in the 5’UTR, is one of the least variant regions of the 
HCV genome. However a quasispecies distribution of 5’UTR variants within the 
plasma of patients with chronic HCV has been described [135]. These variations 
are likely to be of biological significance as small variations in the nucleotide 
sequence in this region can produce considerable differences in translational 
efficiency. Interestingly, a given sequence alteration could enhance or reduce 
translational efficiency in different cell lines in vitro, suggesting that interactions 
between the IRES and specific cellular factors may be important in governing 
translational efficiency, and thus cell tropism [135-137].  
 
Long term culture of HCV in two different lymphoblastoid cell lines resulted in 
selection of three nucleotide substitutions within the 5’UTR (G(107)→A, 
C(204)→A and G(243) →A) [129]. The fact that the same substitutions were 
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selected during growth in two distinct cell lines suggests that they conferred 
favourable characteristics for replication in these lymphoid cells. Indeed, these 
substitutions enhanced translational efficiency in some, but not all, of a panel of 
lymphoid cell lines, compared to that seen in human hepatoma cells [137]. The 
same substitutions have been identified in viral sequences obtained from PBMCs 
and monocyte-derived dendritic cells from patients with chronic HCV [136, 138], 
and the C(204)→A , G(243) →A variant has been identified in post-mortem brain 
samples from patients with chronic HCV. In this case, the translational efficiency 
of these IRES variants was found to be lower in cultured microglial cells than 
human hepatoma cells. One interpretation of this finding is that selection of this 
variant may contribute to viral latency by permitting low-level viral replication, 
insufficient to trigger a host immune response [139]. Clearly, translational 
efficiency measured in vitro using bicistronic dual luciferase reporter systems 
expressing the IRES sequence of interest in immortalised cell lines may exhibit 
critical differences to factors governing translational efficiency in vivo. This makes 
it difficult to draw conclusions regarding the functional significance of these IRES 
substitutions. The selection of these variants does however provide further 
evidence suggesting that low-level replication of HCV can occur in non-hepatic 
cells.  
 
1.5.4 Clinical significance of extrahepatic replication 
The presence of viral genomes in extrahepatic sites has been speculated to lead 
to a number of clinical features seen in chronic HCV infection. For example, the 
presence of HCV RNA in the CNS is postulated to be linked to disproportionate 
fatigue and neurocognitive symptoms reported by patients [140, 141]. HCV 
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infection is associated with a number of extra-hepatic clinical syndromes, 
including mixed cryoglobulinaemia, non-Hodgkin lymphoma, lichen planus and 
Sjogren’s syndrome. The pathogenesis of many of these conditions in the context 
of HCV infection is thought to be multifactorial, related to accumulation of 
circulating immune complexes and also to stimulation of monoclonal rheumatoid 
factors by the virus. Given the predominantly autoimmune nature of these 
conditions it is widely postulated, although controversial, that HCV lymphotropism 
may also contribute [142, 143]. 
 
Replication-competent extrahepatic HCV may additionally represent a reservoir 
for propagation of infection of hepatocytes, reinfection of the grafted liver after 
transplant or possibly even relapse after antiviral therapy, if the extrahepatic virus 
occupies a site which is relatively protected from the effects of treatment. In vitro, 
HCV associated with B lymphocytes could be successfully transferred to 
hepatoma cells, and infection of the hepatoma cells was enhanced by this route 
compared to uptake of free virions [130]. This may suggest a mechanism for 
propagation of infection, for re-infection of the grafted liver after liver 
transplantation, or for relapse after antiviral treatment. Where liver transplant 
recipients are chronically infected with HCV at the time of transplantation, the 
primary source of re-infection of the grafted liver appears to be serum although 
PBMC strains have also been implicated [144]. One study which examined such 
patients found identical sequences in the serum post-relapse as in the explanted 
liver, however the number of patients included was extremely small, and the cell 
types harbouring virus within the liver, whilst presumed to be hepatocytes, were 
not actually characterised [145]. 
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Persistence of HCV in PBMCs has been identified as a risk factor for virological 
relapse after treatment in patients who are co-infected with HIV [146]. However, 
HIV co-infection appears to enhance HCV replication in PBMCs [147], and so 
whether HCV persistence in PBMCs during treatment predicts relapse in HCV 
mono-infected patients remains to be determined. 
 
1.6 Treatment of chronic HCV infection 
Until very recently, weekly subcutaneous injections of pegylated interferon-α 
combined with daily oral ribavirin (pegIFN/RBV) was the established treatment 
for chronic HCV infection of all viral genotypes following the pivotal registration 
trials over a decade ago [148-150]. In these trials, a sustained virological 
response (SVR, defined as undetectable HCV RNA in serum 24 weeks after the 
end of treatment) was achieved in up to 46% of patients with G1 infection 
following 48 weeks of therapy. SVR was seen in up to 82% of patients with G2 or 
3 infection treated with 24 weeks of therapy, although SVR rates have been 
somewhat lower in “real world” studies, particularly in patients with G3 infection 
[151]. Patients with G4 infection have participated in these trials in relatively low 
numbers, but response rates to treatment are thought to lie somewhere between 
that of G1 and G2 or 3 infection, and so patients with G4 HCV were generally 
treated with 48 weeks of therapy. Recent data suggest that treatment responses 
of G5 and 6 also lie somewhere between that of G1 and 2/3 [152-154].  
 
The development and licensing of the first direct-acting antiviral agents (DAAs) 
has radically altered HCV therapy over the last few years, and change is ongoing 
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as further agents are licensed for use. At the time of writing, DAAs targeting the 
HCV NS3 serine protease (protease inhibitors; PI) are in widespread use for 
treatment of G1 infection, although are not licensed for treatment of other viral 
genotypes. Due to an unfavourable side effect profile these first generation PIs 
have recently been eclipsed in treatment guidelines by therapies based on drug 
combinations containing the HCV NS5B inhibitor sofosbuvir [155]. However 
pegIFN/RBV remain, for the time being, important components of HCV treatment 
regimens, and are the only option for treatment in some parts of the world where 
DAAs are not readily available, or for viral genotypes where there is currently 
insufficient evidence to support the use of DAAs. 
 
1.6.1 Interferon-α 
The first report of the potential efficacy of interferon-α monotherapy in treatment 
of chronic HCV infection was published in the late 1980s [156], and it was 
licensed for treatment of HCV in 1991. Interferon-α is a key cytokine component 
of the anti-viral innate immune response. It acts through its cell surface receptor 
to trigger a signalling cascade which culminates in upregulation of transcription 
of numerous interferon-stimulable genes, and establishment of an anti-viral state 
within the cell. Anti-viral functions of some of the better characterised interferon-
stimulable genes include: indirect inhibition of translation initiation by the protein 
kinase PKR; RNA degradation by the OAS synthetase family and RNase L; 
inhibition of RNA synthesis by the family of Mx GTPases; and editing of double 
stranded RNA by deamination of adenosine to inosine by ADAR1 (reviewed in 
[157]). Interferon-α also plays a role in activation and direction of the adaptive 
immune system to assist in the anti-viral response.  
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Treatment with recombinant human interferon-α as monotherapy for chronic HCV 
leads to in SVR in less than 20% of patients [158]. Addition of polyethylene glycol 
to the interferon-α molecule to create pegylated interferon-α (pegIFN) has 
increased the antiviral efficacy, as well as allowing less frequent dosing due to 
sustained absorption and a longer half-life.  
 
1.6.2 Ribavirin 
Ribavirin is a synthetic guanosine analogue, whose exact antiviral mechanism of 
action is still not well understood. Given alone, it has little effect on serum HCV 
RNA. In combination with either unmodified or pegylated interferon, however, it 
substantially enhances treatment response and also appears to reduce the risk 
of virological relapse after treatment [148, 158]. Its antiviral effect likely occurs 
through a number of mechanisms. These may include inhibition of RNA 
synthesis, and thus viral replication, by inhibition of the cellular enzyme inosine 
monophosphate dehydrogenase; direct inhibition of the viral RNA-dependent 
RNA polymerase; promotion of lethal mutagenesis in the HCV RNA genome; 
immunomodulation and promotion of a Th-1 cytokine response pattern; and 
potentiation of the antiviral action of interferon-α (reviewed in [159]). In treatment 
of genotype 1 HCV infection, higher weight-based ribavirin dosing produced 
better outcomes than fixed dosing (1.0 – 1.2 g/day or 0.8 – 1.4 g/day when used 
in combination with pegylated IFN-α2a or pegylated IFN-α2b, respectively) [149]. 
No advantage was seen using weight-based dosing compared to fixed dosing for 
patients with genotype 2 and 3 infection [149], so these patients are usually 
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treated with fixed dose ribavirin 0.8 g/day to limit potential adverse events related 
to ribavirin exposure. 
 
1.6.3 Side effects of pegylated interferon/ribavirin therapy 
A major limitation to pegIFN/RBV treatment is the side effect profile associated 
with these drugs. Common side effects include ‘flu-like symptoms (fatigue, 
headache, pyrexia, myalgia, arthralgia), neuropsychiatric symptoms (insomnia, 
anxiety, irritability, depression), gastrointestinal symptoms (nausea, anorexia, 
weight loss), as well as dermatitis, alopecia and dyspnoea [148, 150]. These 
adverse events were classified as severe in up to a third of patients [149] and a 
similar number required pegIFN and/or RBV dose modification due to side effects 
[149, 150]. Up to 16% withdrew from therapy due to adverse events [149, 150]. 
Since publication of the registration trials, other unusual or severe side effects 
which have been described include seizures, severe bacterial infections, 
autoimmune reactions, interstitial lung disease, neuroretinitis, bone marrow 
aplasia and idiopathic thrombocytopaenia [160]. Laboratory abnormalities 
associated with pegIFN treatment include neutropaenia and thrombocytopaenia, 
whilst RBV is particularly associated with haemolytic anaemia. Transaminase 
flares and thyroid dysfunction may also occur. These may also require dose 
reduction of pegIFN and/or RBV. Reductions in pegIFN/RBV below 80% of the 
recommended dose over the duration of treatment have been associated with 
lower SVR rates [161].  
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1.6.4 Treatment response 
The rate of decline of serum HCV RNA during pegIFN/RBV treatment is 
characterised by two phases: a rapid early decline occurring within the first 24 - 
48 hours of treatment which is thought to reflect clearance of HCV from the blood, 
followed by a slower second phase of decline, thought to reflect clearance of 
infected cells. The rate of response to antiviral treatment is predictive of 
achievement of SVR and the presence or absence of HCV RNA at weeks 4, 12 
and 24 of treatment is used to categorise patients according to virological 
response (Figure 1-4). A slow response to therapy is strongly predictive of a poor 
likelihood of SVR, and forms the basis of “stopping rules”, where antiviral 
treatment which is likely to be futile can be stopped early, thereby avoiding 
unnecessary treatment-related adverse effects and expense.  
 
Patients who fail to respond to pegIFN/RBV therapy most often show either a null 
response, where serum HCV RNA does not decline to any significant extent in 
response to treatment, or a relapse, where serum HCV RNA is undetectable at 
the end of treatment, but becomes detectable again during the follow up period. 
Patterns of treatment failure show genotypic variation, with null response seen 
more commonly in patients with G1 HCV whilst relapse is more frequent in 
patients with G3 HCV. Less commonly, patients may show a partial response to 
treatment or virological breakthrough during the treatment period. The lower limit 
of detection of HCV RNA varies between commercially available assays, but is 
at least <50IU/mL HCV RNA. 
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Patients who achieve a rapid virological response (RVR, defined as undetectable 
viral RNA at week 4) have a high likelihood of SVR. Those who do not, however, 
still have a reasonably good chance of SVR and so lack of RVR is not an 
indication to stop treatment. However, if the viral RNA has not declined by ≥2log10 
from baseline by week 12 (an early virological response, EVR), treatment should 
be stopped as the chance of SVR in such patients who complete the course of 
pegIFN/RBV is less than 2% [148]. Patients with ≥2log10 decline in viral RNA at 
week 12 but who still have detectable serum HCV RNA at week 24 should also 
stop treatment, as the likelihood of SVR is these patients is also very low (less 
than 3%) [150]. These recommendations are based primarily on studies of 
patients with G1 HCV, where rates of null response are higher and allow analysis 
of factors which predict treatment outcome. Null response is less common in 
other viral genotypes (especially G2 and G3), so whilst the same “stopping rules” 
are used in treatment of all viral genotypes, little supporting data in non-G1 
infection is available.  
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Figure 1-4. HCV response to pegylated interferon/ribavirin treatment. Figure shows different 
virological responses which may occur during 48 weeks of treatment with pegIFN/RBV, and 24 
weeks of follow up after treatment. RVR, rapid virological response; EVR, early virological 
response; DVR, delayed virological response. 
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1.7 Predictors of response to pegIFN/RBV treatment 
It would be enormously useful to be able to predict which patients will respond to 
pegIFN/RBV therapy. No single marker can reliably predict the outcome of 
treatment in an individual, but a number of factors have been identified which 
indicate “good risk” or “poor risk” for achievement of SVR following pegIFN/RBV 
therapy. Those most widely used are readily available clinical features, although 
other host characteristics have been identified which may influence response, 
including IL28B genotype and baseline expression of interferon-stimulable genes 
(ISGs). With the exception of viral genotype, virological characteristics which may 
predict treatment response to pegIFN/RBV have remained elusive. An exception 
to this is the identification of a region in the NS5A sequence of G1b strains, 
termed the interferon sensitivity determining region (ISDR). Accumulation of 
mutations in this region predicts better response to interferon-based therapy in 
patients with genotype 1b infection [162, 163]. This phenomenon has not been 
described in patients infected with other viral genotypes.  
 
1.7.1 Clinical features 
The strongest clinical predictors of treatment success are HCV genotype and 
stage of liver fibrosis. To a lesser degree, factors which negatively influence the 
likelihood of achieving SVR include high baseline viral load (>800,000IU/mL), 
older age, higher body mass index, insulin resistance, male gender and co-
infection with another hepatotropic virus or HIV [160]. 
 
Unfortunately, as these patients will benefit most from viral eradication, presence 
of advanced fibrosis or cirrhosis can substantially reduce SVR rates. This effect 
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is seen across viral genotypes; response rates of just 34% have been observed 
in G1 patients with cirrhosis, and as low as 44% in cirrhotic patients with G3 
infection [164].  
 
1.7.2 IL28B genotype 
Host genotype at single nucleotide polymorphisms (SNPs) on chromosome 19 
upstream of the IL28B gene, coding for interferon-λ3, has recently emerged as a 
strong predictor of treatment response to pegIFN/RBV, particularly in patients 
with G1 HCV infection [165, 166]. Increased prevalence of the poor risk T allele 
at the rs12979820 SNP appears to explain much of the poorer treatment 
responses seen in African-American patients with G1 HCV [165]. However, 
although IL28B genotype may assist in estimating the likelihood of response to 
therapy, its individual predictive value is low as a substantial number of patients 
with the poor risk allele will still achieve SVR with pegIFN/RBV (around 40% of 
those heterozygous, and around 30% of those homozygous for the T allele) [165]. 
Further studies have indicated that IL28B genotype is also strongly predictive of 
treatment outcome in G4 infection, but less so in G2, 3 or 5 HCV, although its 
predictive value may be stronger in this context in patients with other poor risk 
features for treatment success [167-170]. The biological mechanism underlying 
the association of these SNPs with treatment outcome remains unknown. Given 
their location upstream of the IL28B gene, it seems reasonable to speculate that 
expression of IFN-λ3 is implicated. The IFN-λ family share a number of 
characteristics with IFN-α and interact with a distinct receptor to induce 
expression of interferon stimulable genes [171]. Furthermore, they have shown 
anti-viral activity against HCV in vitro and in vivo [172, 173]. Conflicting data have 
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been presented on the association between SNP genotype and IL28B gene 
expression in healthy volunteers, and this area awaits further study [174].  
 
1.7.3 Interferon stimulable genes 
The interaction between IFN-α/β and the type I IFN receptor culminates in the 
expression of over 300 interferon stimulable genes (ISGs), many of which have 
yet to be characterised. The overall effect is to create an antiviral state within the 
cell, and they include proteins with antiviral, antiproliferative and 
immunomodulatory functions [175]. Some of the better characterised examples 
include protein kinase R (PKR), adenosine deaminase-1 (ADAR-1), the 2’-5’ 
oligoadenylate synthetases (2-5 OAS)/RNase L system and the MxA family of 
GTPases. PKR is a serine-threonine kinase which phosphorylates eukaryotic 
translation initiation factor-2, thus blocking translation of viral mRNAs [176]. 2-5 
OAS catalyses the synthesis of 2’-5’ oligoadenylates which in turn activate 
RNase-L. RNase-L then degrades both cellular and viral RNA [175]. ADAR-1 
catalyses the deamination of adensine on double stranded RNA to inosine, 
destabilising the secondary structure and leading to the accumulation of 
mutations within the viral genome [175]. Expression of MxA results in degradation 
of cellular RNA, general repression of protein synthesis and apoptotic cell death 
[177].  
 
A high level of expression of these and other ISGs in the liver pre-treatment is 
associated with a poor response to pegIFN/RBV in patients with chronic HCV 
[178]. Interferon responses seem maximally stimulated and refractory to further 
induction in these patients, as no further increase in hepatic ISG expression could 
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be induced following initiation of interferon therapy [179]. Given this association, 
the role of ISGs which can be measured in the serum has been evaluated as a 
pre-treatment predictor of treatment response. Interferon inducible protein-10 (IP-
10) is a T-cell specific chemokine, the levels of which are elevated in the liver and 
serum of patients with chronic HCV. Serum IP-10 levels are higher in treatment 
non-responders than responders [180], and pre-treatment serum IP-10 can be 
used as a predictive factor of pegIFN/RBV treatment response in patients with 
chronic G1 HCV infection [181]. Whether there may be a role for pretreatment 
serum IP-10 as a predictor of treatment response in other viral genotypes is not 
clear. 
 
1.8 Novel antiviral agents 
Greater understanding of the HCV lifecycle and identification of host and viral 
proteins essential for viral replication has hugely accelerated anti-HCV drug 
development in recent years. These novel agents either target viral proteins 
essential for viral replication (direct-acting antiviral agents, DAAs) or host proteins 
which play a critical role in the viral life cycle. 
 
1.8.1 Direct-acting antiviral agents (DAAs) 
The major classes of DAAs either recently licensed or in advanced stages of 
clinical development are inhibitors of the HCV NS3/4A serine protease, 
nucleoside or non-nucleoside inhibitors of NS5B, and NS5A inhibitors. Key 
considerations in use of these drugs are their potency, resistance profile, 
genotypic coverage and side effect profile.  
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1.8.1.1 Protease inhibitors (PI) 
The HCV NS3 protein has helicase/NTPase activity, and also associates with its 
obligatory co-factor NS4A to form a serine protease, the NS3/4A. This protease 
is required for self-cleavage at the NS3/4A, NS4A/4B, NS4B/5A and NS5A/5B 
junctions during viral replication, but may also inhibit activation of interferon 
signalling pathways in infected cells [182]. Antivirals targeting this protease may 
enhance interferon responsiveness as well as inhibiting viral replication, and so 
it has been an attractive early target for DAA development.  
 
The first two pharmacological inhibitors of the NS3/4A protease licensed for 
treatment of G1 chronic hepatitis C infection were telaprevir and boceprevir. 
These first generation protease inhibitors (PI) are orally bioavailable, linear α-
ketoamide derivatives which bind covalently but reversibly to the protease active 
site serine (Ser-139). In clinical trials, these agents demonstrated potent antiviral 
activity and substantially enhanced SVR rates in patients with G1 HCV when 
given together with pegIFN/RBV [183-186].  
 
A significant limitation of these first generation PIs is their side effect profile, most 
notably significant rash (telaprevir) and anaemia (boceprevir). Twice or thrice-
daily dosing means a significant pill burden for patients, and the requirement to 
take these medications with food (and consume a high fat diet) is an additional 
burden for patients struggling with side effects which often include nausea and 
loss of appetite.  
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A further limitation to the use of these PIs is their relatively low genetic barrier to 
resistance, meaning that a single amino acid substitution within the target site is 
sufficient to confer significant drug resistance, and this precludes PI 
monotherapy. For example, a number of mutations conferring varying degrees of 
telaprevir resistance have been identified in vivo and characterised by in vitro 
assessment, particularly at positions 36, 54, 155 and 156 of the NS3 protease 
catalytic domain [187]. Virological breakthrough or plateau in patients treated with 
telaprevir monotherapy for fourteen days was associated with emergence of viral 
strains harbouring mutations at these positions [83, 187]. Amino acid mutations 
T54A, V36A/M, R155K/T and A156S were associated with low-level resistance 
to telaprevir in the replicon model, whilst A156T/V and double mutations 
V36M+R155K and V36M+A156T conferred high-level resistance [187]. Mutations 
V36M and R155K/T have only been detected in G1a isolates, presumably 
because only one nucleotide change is required to generate these amino acid 
substitutions in G1a viral genomes. Differences in the nucleotide composition 
between subtypes 1a and 1b mean that two nucleotide changes are required to 
generate the same amino acid substitutions in G1b strains, providing a higher 
genetic barrier to the development of these particular RAV. Of note, cross-
resistance between NS3/4A protease inhibitors has been described, and 
persistence of selected protease-resistant variants could preclude future 
treatment with other agents in this class. In particular, mutations at positions 155 
appears to confer resistance across most PIs in development [188].  
 
The second wave of PIs, now licensed or in advanced clinical development, 
aimed to achieve comparable or superior potency but with improved genotypic 
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coverage, a more favourable dosing schedule and side effect profile and 
improved resistance profile. Simeprevir is a second generation PI which has 
recently been licensed for treatment of G1 chronic HCV, and at the time of writing 
a number of other agents (including danoprevir, faldaprevir, asunaprevir and 
grazeprevir) are in advanced clinical development. In combination with 
pegIFN/RBV, these agents enhance SVR rates to levels comparable with 
telaprevir and boceprevir in patients with G1 HCV, with improved tolerability 
compared to first generation drugs [80, 81, 189-197]. The pharmacokinetics of 
simeprevir and faldaprevir allow once-daily dosing. Genotypic coverage may be 
broader than first generation PIs, but the extent to which these drugs will be useful 
in patients with non-1 HCV genotypes remains uncertain due to the small 
numbers treated to-date [196, 198-201]. Importantly, G3 HCV remains untreated 
by this class. Although grazeprevir shows activity against G3 HCV at high doses, 
in practice this may be limited by drug toxicity [202]. RAVs at positions 155, 156 
or 168 confer cross-resistance to nearly all the second generation PIs except 
grazeprevir, which may make it a promising new agent for patients who have 
previously failed PI-containing treatment [203].   
 
1.8.1.2 Polymerase Inhibitors 
Inhibitors of the HCV NS5B polymerase can be divided into two categories; 
nucleoside analogue inhibitors (NI) and non-nucleoside inhibitors (NNI). 
 
 1.8.1.2.1 Nucleoside analogue inhibitors 
 Nucleoside analogue inhibitors (NI) compete with the natural nucleoside 
triphosphate substrate of the HCV RNA polymerase and are incorporated into the 
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nascent RNA chain, thereby causing chain termination. In early clinical studies, 
drugs of this class show less potent antiviral activity than PI or NNI [188]. 
However, significant advantages are their broad genotypic range and relatively 
high barrier to development of resistance [188, 204]. These drugs bind tightly to 
the NS5B active site, which is highly conserved across genotypes. Mutations at 
the active site which would confer resistance also significantly impair viral fitness 
and replicative capacity [10, 188]. The leading drug in this class, sofosbuvir, has 
pan-genotypic antiviral activity [205] and has recently been licensed for treatment 
of HCV G1, 2, 3 and 4. In combination with pegIFN/RBV, sofosbuvir enhances 
SVR in patients with G1 or G4 HCV compared to pegIFN/RBV alone [206]. The 
potency of sofosbuvir permits shortening of treatment for patients with G1 HCV 
to just 12 weeks with little impact on SVR. Unlike PI-based therapies, no 
difference was seen in treatment outcome between patients with G1a and G1b 
HCV [205].  Sofosbuvir is well tolerated with few significant adverse events 
reported, and is dosed once daily. In contrast to PIs, where treatment failure is 
predominantly through virological breakthrough or (less commonly) primary non 
response, treatment failure following sofosbuvir-containing treatment is 
predominantly through relapse. Resistance associated with the S282T mutation 
has been identified in vitro but reports of this variant in patients treated with 
sofosbuvir-containing regimens are rare. No other NS5B variants conferring 
resistance in the replicon model have been identified amongst patients who have 
failed sofosbuvir-containing therapy in clinical trials [207]. Thus, similar to 
treatment with pegIFN/RBV, mechanisms underlying relapse following 
sofosbuvir-containing treatment remain to be defined. 
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1.8.1.2.2  Non-nucleoside inhibitors 
In contrast to NI, non-nucleoside inhibitors (NNI) are a heterogenous group which 
inhibit the HCV NS5B by binding to one of at least four different allosteric sites, 
resulting in conformational change of the protein. Similar to other viral 
polymerases, the NS5B has a characteristic right-hand conformation with palm, 
finger and thumb domains. NNIs can be subdivided according to their binding 
site. Site 1 inhibitors bind to the benzimidazole thumb 1 domain, whilst site 2 
inhibitors bind to the thiopene thumb 2 domain. NNI site 3 and 4 inhibitors bind to 
the benzothiadiazine palm 1 and benzofuran palm 2 sites, respectively. In theory, 
as they utilise different binding sites, these agents could be combined, or used 
sequentially to manage the development of resistance [10]. In general, these 
agents show low to average antiviral potency [188]. Unfortunately, they have a 
low genetic barrier to resistance, and mutations conferring resistance do not 
necessarily lead to a poorly replicative virus [10, 188]. Pre-existing variants 
harbouring mutations which confer resistance in vitro to NNIs, but not NIs, have 
been described in serum of HCV G1 infected patients [208, 209]. Furthermore, 
these allosteric sites are less well conserved between viral genotypes than the 
enzymatic active site, leading to a risk of varying antiviral efficacy between 
genotypes and perhaps even between subtypes [188, 209]. Concerns regarding 
both the low barrier to resistance of these agents, and their relatively low antiviral 
potency compared to other classes of DAA were borne out in Phase II study of 
the NNI filibuvir in combination with pegIFN/RBV which showed high relapse 
rates and no enhancement of SVR compared to pegIFN/RBV [210]. The focus 
for potential further development of these agents is likely to be as part of multi-
drug interferon-free regimens. 
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1.8.1.3 NS5A inhibitors 
Development of DAAs targeting the HCV NS5A has progressed more slowly than 
for drugs targeting the NS3/4A protease or NS5B polymerase, largely due to the 
lack of enzymatic activity of the NS5A protein and consequent difficulties in drug 
candidate screening. Despite this, a small number of agents are now in use, with 
daclatasvir, ledipasvir and ombitasvir licensed or in advanced clinical 
development. In early clinical studies daclatasvir showed potent antiviral activity, 
but a relatively low genetic barrier to resistance; single amino acid mutations 
appear sufficient to confer reduced drug sensitivity [211, 212]. Considerable 
NS5A sequence diversity between HCV genotypes suggests that antiviral 
efficacy of drugs targeting this region may differ between genotypes, and early 
data suggested daclatasvir may have greater efficacy against G1b than G1a 
strains [212, 213]. This has been supported by Phase 2 data where SVR following 
daclatasvir with pegIFN/RBV was higher amongst patients with G1b HCV than 
G1a [214]. Furthermore, in vitro data have suggested that HCV G2 and 3 may 
have a lower barrier to development of daclatasvir resistance than other viral 
genotypes [215]. However, clinical data have demonstrated efficacy in patients 
with HCV G2/3. The addition of daclatasvir to pegIFN/RBV treatment enabled 
shortening of therapy for patients with G2/3 HCV to 12 weeks, with non-inferior 
SVR rates to 24 weeks of pegIFN/RBV alone [216]. Given their high antiviral 
potency but relatively low barrier to resistance development, NS5A inhibitors are 
attractive candidates for combination therapy as part of IFN-free treatment 
regimens.  
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1.8.2 Host-targeting antiviral agents 
A multiplicity of host factors are increasingly recognised to play a role in the viral 
life cycle, from cell entry and replication to packaging and cell egress. These 
cellular factors provide additional potential targets for antiviral therapeutics, and 
could potentially be combined with DAAs in the quest for interferon-free drug 
regimens. They have the advantage of a higher barrier to development of 
resistance than viral targets, although the possibility of deleterious effects as a 
result of inhibiting essential host cell factors must also be considered.  
 
Proteins of the cyclophilin family appear critical for HCV replication. The exact 
role of cyclophilin proteins in HCV replication is not yet clear, although an 
interaction with NS5A has been postulated [59, 60]. Pharmacological inhibition of 
cyclophilin A potently inhibits HCV replication in vitro [58].  The cyclophilin 
inhibitor alisporivir showed pan-genotypic activity, although with higher efficacy 
in genotypes 2 and 3 than 1 or 4 [217]. Although HCV variants with NS5A 
mutations conferring alisporivir resistance had been identified in vitro, rates of 
virological breakthrough in clinical trials are low [218]. Development of this drug 
was delayed following a small number of cases of pancreatitis, including one 
fatality, in patients receiving alisporivir in combination with interferon. It retains 
the potential to be a valuable backbone in interferon-free regimens.  
 
Recently, the liver-specific microRNA miR-122 has been identified as a host 
factor which enhances HCV replication [55]. MicroRNAs are small (18-22 
nucleotides) non-coding RNA molecules which regulate mRNA expression.  MiR-
122 appears to interact with the 5’UTR to enhance HCV replication, perhaps by 
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protecting the HCV RNA from degradation by the host cell [56], or by enhancing 
the interaction between the IRES and ribosome [57]. Miravirsen is a locked 
nucleic acid–modified phosphorothioate antisense oligonucleotide which targets 
miR-122. As the miR-122 binding site is well-conserved, it would be expected to 
show a broad genotypic range of anti-viral activity, and this has been 
corroborated in vitro [219]. A recent proof-of-concept study in patients with 
chronic genotype 1 HCV demonstrated moderate anti-viral activity with no 
emergence of resistant strains over a 4 week dosing period [220].  
 
As our knowledge of the mechanisms governing the HCV life cycle increases, 
further potential drug targets may emerge. For example, another recently 
identified cellular factor necessary for HCV replication is phosphatidylinositol 4-
kinase type III-α (PI4KIII-α). This enzyme appears to interact with the viral NS5A 
and may be required for structural integrity of the replication complex [63, 64]. 
However, at present it is unclear whether it will be possible to design a sufficiently 
specific and potent inhibitor of this enzyme whilst avoiding significant host toxicity 
[44]. 
 
An alternative approach is modification of existing HCV treatments (pegIFN and 
ribavirin) to increase efficacy and, more importantly, tolerability. Interferon 
lambda has similar intracellular antiviral effects to interferon alpha, but affects 
fewer cell types due to differences in receptor distribution. Phase 1 studies 
support the hope that this may translate to equivalent antiviral efficacy with a 
reduced side effect profile [221]. However, further clinical trials comparing 
pegylated interferons alpha and lambda have been put on hold given the recent 
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rapid development of DAAs and likely imminent arrival of all-oral treatment 
regimens. 
 
Ribavirin is associated with anaemia, often managed by ribavirin dose reduction, 
which could compromise achievement of SVR. Taribavirin is an oral prodrug of 
ribavirin which is not concentrated in erythrocytes. A comparison of weight-based 
taribavirin with ribavirin did show less anaemia, but no improvement in SVR rates 
amongst those receiving taribavirin [222]. Whether there may be a role for 
taribavirin in future combination therapy is not yet clear. It may perhaps prove 
useful in combination with DAAs in treatment of patients at particular risk of 
anaemia, such as those with renal impairment. 
 
1.8.3 Interferon-free treatment regimens 
The ultimate aim of anti-HCV drug development is to achieve a well-tolerated, all-
oral treatment regimen which will cure all patients with a short course of therapy. 
Many of the side effects associated with current HCV treatment are caused by 
interferon, and so development of interferon-free regimens is a logical first step 
in improvement of treatment tolerability. Proof-of-concept of interferon-free HCV 
treatment was provided by the INFORM-1 trial, in which potent viral suppression 
was seen over 14 days of treatment with the PI danoprevir and NI mericitabine 
[223]. Following the experience of drug development in HIV, where DAAs 
targeting different viral proteins have been combined to minimise viral resistance, 
a number of interferon-free regimens are now in development for chronic HCV.  
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Early mathematical modelling suggested that combinations of three drugs would 
be required for treatment of chronic HCV, to avoid acquisition of viral resistance 
[224]. In practice, successful treatment outcomes for some patient groups have 
been observed with 2 drugs, perhaps due to the trade-off between resistance and 
viral fitness. For example, successful treatment of G1b strains may be achieved 
by combining a PI with a relatively low barrier drug (NNI/NS5A inhibitor), whereas 
G1a strains may require a PI plus 2 additional drugs, as they are more susceptible 
to emergence of relatively fit RAVs at the 155 position. Following this theory, 
combinations of NI (high barrier to resistance) with 2 lower barrier drugs 
(NNI/NS5A inhibitor) might be suitable for both G1a and G1b, whilst combining 
an NI with a PI might be suitable for all patients, regardless of genotype.  
 
Trial data to-date appear to support this model. Combining asunaprevir (PI) with 
daclatasvir (NS5A inhibitor) achieved high rates of SVR in patients with G1b HCV 
but less so for G1a [225, 226]. Addition of a third DAA (an NNI) overcame this 
and produced comparable SVR between G1a and G1b [227]. In Phase 3 studies 
evaluating a PI (ABT-450), NNI (dasabuvir) and NS5A inhibitor (ombitasvir) with 
or without ribavirin, SVR was lower in the ribavirin-free arm in patients with G1a 
than G1b HCV, but comparable amongst G1a/G1b patients treated with 
quadruple therapy [228-230]. These data highlight potential differences in 
treatment response to PI-based therapy between G1a and G1b. A “one-size-fits-
all” treatment approach has advantage of simplicity but risks over-treating 
patients who may do well with fewer drugs [231]. 
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Alternatively, a NI could be used as the backbone for interferon-free combination 
therapy, given the broader genotypic coverage of this drug class than PIs, and 
relatively high barrier to resistance. Sofosbuvir is particularly attractive for this 
role, given its high antiviral potency. The potency of the NI in interferon-free 
combination therapy appears to be important, as a combination of mericitabine 
(NI) and danoprevir (PI), with or without ribavirin, was associated with high rates 
of treatment failure, especially amongst G1a patients, and acquisition of 
danoprevir RAVs [232]. In contrast, a combination of sofosbuvir (NI) and 
simeprevir (PI), with or without ribavirin, produced high rates of SVR with just 12 
weeks of treatment, with or without ribavirin, for non-cirrhotic patients with both 
G1a and G1b HCV [233]. 
 
Given its high antiviral potency, broad genotypic coverage and high barrier to 
resistance development, sofosbuvir has been investigated in interferon-free 
regimens with ribavirin alone. At the time of writing, these relatively small studies 
have suggested that for patients with G1 HCV, outcomes are less favourable than 
with sofosbuvir, pegIFN/RBV triple therapy, particularly amongst treatment-
experienced patients and those with risk factors for treatment failure [234, 235]. 
In contrast, interferon-free sofosbuvir/RBV appears adequate for patients with G2 
HCV, although patients with cirrhosis may have better outcomes with longer 
durations of therapy than the standard 12 weeks [205, 236, 237]. Regarding G3 
HCV, treatment outcomes with sofosbuvir/RBV dual therapy appear inferior to 
sofosbuvir with pegIFN/RBV, although at present little clinical trial data is 
available for G3 patents treated with this triple therapy combination [205, 234, 
238]. Current treatment guidelines recommend sofosbuvir/RBV dual therapy for 
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G2 HCV but not for G1 HCV unless no other interferon-free option is available 
[155]. Patients with G3 HCV in whom interferon is contra-indicated may have 
good treatment outcomes if the duration of sofosbuvir/RBV dual therapy is 
extended to 24 weeks, but this is not recommended for patients with cirrhosis or 
previous pegIFN/RBV treatment failure [155, 237]. The BOSON trial was 
conducted recently to clarify optimal treatment regimens for these viral 
genotypes.  Sofosbuvir/RBV for 16 or 24 weeks was compared with 12 weeks of 
sofosbuvir/pegIFN/RBV in patients with G2 and G3 HCV. In patients with G3 
HCV, sofosbuvir/pegIFN/RBV for 12 weeks was superior to sofosbuvir/RBV 
regimens of 16 or 24 weeks, regardless of treatment experience or cirrhosis [239]. 
In the future, sofosbuvir-based regimens may be superseded for G3 HCV but for 
now, inclusion of pegIFN in sofosbuvir-based treatment should remain an option. 
 
Ribavirin also contributes to the significant burden of side effects experienced by 
patients receiving anti-HCV therapy. To avoid pegIFN and RBV exposure, 
sofosbuvir has been investigated in combination with the NS5A inhibitor 
daclatasvir and also combined in a single pill with another NS5A inhibitor, 
ledipasvir. Both combination therapies have been investigated with and without 
RBV. Sofosbuvir and daclatasvir appears highly effective in treatment of G1, G2 
and G3 HCV, although SVR rates were slightly higher amongst patients with G1 
than G2 or G3 HCV. The addition of RBV did not appear to enhance SVR, 
although it is notable that in this small study the G3 patients who relapsed did not 
receive RBV [240]. Sofosbuvir/ledipasvir with or without RBV appears highly 
effective in treatment of G1 HCV, including patients who have previously failed 
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PI-based therapies [241-243].  However, efficacy is lower in other viral genotypes, 
particularly G3, although addition of ribavirin improves SVR [244].  
 
Patients who relapse after DAA therapy represent a new and growing population 
of “hard-to-treat” patients for whom there is a shortage of information regarding 
best management. One option is to retreat with extended duration of therapy. To 
explore the efficacy of this, patients with G1 HCV who had previously failed 8-12 
weeks of sofosbuvir/ledipasvir-based therapy were retreated with a prolonged 
course of 24 weeks sofosbuvir/ledipasvir. Overall, 71% of retreated patients 
achieved SVR12. Retreatment success was influenced by duration of previous 
therapy (80% SVR12 in patients previously treated for 8 weeks versus 46% in 
those previously treated for 12 weeks) and the presence of NS5A RAVs at 
retreatment baseline (100% SVR12 if no RAVs versus 60% if RAVs present). 
Furthermore, a small number of patients with NS5A RAVs acquired the sofosbuvir 
resistance-conferring RAV S282T during retreatment [245]. Thus whilst 
combinations of sofosbuvir and NS5A inhibitor appear promising as highly 
efficacious, well tolerated interferon-free therapies, the role of RBV in preventing 
relapse remains uncertain, and the best option for retreatment of patients who fail 
these IFN-free regimens remains to be established. 
 
1.9 Predictors of response to novel anti-HCV therapies 
As anti-HCV drug development has progressed to include ever more potent 
combinations of antiviral drugs, fewer patients are failing to respond to therapy. 
However, failure rates are likely to be higher in “real world” settings than in clinical 
trials, and even 5-10% treatment failure observed in a trial will represent 
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significant numbers of patients as these treatments become more widely 
available. Treatment failure risks acquisition of resistance to novel antiviral 
therapies and as yet it is unclear how great the clinical significance of this may 
be. In the era of interferon-free treatments and with increasing numbers of drugs 
available which vary in potency, pan-genotypic efficacy and barrier to resistance, 
care will need to be taken to avoid generation of “multi-drug resistant” HCV. The 
ability to predict which patients will respond to which combinations of drugs would 
be valuable to minimise toxicity, optimise outcomes and rationalise costs. 
 
As with pegIFN/RBV therapy, no single factor exists which allows prediction of 
treatment outcome to novel antiviral therapies. Viral genotype/subtype and 
clinical features, particularly presence of advanced fibrosis/cirrhosis, remain 
important. Other factors, such as IL28B status, previous treatment history, pre-
treatment presence of antiviral resistance-associated mutations, may be more 
important in treatment with some DAAs and drug combinations than others. 
 
1.9.1 Clinical features 
As with pegIFN/RBV therapy, the infecting viral genotype significantly affects 
response to most DAAs. As discussed above, PIs are licensed only for treatment 
of G1 HCV as they have little clinical efficacy against other viral genotypes 
investigated in clinical trials [198, 199]. Greater treatment response to PI-based 
therapies in patients with G1b than G1a HCV has been consistently observed, as 
is discussed in greater detail above. DAAs with broad genotypic coverage are still 
more efficacious is some genotypes than others. Dual therapy with sofosbuvir 
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and ribavirin is highly efficacious in G2 HCV, but less so in G1 and G3 infection 
[234, 236]. 
 
Emerging data also suggest that there may be HCV strain-specific differences in 
response to DAAs, which are not readily identified by current genotyping or 
phenotyping assays. For example, although the overall antiviral efficacy of 
telaprevir in patients with G3 HCV is low, a minority of patients did show some 
antiviral response [199]. Furthermore, simeprevir efficacy appears heterogenous 
amongst patients with G5a infection [246]. This within-subtype variation, 
demonstrated in very small series, may be due to naturally occurring amino acid 
changes within the NS3 protease domain [100]. Whether similar stain-specific 
variation will occur upon treatment with other DAAs, and the clinical importance 
of this, remains to be established. 
 
The presence of advanced fibrosis or cirrhosis strongly impacts on outcome of 
most DAA-containing therapies. Although SVR is improved relative to 
pegIFN/RBV alone, treatment outcomes remain worse in cirrhotic than non-
cirrhotic patients treated with PI (telaprevir, boceprevir or simeprevir) and 
pegIFN/RBV [80, 183-186]. Outcomes for cirrhotic patients treated with IFN-free 
regimens are inferior for G1 or G3 patients receiving sofosbuvir/ribavirin dual 
therapy compared to patients without cirrhosis [235, 236]. Initial studies on 
treatment of G1 patients with sofosbuvir/simeprevir and sofosbuvir/ledipasvir 
(both regimens with and without RBV) found equivalent outcomes in cirrhotic and 
non-cirrhotic patients, regardless of inclusion of RBV, although the number of 
cirrhotic patients was small [233, 247]. A subsequent larger trial, OPTIMIST-2, 
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investigated sofosbuvir/simeprevir in G1 HCV patients with cirrhosis. This study 
found SVR rates slightly lower than previously observed, and suggested that 
factors associated with poor response (IL28B status, previous treatment 
experience, presence of simeprevir-resistance conferring Q80K variant) may 
have a greater influence on treatment outcome amongst cirrhotic patients [248].  
 
1.9.2 Previous response to pegIFN/RBV treatment 
Many patients being treated with DAA-containing therapy, especially in the early 
phase of availability, will have previously failed treatment with pegIFN/RBV. The 
impact of a patient’s interferon response is particularly important when 
administering therapies combining a single DAA with pegIFN/RBV. Patients who 
are poorly interferon sensitive will effectively receive DAA/RBV dual therapy, and 
are at high risk of viral resistance and treatment failure, particularly when the DAA 
is of a class with a relatively low barrier to resistance. This is demonstrated in 
clinical trials of PI with pegIFN/RBV, where SVR rates are much lower in patients 
with previous null response to pegIFN/RBV treatment than prior relapse or partial 
response [183, 186, 190]. However, a previous null response to pegIFN/RBV is 
not an absolute predictor of outcome of PI-containing triple therapy, as a greater 
proportion of such patients went on to achieve SVR than those treated with a 
further course of pegIFN/RBV alone. In an attempt to predict which of these 
patients may benefit from further treatment with PI and pegIFN/RBV, a four-week 
pegIFN/RBV lead-in has been used to establish interferon response before 
commencing PI. In clinical trials of boceprevir-containing triple therapy, >1 log10 
decline in viral RNA during the lead-in phase was associated with higher rates of 
SVR [183, 185, 249, 250]. Conflicting data have been presented on whether the 
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use of a lead-in enhances SVR following treatment with telaprevir-based triple 
therapy, although results may have been influenced by clinician selection of 
patients receiving lead-in or higher patient drop-out due to pegIFN/RBV-related 
adverse events [186, 251]. Amongst pegIFN/RBV-experienced patients treated 
with telaprevir and pegIFN/RBV, >1 log10 decline in HCV RNA during a four week 
pegIFN/RBV lead-in was associated with higher rates of SVR. However, the 
authors cautioned that response to lead-in should be combined with detailed 
clinical history of prior pegIFN/RBV treatment response, as a significant number 
of prior relapsers and partial responders still achieved SVR despite </=1 log10 
decline in HCV RNA during lead-in [252]. 
 
1.9.3 IL28B genotype 
The strength of association between IL28B genotype and treatment outcome 
appears to decrease in proportion to the antiviral potency of DAA-based regimens 
[253]. IL28B status retains some predictive value in patients receiving PI and 
pegIFN/RBV, especially treatment-naïve patients [80, 249, 254]. Patients with 
poor-risk T allele appear to gain the most benefit from addition of PI to 
pegIFN/RBV therapy, whilst patients homozygous for the good-risk C allele do 
well with shorter duration of therapy [255]. The strength of the association is lost 
in treatment-experienced patients, a population which may be enriched for the 
poor-risk T allele, where previous response to pegIFN/RBV treatment is a much 
stronger predictor of treatment outcome than IL28B status [249, 256]. The 
association between IL28B genotype and treatment outcome also appears lost 
following treatment with more potent sofosbuvir-based IFN-containing and IFN-
free regimens [206, 240, 247]. The importance of IL28B genotype in prediction of 
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treatment outcome is likely to decline as the use of interferon-free treatments 
becomes more widespread. 
 
1.9.4 Resistance associated variants 
As discussed above (Section 1.2.3), the HCV RNA-dependent RNA polymerase 
lacks any proof-reading capacity, which, combined with the high rate of HCV 
replication, results in a very high rate of viral mutation. In theory, all single and 
double mutations pre-exist before treatment in an infected individual, although in 
practice mutation rates are not equally distributed over the whole genome, and 
whether a mutation will persist in the quasispecies is also influenced by other 
factors such as viral fitness and the replication environment [224, 257]. Mutations 
which confer reduced susceptibility to DAAs (resistance associated variants, 
RAV) are detectable pre-treatment in a small proportion of treatment-naïve 
patients (up to 5%) [208, 258], although their clinical significance is uncertain. 
Baseline RAV conferring decreased susceptibility to telaprevir or boceprevir do 
not appear to affect SVR rates amongst patients treated with these PIs and 
pegIFN/RBV, provided patients had a good pegIFN/RBV response [259-262]. 
 
The Q80K variant, which confers reduced susceptibility to simeprevir, appears to 
be of greater clinical significance. In clinical trials, this variant was present at 
baseline in 23-41% of patients with G1a HCV (it is rarely detected in G1b) and 
substantially reduced clinical response to simeprevir and pegIFN/RBV in both 
treatment-naïve and treatment-experienced patients [80, 81, 189]. Screening for 
the Q80K variant is recommended for G1a patients prior to treatment with 
simeprevir and pegIFN/RBV, with consideration of alternate therapy if this variant 
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is identified. Interestingly, replacement of pegIFN/RBV with sofosbuvir in 
combination with simeprevir appears to negate the impact of the Q80K variant, 
as sofosbuvir/simeprevir dual therapy produced high SVR rates amongst non-
cirrhotic patients with G1a HCV regardless of Q80K status [233]. This benefit 
appears to be lost in cirrhotic patients treated with sofosbuvir/simeprevir, where 
SVR rates were higher amongst G1a patients without Q80K than patient with 
Q80K [248]. The full impact of Q80K mutations in interferon free regimens 
remains to be determined. 
 
The implications of acquisition of RAV in patients who have failed DAA therapy 
are also unclear. As HCV is an RNA virus, unlike HIV or HBV, resistant variants 
cannot be archived as DNA. Sequencing studies suggest that PI RAV, which 
have relatively poor replicative fitness, are gradually replaced by wild type virus 
over weeks to months after cessation of the PI. For example, follow-up viral 
sequencing after telaprevir-based treatment found resistant variants in 77% of 
patients without SVR by population sequencing. Kaplan-Meier estimates of loss 
predicted a median time of 10.6 months for G1a patients and 0.9 months for G1b 
patients to revert fully to wild-type [79]. RAVs occurring after failure of boceprevir-
based triple therapy have also been found to decline over time [261]. Of note, 
these analyses by population sequencing may not detect persistence of RAVs at 
very low frequencies within the quasispecies. Studies of retreatment of PI 
treatment failures with DAA/pegIFN/RBV triple therapy have not been performed, 
and so the clinical significance of previous PI treatment failure in this context is 
unknown. However, retreatment with an interferon-free regimen using potent 
antivirals with no overlapping resistance has been explored and appears 
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promising. The two small studies investigating interferon-free 
sofosbuvir/daclatasvir and sofosbuvir/ledipasvir both included patients who had 
previously failed treatment with PI/pegIFN/RBV, and rates of SVR were high [240, 
247]. The PI grazoprevir is unique in that it is not inhibited by NS3 RAVs which 
confer cross-resistance to other PIs. Treatment of patients who had previously 
failed PI/pegIFN/RBV with grazoprevir, elbasvir (an NS5A inhibitor) and RBV 
resulted in high SVR rates, regardless of previous PI virological failure. However, 
treatment-emergent NS3 and NS5A RAVs were reported in the small number of 
patients who failed therapy [263]. 
 
Pre- and post-treatment RAVs conferring reduced susceptibility to other classes 
of DAA have been described, but the natural history of these variants and their 
clinical significance is even less clear at present. Unlike PI RAVs, RAVs 
conferring resistance to NS5A inhibitors appear to be relatively fit and have been 
found to persist for at least 12 months after therapy [264]. Acquisition of RAVs 
conferring decreased susceptibility to sofosbuvir (S282T variant) is very rare, but 
has been described in a patient treated with sofosbuvir monotherapy, where 
S282T became undetectable (by deep sequencing) by 12 weeks after treatment 
[207], and after sofosbuvir/ledipasvir dual therapy, in the context of RAVs 
conferring reduced NS5A inhibitor sensitivity both at baseline and at the time of 
relapse [247]. In a clinical trial of prolonged (24 weeks) sofosbuvir/ledipasvir 
retreatment of patients who had failed 8-12 weeks of sofosbuvir/ledipasvir 
therapy, presence of NS5A RAVs at retreatment baseline was associated with 
considerably lower SVR rates (100% SVR12 if no RAVs versus 60% if RAVs 
present) [245]. However, patients with NS5A inhibitor RAVs at baseline did 
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achieve SVR, so these alone do not appear predictive of response to 
sofosbuvir/ledipavir therapy [247]. The implications of these variants in future 
treatment response is currently unknown. 
 
Overall, previous widely used predictors of treatment response (infecting viral 
genotype, advanced fibrosis/cirrhosis) remain relevant to DAA-based therapies, 
although less so to highly potent IFN-free regimens. However the number of 
participants has so far been small, and some cases of treatment failure have been 
seen. These numbers are likely to become much more significant as the use of 
such regimens increases. Given the high rates of treatment success with current 
interferon-free regimens in patients with traditional “poor risk” factors for SVR 
(e.g. cirrhosis, previous failure to respond to pegIFN/RBV) new strategies may 
be necessary to identify individuals at risk of treatment failure, particularly those 
undergoing “second line” therapy, to maximise outcomes and minimise the risk 
of generating multi-drug resistant HCV. 
 
1.10 Aims and objectives 
The hypothesis of this study was that a novel replication system for patient-
derived HCV could be developed, using a fusion technique recently established 
in the group, and that this replication system could be used to predict patient-
specific responses to antiviral therapies. 
 
A novel system to study replication of patient-derived HCV has recently been 
developed within our group. This system is based around fusion of patient-
derived monocytes with cultured hepatocytes and has demonstrated that patient-
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derived HCV replicates in the hybrid cells. This project aimed to examine whether 
this viral replication model can be used to predict outcome of treatment with 
pegIFN/RBV as well as novel antiviral therapies. Given the rapid progress in 
development of novel antiviral agents, the ability to screen individual patient 
sensitivity to novel antivirals could be enormously useful, especially for patients 
who have already failed therapy. Patient-derived monocytes have a number of 
limitations for such use, including the low yield of cells, difficulty in storing and 
difficulty transferring cells between laboratories. In this project, we sought to 
modify the fusion model such that instead of patient monocytes, HCV from patient 
serum would be “captured” by cell culture monocytes prior to transfer to 
hepatocytes by cell fusion. We aimed to validate this “capture-fusion” assay as a 
clinically useful tool to screen patient drug sensitivity. Furthermore, we aimed to 
study the mechanisms underlying HCV infection of monocytes and which permit 
viral replication after fusion in the hybrid cells.  
 
Specifically, the project objectives are: 
• To develop a novel assay to study replication of patient-derived HCV, using 
cell culture monocytes to capture HCV from patient serum, prior to fusion with 
hepatocytes. 
• To assess whether this novel “capture-fusion” model for viral replication can 
be used to predict sensitivity of patient-derived HCV to interferon, ribavirin 
and novel direct-acting antiviral drugs. 
• To test the hypothesis that presence of viable HCV in monocytes at the end 
of therapy predicts relapse in patients receiving treatment for chronic HCV 
infection. 
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• To investigate whether this model can be used to study the mechanisms 
underlying HCV infection of monocytes. 
• To study the mechanisms which permit viral replication in hybrid cells. 
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2.0 Materials and methods 
2.1 Cell lines 
2.1.1 Huh7.5 cells 
Huh7.5 is a hepatocellular carcinoma derived cell line which is highly permissive 
to replication of HCV subgenomic constructs and cell culture adapted strains. 
These cells (kind gift from Charles Rice, Rockefeller Institute, New York) were 
maintained at 37˚C in 75cm3 flasks in DMEM supplemented with 10% fetal calf 
serum (FCS) and antibiotics (penicillin and streptomycin). Cell passage was 
performed every 3-4 days, or when the cells reached 80-90% confluence.  
 
2.1.2 Replicon cells 
This is a Huh7 cell line which stably expresses a subgenomic, autonomously 
replicating HCV construct, and was a kind gift from Ralf Bartenschlager 
(University of Heidelberg, Germany). The construct comprises the HCV 5’UTR, a 
neomycin resistance marker, a heterologous internal ribosomal entry site and the 
HCV NS3-NS5B and 3’UTR. The cells were maintained at 37˚C in 75cm3 flasks 
in DMEM supplemented with 10% FCS and neomycin. Cell passage was 
performed when the cells reached 80-90% confluence. 
 
2.1.3 Huh7-J20 cells 
This is a Huh7 cell line which stably expresses a fusion protein comprising 
enhanced green fluorescent protein and secreted alkaline phosphatase, linked 
by the HCV NS4A/NS4B cleavage site. These cells were a kind gift from Arvind 
Patel (Centre for Virus Research, University of Glasgow). The cells were 
maintained at 37˚C in 75cm3 flasks in DMEM supplemented with 10% FCS and 
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antibiotics (penicillin and streptomycin). Cell passage was performed when the 
cells reached 80-90% confluence. 
 
2.1.4 THP-1 cells 
THP-1 is a human monocyte cell line, derived from a 1 year old male with acute 
monocytic leukaemia [265]. This suspension cell line was purchased from ATCC 
(Teddington, Middlesex, UK) and maintained at 37˚C in 75cm3 flasks in RPMI 
supplemented with 10% FCS and antibiotics (penicillin and streptomycin). Cell 
passage was performed every 3-4 days. 
 
2.1.5 Passage of adherent cell lines 
Medium was removed and the cells washed with sterile PBS. The cells were 
incubated at 37˚C with 5x trypsin diluted in PBS for 4 minutes. The trypsin was 
poured off and the cells removed from the flask by washing with 10mL DMEM 
plus 10% FCS. 2mL of the resulting cell suspension was transferred to a fresh 
75cm3 flask and made up to 20mL with growth medium. 
 
2.1.6 Passage of suspension cell lines 
Cells and medium were transferred to a 50mL Falcon tube and the cells were 
pelleted (5 minute centrifugation at 1200rpm). The medium was poured off, and 
the cell pellet resuspended in 5mL RPMI. 1mL of this suspension was transferred 
to a fresh 75cm3 flask and made up to 20mL with growth medium. 
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2.2 Primary human monocytes 
2.2.1 Collection and separation of total peripheral blood mononuclear 
cells (PBMCs) 
40mL peripheral blood was taken into heparinised tubes from patients attending 
their end of treatment visit for genotype 3 HCV. All patients gave written informed 
consent to participate, and the protocol was approved by Moorfields and 
Whittington Research Ethics Committee (reference 09/H0721/25).  
 
Whole blood was diluted 50:50 with RPMI and layered on Ficoll-Paque (GE 
Healthcare, Buckinghamshire, UK), before centrifugation at 2500rpm for 20 
minutes. The resulting PBMC layer was removed to a fresh 50mL Falcon tube 
and washed twice, by suspension in 50mL RPMI and centrifugation at 1500rpm 
for 5 minutes. The total PBMCs were counted and frozen in aliquots of 5x106 
cells/mL in freezing medium comprising 70% RPMI, 20% FCS, 10% DMSO. The 
cells were frozen at -80˚C and then transferred to liquid nitrogen storage until use. 
 
2.2.2 Separation of CD14 (+) monocytes 
When ready for use, vials of PBMCs were thawed to room temperature, then 
washed by slowly adding 10mL cold RPMI and centrifugation at 1200rpm for 5 
minutes. The supernatant was discarded and the cell pellet resuspended in 20mL 
pre-warmed RPMI plus additives (10% FCS and penicillin/streptomycin). The 
cells were left for at least 4 hours before further manipulation. 
 
CD14(+) cells were isolated from total PBMCs by magnetic separation (Milteyi 
Biotec, Surrey, UK). Thawed PBMCs were counted, then pelleted and washed 
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once in MACS buffer (PBS with 2% FCS and 0.5% EDTA). The pellet was 
resuspended in 80µL MACS buffer per 107 cells. CD14 (+) microbeads were 
added at 20µL per 107 cells and gently mixed, before incubation at 4˚C for 15 
minutes. The cells and microbeads were then made up to 500µL with MACS 
buffer before being passed through a magnetic cell separation column using LS 
columns (suitable for up to 108 total cells). The column was washed 3 times with 
500µL MACS buffer. After all the eluate had passed through, the column was 
removed from the magnet and transferred to a clean Falcon tube, where the 
isolated CD14(+) cells were washed through in 1mL MACS buffer. The CD14 (+) 
cells obtained were counted and cell fusion using these cells proceeded 
immediately. During optimisation experiments (performed by Dr Alia Javaid), flow 
cytometry found that cell population isolated using this technique comprised 98% 
CD14+ cells. 
 
2.3 Fusion of primary monocytes or THP-1 cells with Huh7.5 cells 
2.3.1 Pre-stimulation of THP-1 cells 
Where THP-1 cells were pre-stimulated prior to infection and fusion, the cells 
were seeded in 6 well plates at 1x106 cells per well. Stimulants were added at the 
appropriate concentration, and incubated at 37˚C for 18-24 hours. The agents 
used for stimulation were lipopolysccharide (LPS) at 1mg/mL, phorbol 12-
myristate 13-acetate (PMA) at 200ng/mL (both from Sigma-Aldrich, Dorset, UK) 
and interferon-γ (IFNγ) at 10ng/mL (Invitrogen, Paisley, UK). 
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2.3.2 Infection of THP-1 cells 
20mL peripheral blood was taken from patients with chronic HCV. All patients 
gave written informed consent to participate, and the protocol was approved by 
Moorfields and Whittington Research Ethics Committee (reference 
09/H0721/25). The blood was allowed to clot for at least 20 minutes and then 
centrifuged at 1500rpm for 10 minutes. The serum layer was removed and stored 
in aliquots at -80˚C until use. Viral load was available from the clinical record of 
all patients, and was measured using the Roche Cobas Amplicor. 
 
Where THP-1 cells had been pre-stimulated, the vast majority of cells were 
adherent. Medium and non-adherent cells were removed, and the adherent cells 
were washed 3 times with PBS. The medium was replaced with RPMI plus 2% 
FCS. Unstimulated THP-1 cells in suspension were pelleted by centrifugation at 
1200prm for 5 minutes then resuspended in RPMI plus 2% FCS. The cells were 
seeded at a density of 106 cells/mL. Serum from patients with chronic HCV 
infection was added to the cells at a ratio of 1 viral copy per cell. Where HCVcc 
was used, this was added at a ratio of 10 viral copies/cell. Cells were incubated 
with virus at 37˚C overnight. 
 
After this incubation period, the medium containing virus was removed and the 
cells were washed 3 times to remove non-bound virions. Adherent pre-stimulated 
THP-1 cells were washed in the flask, whilst suspension cells were transferred to 
a 15mL Falcon tube then centrifuged at 1500rpm for 5 minutes and resuspended 
in fresh RPMI for each wash. Adherent cells were removed from the flask using 
a rubber cell scraper and transferred to a 15mL Falcon tube for fusion. 
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2.3.3 Cell fusion 
The cell fusion protocol using primary human monocytes was optimised by Dr 
Alia Javaid. An identical fusion protocol was followed whether primary monocytes 
or THP-1 cells were used. 
 
Huh7.5 cells were trypsinised and residual trypsin removed by washing once in 
DMEM. They were counted, and mixed with the monocytes at a 1:1 ratio. The 
cells were pelleted together by centrifugation at 1500rpm for 5 minutes. The 
supernatant was removed completely before resuspension of the cell mix in pre-
warmed polyethylene glycol 1500 (PEG-1500; Roche Diagnostics, Burgess Hill, 
UK), 250µL per 2x106 total cells. PEG-1500 was added slowly to the cells over 1 
minute with gentle stirring, before incubation at 37˚C for 2 minutes. 10mL pre-
warmed DMEM with additives (10% FCS/antibiotics) was slowly added over 3 
minutes with gentle stirring to dilute the PEG. After a further 5 minute incubation 
at 37˚C, the cells were pelleted by gentle centrifugation (1200rpm for 5 minutes), 
before resuspension in DMEM plus additives. The cells were seeded in 6 well 
plates at a density of 2x105 cells per well (when THP-1 cells were used for fusion) 
or 5x105 cells per well (when primary monocytes were used). The fused cells 
were maintained at 37˚C for up to 7 days, with RNA extraction for HCV RNA 
quantification at various time points.  
 
2.4 Drug inhibition assays 
After fusion, the cells were left to settle overnight. The following day, inhibitory 
drugs were added to each well at a range of concentrations. Drugs were diluted 
in drug dilution medium (RPMI plus 2% FCS and 0.5% DMSO). Control wells with 
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no active drug were treated with drug dilution medium only. The plates were 
maintained at 37˚C for up to 5 days, with RNA extraction for HCV RNA 
quantification at various time points. Where the cells were maintained for more 
than 3 days, the medium was removed at day 3 and replaced with fresh growth 
medium and drug. 
 
2.4.1 Antiviral drugs 
The antiviral agents used were interferon-α2a (Cambridge Bioscience, 
Cambridge, UK), ribavirin (Sigma-Aldrich), telaprevir (kind gift from Janssen 
Virology), alisporivir (kind gift from Novartis Pharma, Switzerland) and SB 9200 
(supplied by Spring Bank Pharmaceuticals, Milford, MA). The range of 
concentrations used was 10-100 IU/mL (IFN- α2a); 5-50 IU/mL (ribavirin); 0.05-
1.0µM (telaprevir and alisporivir) and 0.01-10µM (SB 9200). 
 
2.4.2 Cytokines and stimulants 
Where cytokines/stimulants were added to fused cells, this was done immediately 
after cell fusion. Agents used were osteopontin (PeproTech, London, UK) and 
SAG (Enzo Life Sciences (UK) Ltd, Exeter, UK). 
 
2.4.3 Cell viability assay 
Cell viability was measured after incubation with antiviral drugs to exclude 
significant drug toxicity at the drug concentrations used. An ATP quantification 
assay was used (CellTiter-Glo; Promega, Southampton, UK). Fused cells were 
seeded into opaque 96 well plates and left overnight. Antiviral drugs or drug 
dilution medium were then added, with each drug concentration tested in 
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quadruplicate. Media and drugs were refreshed at day 3. On day 5 after fusion, 
the plates were brought to room temperature and plain medium (with no cells) 
was applied to the control wells. An equal volume of CellTiter-Glo Reagent was 
added to each well and gently mixed by swirling for 2 minutes. The plates were 
incubated at room temperature for 10 minutes before the luminescence signal 
was read on a BMG FLUOstar Optima plate reader. 
 
2.5 Concentration of viral particles on a sucrose gradient 
To establish if infectious viral particles were released during replication in the 
capture-fusion system, supernatants were collected from non-drug treated wells 
of two capture-fusion experiments (1 with serum from a HCV G1 donor and 1 with 
a G3 donor). In each experiment, a total of 12 mL supernatant was collected from 
non-drug treated wells at day 5 post fusion. Cell debris were removed by filtration 
through a 0.45µm filter, then 10 mL was layered on 4 mL 20% sucrose. 
Supernatants were centrifuged (24,000 x g) for 2 hours and the pellet 
resuspended in 1mL RPMI. For capture-fusion experiments using concentrated 
supernatant, 1x106 prestimulated THP-1 cells were incubated with 1 mL of 
concentrated supernatant for 24 hours before fusion. 
 
 
2.6 Molecular biology techniques 
  
2.6.1 RNA extraction from cells using TRIzol reagent 
For RNA extraction from adherent cells, the supernatant was removed from each 
well and 1mL TRIzol reagent (Invitrogen) added to the adherent cells. The cellular 
proteins and nucleic acids were dissolved in TRIzol by repeated pipetting, then 
transferred to a 1.5mL Eppendorf tube and stored at -80˚C prior to RNA 
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purification. In certain experiments, supernatants removed from the cells were 
filtered and stored at -80˚C for subsequent HCV RNA detection and use in re-
infection experiments. 
 
For RNA extraction from suspension cells (primary monocytes, unstimulated 
THP-1 cells and fused cells immediately following fusion), an aliquot containing 
5x105 cells was centrifuged at 1500rpm for 5 minutes. The supernatant was 
discarded and the pellet resuspended in 1 mL TRIzol reagent, with repeated 
pipetting, before transfer to a 1.5mL Eppendorf tube and storage at -80˚C. 
 
2.6.2 RNA purification 
Frozen samples of RNA in TRIzol reagent were thawed at room temperature to 
allow dissociation of the nucleoprotein complexes. 200µL chloroform was added 
to each sample and mixed by shaking. After 5 minutes at room temperature, the 
samples were centrifuged at 12,000rpm at 4˚C, for 15 minutes. 400µL of the 
upper (aqueous) phase containing RNA was transferred to a clean Eppendorf 
tube. 500µL ice-cold isopropanol was added to each, and mixed by inverting. The 
samples were incubated for 10 minutes at -20˚C before centrifugation at 
12,000rpm at 4˚C, for 15 minutes. The supernatant was discarded and 1mL cold 
70% ethanol added to each tube to wash the RNA pellet. After centrifugation at 
7500rpm for 10 minutes at 4˚C, the ethanol was removed and the RNA pellet 
allowed to air dry, before resuspension in nuclease-free water. The samples were 
heated to 65˚C for 5 minutes to aid dissolution. RNA per sample was then 
quantified using a Nanodrop spectrophotometer. 
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2.6.3 DNase treatment of purified RNA 
If necessary, purified RNA was further diluted in nuclease-free water to a 
concentration of less than 500ng/µL. RNA was then combined with DNase and 
10x DNase buffer (Promega) in the following quantities per sample: 
2µL RNA 
1µL DNase 
1µL 10x DNase buffer 
6µL nuclease-free water 
Each 10µL reaction was incubated at 37˚C for 30 minutes. 1µL stop solution was 
added to each, followed by incubation at 65˚C for 10 minutes before being placed 
back on ice.  
 
2.6.4 Quantification of total RNA by the RiboGreen assay 
Spectrophotometric estimation of RNA yield can be inaccurate due to presence 
of even trace amounts of contaminants such as DNA, phenol or protein. Where 
the final measurement of HCV RNA is to be normalised against total RNA 
extracted from the sample, a more accurate method should be used for 
quantification of total RNA, such as the RiboGreen assay (Invitrogen). RNA is 
DNase treated prior to measurement, as the RiboGreen dye will bind both RNA 
and DNA, thus falsely elevating results in untreated samples. 
 
RNA taken from the 10ul DNase reaction was diluted 1in 100 in TE buffer, 
sufficient to allow each RNA sample to be measured in duplicate. 100µL of each 
diluted RNA was transferred to a white 96 well plate, in duplicate. The 
manufacturer’s RNA standard was diluted to provide a standard curve ranging 
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from 20ng/mL to 1000ng/mL, and was also added to the plate in duplicate. 100µL 
TE buffer was used to measure background fluorescence. RiboGreen dye was 
diluted 1/200 in TE buffer and 100µL added to each well of RNA samples and 
standards. The plate was incubated for 5 minutes in the dark before being read 
on a BMG FLUOstar Optima plate reader. The average of the background values 
was subtracted from all other measurements. Values generated from the diluted 
standard were used to construct a standard curve using Prism software 
(GraphPad, La Jolla, CA). RNA concentrations for each sample were interpolated 
from the standard curve. 
 
2.6.5 Extraction of viral RNA from supernatants 
Viral RNA was extracted from supernatants using the QIAamp Viral RNA Mini Kit 
(Qiagen, Crawley, UK). 280µL of supernatant was thoroughly mixed with 1.12mL 
Buffer AVL (premixed with 11.2µL carrier RNA) and left at room temperature for 
10 minutes. 1.12mL 100% ethanol was added and vortexed to mix. The sample 
was applied to a QIAamp Mini column, 600µL at a time, and centrifuged at 
8000rpm for 1 minute until all the sample had been passed through the column. 
The filtrate was discarded after each centrifugation. 500µL of Buffer AW1 was 
added to the column and centrifuged at 8000rpm for 1 minute. The filtrate was 
discarded, and 500µL of Buffer AW2 was added to the column before 
centrifugation at 14000rpm for 3 minutes. The filtrate was discarded and the 
column centrifuged again at 14000rpm for 1 minute to remove any residual Buffer 
AW2. The column was transferred to a 1.5mL Eppendorf tube and 60µL Buffer 
AVE added. After 1 minute incubation at room temperature, the column and tube 
were centrifuged at 8000rpm for 1 minute to elute the RNA. Due to the presence 
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of carrier RNA, the RNA obtained was not quantified by spectrophotometer. RNA 
was stored at -80˚C. 
 
2.6.6 Production of an RNA standard for absolute quantification of HCV 
RNA 
In order to measure HCV RNA quantitatively by PCR, a standard of known copy 
number is required to generate a standard curve. An RNA standard 
corresponding to an area of the viral genome slightly larger than the region 
amplified during the quantitative RT-PCR reaction was chosen to act as a 
standard in these experiments. An RNA standard was chosen over a PCR 
product DNA standard as there were theoretical concerns that a DNA standard 
may underestimate sample copy number as the PCR reaction efficiency for the 
DNA standard may be higher than that of sample, due to lack of the reverse 
transcription step, relatively small product size and lack of secondary structure. 
Use of an RNA standard addresses at least some of these concerns.  
 
To generate the RNA standard, a plasmid containing DNA reverse transcribed 
from the JFH-1 genome was kindly supplied by Dr John McLauchlan (University 
of Glasgow Centre for Virus Research, Glasgow, UK).  
 
To isolate the JFH-1 DNA, the plasmid was digested using the restriction 
endonuclease Xba1 (New England Biolabs). The reaction mix comprised: 
20µg plasmid DNA 
3µL Xba1 
5µL 10x endonuclease buffer 
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Nuclease-free water to a final volume of 50µL. 
The reaction was incubated at 37˚C for 2 hours. 
 
The DNA was then cleaned up using a phenol/chloroform extraction step. The 
reaction volume was adjusted to 100µL with water. 100µL phenol/chloroform was 
added, and centrifuged at 12000rpm for 1 minute. The upper aqueous layer was 
transferred to a fresh Eppendorf tube and 100µL chloroform added. After mixing, 
the reaction was again centrifuged at 12000rpm for 1 minute. The upper aqueous 
layer was transferred into a fresh Eppendorf tube. The DNA was precipitated by 
adding 0.3M sodium acetate and 250µL 100% ethanol then incubating at -20˚C 
for at least 10 minutes. DNA was pelleted by centrifugation for 2 minutes at 
12000rpm, then washed in 70% ethanol. After another 2 minute centrifugation at 
12000rpm the supernatant was discarded and the pellet air-dried then 
resuspended in 52µL water.  
 
To convert the ends of the excised JFH-1 DNA from sticky to blunt, to facilitate 
transcription, it was treated with mung bean nuclease (New England Biolabs). 
The reaction mix contained: 
52µL linearised, clean DNA 
6µL 10x Buffer 
2µL mung bean nuclease 
This reaction was incubated at 30˚C for 30 minutes before a further 
phenol/chloroform clean up step, which was performed as described above. The 
DNA pellet was resuspended in 20 µL nuclease-free water and quantified using 
a Nanodrop spectrophotometer.  
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The excised JFH-1 DNA contains a RNA polymerase promoter sequence which 
was used to initiate transcription, using the T7 Megascript Kit (Ambion, Paisley, 
UK). 
A reaction mix was made up as follows: 
1µg linearised, mung bean nuclease treated, clean DNA 
2µL ATP 
2µL CTP 
2µL GTP 
2µL UTP 
2µL 2x Reaction Buffer 
2µL T7 enzyme mix 
Nuclease-free water to a final volume of 20µL  
The mixture was gently mixed by flicking and incubated at 37˚C for 3 hours. 2µL 
of the reaction product was run on a 1% agarose gel containing GelRed to ensure 
the presence and integrity of the transcribed RNA. 
 
The RNA product was treated with TurboDNAse for 15min at 37 ˚C, then 15 µL 
ammonium acetate and 115 µL nuclease free water were added to the reaction 
mix. A further phenol/chloroform clean-up step was performed, as described 
above. The RNA pellet was resuspended in 50 µL nuclease free water and 
quantified using the RiboGreen assay (as described in Section 2.6.4). The 
approximate number of RNA copies in the sample was calculated as follows: 
 
Copies/µL = (total RNA (ng/µL)/340 x JFH-1 genome (bases)) x 6.022x1023 
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Based on published literature, the length of the JFH-1 genome was taken as 9678 
bases [131]. Once RNA copies/µL in the sample was calculated, the undiluted 
standard stock was stored at -80 ˚C. The RNA standard was diluted to a 
concentration of 2x109 copies/µL in Qiagen nucleic acid buffer and stored in 10µL 
aliquots at -80 ˚C which were used to make fresh serial dilutions for each PCR 
experiment. 
 
2.6.7 RTqPCR measurement of HCV RNA 
HCV RNA was quantified using the QuantiTect Virus Kit (Qiagen) and a TaqMan 
HCV-specific primer and probe set (Applied Biosystems, Paisley, UK). Serial 
dilutions of the RNA standard, described above, amplified in this assay 
reproducibly generated a standard curve ranging from 10 – 107 copies, with an 
efficiency of close to 100%. Unfortunately, no data were available calibrating this 
assay against the WHO HCV RNA reference standard, so sensitivity limits could 
not be expressed in IU/mL [266]. 
 
Samples were set up for this combined reverse transcription-qPCR assay on ice 
as follows: 
25-50ng RNA template 
4µL 5x QuantiTect Virus NR MasterMix 
0.2µL 100x QuantiTect virus RT mix 
1µL primer/probe 
RNase-free water to final volume 20µL 
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The samples were run on a RotorGene 3000 real time cycler using the following 
cycling conditions: 
Reverse transcription: 50˚C for 20 minutes 
Activation of hot-start Taq polymerase: 95˚C for 5 minutes 
Cycling: 95˚C for 15 seconds/60˚C for 45 seconds, for 45 cycles. 
Serial dilutions of the HCV IRES PCR product and no-template negative controls 
were included in all experiments. HCV RNA was quantified by extrapolation from 
the standard curve, and normalised to total RNA present in the sample. 
 
2.6.8 TOPO cloning and sequencing of HCV RNA 
The 5’UTR of HCV RNA obtained from fusion experiments using serum from HCV 
genotype 1a infected donors was amplified, cloned and sequenced to confirm 
alignment with HCV genotype 1a reference sequence H77, and not with the 
genotype 2 high replicating laboratory strain JFH-1.  
 
For cDNA synthesis, purified RNA was obtained as described above. 1µg of each 
RNA sample was treated with 1µL DNase (Promega) and an appropriate volume 
of 10x DNase buffer and water and incubated at 37C for 30 minutes. 16µL of 
DNase-treated RNA was then mixed with 4µL SuperScript VILO MasterMix (Life 
Technologies, Paisley, UK) and run on a thermal cycler under the following 
conditions: 
25⁰C for 10 minutes/42⁰C for 60 minutes/85⁰C for 5 minutes. 
cDNA was stored at -20⁰C until use. 
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The Expand High Fidelity PCR system (Roche Diagnostics) was used to produce 
a blunt-ended PCR product for subsequent cloning. Mix 1 and Mix 2 were 
prepared separately. 
Mix 1:  
 0.5 µL dNTP (0.25mM) 
1.5 µL forward primer 
1.5 µL reverse primer 
2 µL cDNA 
RNase-free water to final volume 25µL 
 
Mix 2: 
0.75 µL polymerase enzyme mix 
5 µL Buffer without Mg 
5 µL Mg (final concentration 2.5mM) 
RNase-free water to final volume 25µL 
 
Primers used were: 
Forward: 5’-AGCGTCTAGCCATGGCGT-3’ 
Reverse: 5’-GCACGGTCTACGAGACCT-3’ 
 
Mix 1 and Mix 2 were combined on ice run on a RotorGene 3000 real time cycler 
using the following cycling conditions: 
Activation: 95⁰C for 15 minutes 
Cycling: 95⁰C for 15 sec/58⁰C for 30 sec/72⁰C for 2 min for 45 cycles 
Extension: 72⁰C for 7 minutes. 
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The products were stored at -20⁰C until purification and concentration, which was 
performed using the Qiagen MinElute PCR Purification kit (Qiagen). 250 µL 
Buffer PB was added to each PCR reaction and mixed. Each sample was applied 
to a MinElute column in a 2mL collection tube and centrifuged at 13,000rpm for 
1 minute. The flow-through was discarded and the sample washed with 750 µL 
Buffer PE and centrifuged at 13,000rpm for 1 minute. The flow-through was 
discarded again and the sample centrifuged at 14,200rpm for 1 minute. The 
column was placed in a clean 1.5 mL microcentrifuge tube and 10 µL Buffer EB 
applied. The column was left to stand for 1 minute then centrifuged at 13,000rpm 
for 1 minute. 
 
Cloning was performed using the ZeroBlunt TOPO PCR Cloning Kit for 
Sequencing (Invitrogen). The cloning reaction was prepared by combining the 
following for each PCR sample: 
4 µL PCR product 
1µL salt solution 
1µL TOPO vector. 
 
The cloning reaction mixture was incubated at room temperature for 30 minutes 
and then placed on ice. For transformation, 100 µL chemically competent E. coli 
(DH5αTM-T1R) were thawed on ice for each transformation reaction. Each cloning 
reaction mixture was added to an aliquot of cells, mixed gently and incubated on 
ice for 30 minutes. The cells were then heat-shocked on a heat block at 42⁰C for 
30 seconds and immediately placed back on ice. 250µL S.O.C. medium at room 
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temperature was added to each sample, then incubated at 37⁰C for 1 hour with 
horizontal shaking (200rpm). 50µL from each transformation was spread onto a 
pre-warmed agar plate containing ampicillin (50µg/mL). The plates were 
incubated at 37⁰C overnight. The following day, 2 colonies from each plate were 
transferred into 5mL LB Broth containing ampicillin (50µg/mL). The tubes were 
incubated at 37⁰C overnight with horizontal shaking (200rpm). 
 
For each sample, DNA was isolated and purified from the total volume of 
overnight culture using the PureLink HighPure Plasmid MiniPrep Kit (Invitrogen). 
The cells were isolated by centrifugation at 4000xg for 10 minutes and the 
medium removed. 0.4mL of resuspension buffer with RNaseA was added, and 
the cells were resuspended until the mixture was homogenous. 0.4mL lysis buffer 
was added, the mixture inverted, and left to stand for 5 minutes. 0.4mL 
precipitation buffer was added and mixed by inverting the tube until the sample 
appeared homogenous. The lysate was centrifuged at 13,000xg for 10 minutes 
at room temperature. The supernatant was transferred to a column, previously 
equilibrated with 2 mL equilibration buffer. The column was washed twice with 
2.5 mL wash buffer. 0.9 mL elution buffer was applied to the column and the DNA 
eluted into a clean microcentrifuge tube. 0.63 mL isopropanol was added to the 
tube, mixed well, and centrifuged at 12,000xg for 30 minutes at 4⁰C. The 
supernatant was discarded and the DNA pellet resuspended in 1 mL 70% 
ethanol. The tube was centrifuged again at 12,000xg for 5 minutes at 4⁰C, the 
supernatant discarded, and the pellet left to air dry for 10 minutes before 
resuspension in 30 µL TE buffer. DNA in each sample was quantified using a 
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Nanodrop spectrophotometer and the samples were stored at -20 ⁰C until further 
use. 
 
To confirm the presence of a correctly sized (265bp) product in each cloned 
plasmid DNA sample, an EcoR1 digest was performed (New England Biolabs, 
Hitchin, UK). For each sample, the following reaction mixture was prepared: 
1 µg purified plasmid DNA 
1 µL EcoR1 
2µL EcoR1 Buffer 
RNase-free water to final volume 20µL. 
This mixture was incubated at 37⁰C for 2 hours before 5 µL was run on a 2% 
agarose gel alongside a 100bp ladder. 
 
It was not possible to check the orientation of the PCR product within the plasmid 
by restriction enzyme analysis as no suitable single cut site in the plasmid and 
product could be identified. Therefore each sample containing an appropriately-
sized insert on Eco-R1 digestion was sent for sequencing (performed by Source 
Bioscience, Nottingham, UK) using both T3 and T7 stock primers. Sequences 
obtained were aligned with the 5’UTR of the G1a reference sequence H77 and 
JFH-1 using BioEdit Sequence Alignment Editor software [267].  
 
2.6.9 Quantification of mRNA expression 
For analysis of host gene expression by mRNA quantification, cDNA was 
synthesised from purified, DNase-treated sample RNA, as described above. 1 µL 
oligodTs and 1 µL random hexamers (Promega) were added to each sample of 
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10 µL DNase-treated RNA and heated at 65⁰C for 5 minutes before being placed 
on ice. 
 
 For reverse transcription, the following mix was prepared (using Promega RT 
reagents) and added to each sample: 
14 µL RT buffer 
2 µL dNTP (10mM) 
1 µL RNAsin 
1µL MMLV reverse transcriptase 
6 µL RNase-free water. 
The reaction was incubated at 42⁰C for 1 hour, then 75⁰C for 10 minutes and 
cDNA product stored at -20⁰C for subsequent PCR. 
 
mRNA quantification was performed by real-time PCR using the QuantiTect-
SYBR-Green real time PCR system (Qiagen). cDNA was diluted 1/10 in nuclease 
free water.  
 
For each PCR, the following reaction mix was set up: 
12.5µL 2x QuantiTect SYBR-Green PCR MasterMix 
0.5 µL Forward Primer (10µM) 
0.5 µL Reverse Primer (10µM) 
2 µL diluted cDNA 
RNase free water to final volume 25 µL. 
PCR reactions were run in duplicate for each sample. Cycling conditions were: 
Activation: 95̊C for 15 minutes 
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Cycling: 94̊C for 15 sec (denaturation)/60̊C for 30 sec (annealing)/72C̊ for 30 sec 
(extension) for 45 cycles. 
 
Primers used were: 
MxA:   Forward: 5’-GTTGGAGGCACTGTCAGGAGTTGC-3’ 
Reverse: 5’-CTACCTCTGAAGCATCCGAAATCTC-3’ 
CD81:  Forward: 5’-AAGCAGTTCTATGACCAGGCCCTAC-3’ 
  Reverse: 5’-TGAGGTGGTCAAAGCAGTCAGTG-3’ 
SR-B1: Forward: 5’- ATGAAATCTGTCGCAGGCATTG-3’ 
  Reverse: 5’-TGCATCACCTTGGGCATCA-3’ 
CD32:  Forward: 5’-TTCAAGGCCAACAACAATGA-3’ 
  Reverse: 5’-GGAGAAGGTGGGATCCAAAT-3’ 
CD64:  Forward: 5’-GTGTCATGCGTGGAAGGATA-3’ 
  Reverse: 5’-GCACTGGAGCTGGAAATA-3’ 
CD16:  Forward: 5’-ACAGGTGCCAGACAAACCTC-3’ 
  Reverse: 5’-TTCCAGCTGTGACACCTCAG-3’ 
Claudin-1: Forward: 5’-GCATGAAGTGTATGAAGTGCTTGGA-3’ 
  Reverse: 5’-CGATTCTATTGCCATACCATGCTG-3’ 
Occludin:  Forward: 5’-AAGAGTTGACAGTCCCATGGCATAC-3’ 
  Reverse 5’-ATCCACAGGCGAAGTTAATGGAAG-3’ 
LDL-R: Forward: 5’-CAACGGCTCAGACGAGCAAG-3’ 
  Reverse: 5’-AGTCACAGACGAACTGCCGAGA-3’ 
GAPDH: Forward and reverse primers obtained from PrimerDesign 
(Southampton, UK). Sequences not available. 
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Data acquisition was performed during the extension step. Melt curve analysis 
was performed to exclude mispriming. Results were normalised to expression of 
GAPDH, measured in the same PCR run, and expressed as relative gene 
expression using the ^^CT method. 
 
2.5.10 Confirmation of stability of GAPDH expression 
In this project, cellular mRNA expression was measured in 2 separate series of 
experiments - quantification of interferon stimulable gene expression in fusion 
experiments, and quantification of receptor expression by stimulated THP-1 cells. 
Stability of reference gene expression for normalisation of mRNA quantification 
was tested in both experimental conditions. The geNorm Plus kit (PrimerDesign) 
was used, which tested the stability of a panel of 12 reference genes (beta actin, 
GAPDH, VIPAR, ERCC6, UBE2D2, UBE4A, PRDM4, ENOX2, SCLY, TWY1, 
RNF20 and 18S rRNA). To test reference gene stability in fusion experiments, 
cDNA was synthesised (as described above) from RNA extracted from unfused 
Huh7.5 cells and from RNA extracted at 5 days after fusion from fused cells 
treated with drug dilution medium or telaprevir at a range of concentrations. For 
THP-1 stimulation experiments, cDNA was synthesised from RNA extracted from 
unstimulated THP-1 cells, and 2, 6, 12 and 24 hours after treatment with PMA 
(200ng/mL) and IFNγ (10ng/mL). In each PCR run, expression of 4 reference 
genes was measured from 8 experimental samples, each in duplicate.  cDNA 
from the same experimental samples was used in the 3 PCR runs required to 
measure expression of all 12 reference genes. Results were analysed using 
qbase+ software (Biogazelle, Zwijnaarde, Belgium). Considering both series of 
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experiments, stability of GAPDH expression was considered acceptable for use 
as a reference gene for normalisation in these experiments (Figure 2-1). 
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Figure 2-1. Average relative expression stability of reference genes. Of the panel of 12 
reference genes tested, relative stability in capture-fusion experiments (A) or stimulation of THP-
1 cells (B) was measured using the geNorm assay. The lower the geNorm M value, the greater 
relative stability in the experimental samples tested (calculated according to methods described 
by Hellemans et al 2007 [268]).  
B 
A 
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2.7 Generation of cell culture produced HCV (HCVcc) 
JFH-1 is a unique strain of HCV which can replicate in tissue culture, producing 
virions which are infectious to Huh-7.5 cells (HCVcc) [28, 99].  
 
A plasmid containing DNA reverse transcribed from the JFH-1 genome was kindly 
supplied by Dr John McLauchlan (University of Glasgow Centre for Virus 
Research, Glasgow, UK). Digestion and clean-up of the plasmid DNA, conversion 
of the excised DNA ends from sticky to blunt by mung bean nuclease treatment 
and transcription of JFH-1 DNA was performed as described in Section 2.6.6. 
 
2.7.1 Electroporation of transcribed JFH-1 RNA into Huh7.5 cells 
106 Huh7.5 cells were suspended in 400µL PBS and transferred to an 
electroporation cuvette. 10µL transcribed RNA was added to the cuvette, and 
electroporated in a BioRad electroporator set to a voltage of 270V and 
capacitance of 950µF. The electroporated cells were made up to 6mL with DMEM 
plus additives and split between 3 wells of a 6 well plate. They were maintained 
at 37˚C for up to 12 days. After the first 72 hours, the medium was changed every 
2-3 days and supernatants stored at -80˚C to provide HCVcc stocks. 
 
2.7.2 Quantification of HCVcc by RT-qPCR 
Supernatants from cells electroporated with JFH-1 RNA were filtered through 
0.45µM sterile filters to remove any cellular debris. Viral RNA was extracted from 
the supernatants using the QIAamp Viral RNA Mini Kit, as described in section 
2.5.5. 2µL of extracted, purified RNA was used as a template for in the RT-qPCR 
assay as described in section 2.5.7. The resulting HCV measurement was related 
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to the original supernatant by back-calculation and expressed as HCVcc 
copies/mL supernatant. 
 
2.7.3 Measurement of HCVcc infectivity by the 50% tissue culture 
infectious dose (TCID50) assay 
Due to the high error rate intrinsic in HCV replication, a substantial number of 
virions produced will be defective, or poorly infective/replicative. Therefore 
quantification of HCVcc by PCR is likely to overestimate the number of functional 
viral particles. An infectivity assay is more useful to quantify the infectiousness of 
the HCVcc produced. 
 
Huh7.5 cells were seeded into 96 well plates at a density of 3000 cells in 100µL 
per well. After overnight incubation at 37˚C, 50µL of supernatant containing 
HCVcc was added to each well in row A of the plate. After mixing, 50µL of the 
row A supernatant was transferred to row B, and so on to make serial 1 in 3 
dilutions of HCVcc down the plate. The plate was incubated at 37˚C for 72 hours, 
then the cells fixed by removal of supernatant and submersion of the plate in ice-
cold methanol for 20 minutes. For immunofluorescence staining, the fixed cells 
were washed 3 times by submersion of the plate in PBS. Primary antibody (sheep 
anti-NS5A) was diluted 1/5000 in PBS/1% FCS and 50µL added to each well for 
1 hour at room temperature. After 3 further washes in PBS, 50µL of secondary 
antibody (AlexaFluor 488 donkey anti-sheep, diluted 1/500 in PBS/1% FCS) was 
added per well and incubated in the dark at room temperature for one hour. The 
cells were washed in PBS 3 times. 50µL water was added per well for storage at 
4˚C in the dark until the cells were imaged. 
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For calculation of the TCID50, the plate was visualised using an Olympus 
Timelapse fluorescence microscope at 5x magnification. The number of wells 
with foci of HCV infection at each dilution of input supernatant were enumerated, 
and used to calculate the TCID50 using the formula devised by Reed and Muench 
[269]. 
 
2.7.4 HCV quantification in Huh7-J20 cells 
Huh7-J20 cells stably express a fusion protein comprising enhanced green 
fluorescent protein and secreted alkaline phosphatase (SEAP), linked by the 
HCV NS4A/NS4B cleavage site. In the presence of sufficient HCV replication, the 
enzymatic action of the HCV NS3/4A protease acts on the cleavage site to 
release SEAP into the supernatant. To quantify replication of JFH-1 using this 
technique, Huh7-J20 cells were seeded into a 96 well tissue culture plate at a 
density of 1x103 cells per well. After overnight incubation at 37̊C, the cells were 
infected in quadruplicate with JFH-1 at concentrations of 0.1, 0.2 or 0.3 
TCID50/well. The cells were then maintained at 37̊C for 72 hours.  
 
Quantification of SEAP in the cell supernatants was performed using the Great 
EscAPe chemiluminescent SEAP assay kit (ClonTech, Takara Bio Europe SAS, 
Saint-Germain-en-Laye, France). Supernatant was transferred from each well to 
a microcentrifuge tube and centrifuged briefly. 25 µL of each supernatant was 
transferred to a white 96 well plate. Each sample was tested in triplicate. 
Placental alkaline phosphatase (diluted 1/40) and plain medium (DMEM) were 
included as positive and negative controls, respectively. 75 µL 1x SEAP assay 
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Dilution Buffer was added to each well. The plate was sealed and incubated on 
a heat block for 30 minutes at 65̊C. The plate was cooled on ice for a few minutes 
then allowed to come to room temperature. 100 µL of SEAP Substrate Solution 
at room temperature was added to each well and the plates incubated at room 
temperature for a further 30 minutes before luminescence was read on a BMG 
FLUOstar Optima plate reader. To quantify replication of patient-derived HCV, 
Huh7-J20 cells were used in cell fusion experiments in place of Huh7.5 cells.  
2.5x105 fused cells/well were plated in triplicate per fusion in 12 well tissue culture 
plates. Medium was changed at day 3 and supernatants stored at -80̊C. 
Supernatants were also taken at day 5 post-fusion, at which time RNA was 
extracted from the cells using TRIzol, for subsequent confirmation of HCV RNA 
by RT-qPCR (as described in section 2.5.7). SEAP was measured in the day 3 
and day post-fusion supernatants, using the method described above. 
 
2.8 Enzyme-linked immunosorbent assay (ELISA) 
To identify HCV IgG (+), RNA (-) samples containing antibody with the greatest 
avidity for JFH-1, an ELISA was performed based on published methodology 
[270]. ELISA Immunosorb plates were coated with 50 µL/well galanthus nivalis 
agglutinin (5µg/mL diluted in bicarbonate buffer; Sigma-Aldrich) and incubated at 
37̊C for 2 hours. The wells were washed once with PBS/Tween (1 x PBS/0.05% 
Tween) then blocked overnight with 200 µL/well 5% milk in PBS/Tween. The 
following day, the plates were washed thrice with PBS/Tween. Lysed Huh7.5 cells 
infected with JFH-1 were diluted 1/50 in 5% milk/PBS/Tween and 50 µL applied 
to each well. Lysed 298T cells were included at the same concentration as a 
negative control. The plates were incubated at room temperature for 2 hours 
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before being washed thrice with PBS/Tween. Test sera were diluted 1/50 in 5% 
milk/PBS/Tween and 50 µL applied to each well. Each serum was tested in 
triplicate, and known HCV IgG (-) serum was included as a negative control. The 
plates were incubated at room temperature for 2 hours before being washed 5 
times with PBS/Tween. AP labelled goat anti-human IgG (Life Technologies) was 
diluted 1/500 in 5% milk/PBS/Tween and 50 µL added to each well. The plates 
were incubated at room temperature for 2 hours before being washed 5 times 
with PBS/Tween. 50 µL p-nitrophenyl phosphate substrate (Sigma-Aldrich) was 
added to each well, then incubated in the dark at room temperature for 30 minutes 
before luminescence was read at 405nm. The samples with greatest 
luminescence (and therefore greatest titre of antibodies to JFH-1 proteins) were 
used in subsequent experiments investigating antibody-mediated enhancement 
of JFH-1 entry into monocytes. 
 
2.9 Immunofluorescence 
Stimulated THP-1 cells or fused cells for immunofluorescence were seeded onto 
coverslips and grown for 3 to 5 days before fixation in 4% paraformaldehyde 
(PFA). After fixation, the cells were washed with PBS and permeabilised using 
PBS/0.2% Triton for 30 minutes at room temperature. They were washed again 
in PBS prior to blocking in PBS/10% FCS for 30 minutes at room temperature. 
After a further wash in PBS, primary antibody diluted in PBS/10% FCS was added 
for one hour at room temperature. Unbound primary antibody was removed by 3 
washes with PBS/0.05% Tween, each lasting 10 minutes. Secondary antibody 
diluted in PBS/10%FCS was then added for an hour in the dark at room 
temperature, followed by 3 further washes in PBS/0.05% Tween. The process 
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was repeated for immunostaining of a second target. When staining for HCV non-
structural proteins, replicon cells and uninfected Huh-7.5 cells were included as 
positive and negative controls. 
 
After staining, the coverslips were mounted on microscope slides using a drop of 
Vectashield mounting medium (Vector Laboratories Ltd, Peterborough, UK). The 
slides were stored at -20˚C overnight before imaging on an Olympus MM Leica 
Fluorescence microscope at 60x magnification.  
 
2.9.1 Antibodies used for immunofluorescence 
The primary antibodies used were sheep anti-NS5A (used at 1/5000; kind gift 
from Prof Mark Harris, University of Leeds) and rabbit anti-human albumin (used 
at 1/500; Dako UK Ltd, Ely, UK). The secondary antibodies used were AlexaFluor 
488 donkey anti-sheep (used at 1/500) and AlexaFluor 568 donkey anti-rabbit 
(used at 1/500; both from Life Technologies). 
 
2.10 Flow cytometry and fluorescence-activated cell sorting (FACS) 
2.10.1 Flow cytometry 
Flow cytometry was used to quantify receptor expression on stimulated and 
unstimulated THP-1 cells. THP-1 cells were incubated for 24 hours in medium 
alone (RPMI/2% FCS), medium plus PMA 200ng/mL, or medium plus PMA 
200ng/mL and IFNγ 10ng/mL. The cells were washed in PBS and adherent cells 
removed using a cell scraper. Viable cells were identified by trypan blue staining 
and 0.5x106 cells from each group transferred to each of 10 FACS tubes. The 
tubes were centrifuged at 1700rpm for 5 minutes, the supernatant discarded and 
106 
the cells resuspended in 1 mL ice-cold FACS buffer (PBS/5% FCS/0.5% sodium 
azide/0.9% EDTA). The cells were centrifuged again at 1700rpm for 5 minutes, 
the supernatant discarded, and the cells resuspended in 100 µL FACS buffer and 
incubated on ice for 1 hour. Appropriate primary antibody or isotype control was 
added to each tube, diluted where necessary in PBS/3% BSA. The tubes were 
incubated at 4̊C in the dark for 45 minutes. FACS buffer was added to each tube 
to a volume of 1mL and the tubes centrifuged at 1700rpm for 5 minutes. The 
supernatants were discarded and this wash step repeated twice more. The cells 
were resuspended in 100 µL FACS buffer and appropriate secondary antibody 
added to each tube, diluted in PSA/3% BSA where necessary.  The tubes were 
incubated at 4̊C in the dark for 30 minutes. Again, FACS buffer was added to 
each tube to a volume of 1mL and the tubes centrifuged at 1700rpm for 5 minutes. 
The supernatants were discarded and this wash step repeated twice more. 300 
µL 2% paraformaldehyde (PFA) was added to each tube and stored at 4̊C in the 
dark until analysis. 
 
Flow cytometry was performed using a BD FACS Canto II Flow Cytometer, in 
conjunction with Mr Gary Warnes (Blizard Institute Flow Cytometry Core Facility). 
Compensation limits were set with CompBeads (BD Biosciences, Oxford, UK) 
stained using the same protocol. 
 
2.10.2 Fluorescence activated cell sorting (FACS) 
FACS was employed in two separate experiments; firstly to separate CD14+, 
CD16- and CD14+ CD16+ monocyte subsets from infected patients for 
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subsequent fusion experiments, and secondly to isolate fused THP-1/Huh7.5 
from unfused cells prior to infection with JFH-1.  
 
To separate monocyte subsets, total PBMCs were obtained from an HCV-
infected patient, as described above. Cells were counted and transferred to a 
FACS tube, centrifuged at 1700rpm for 5 minutes. The supernatant was 
discarded and the cell pellet resuspended in 1 mL FACS buffer. This wash step 
was repeated twice. After the final wash, the cells were resuspended in 100µL 
FACS buffer and fluorescence-conjugated primary antibodies were added. After 
mixing, the cells were incubated at 4̊C in the dark for 20 minutes. FACS buffer 
was added to final volume 1mL and the cells were centrifuged at 1700rpm for 5 
minutes. The supernatant was discarded and this wash step was repeated twice. 
The cells were resuspended in 500 µL FACS buffer and sorted using a BD 
FACSAria Illu Cell Sorter, in conjunction with Mr Gary Warnes (Blizard Institute 
Flow Cytometry Core Facility). Compensation limits were set with CompBeads 
(BD Biosciences) stained using the same protocol. 
 
To separate fused from unfused cells, 5x106 THP-1 cells and 5X106 Huh7.5 cells 
were suspended in RPMI at a density of 106 cells/mL and incubated with the 
fluorescent membrane dyes DiI (THP-1) or DiO (Huh7.5; both from Life 
Technologies) at 2.5 µL/mL, at 37 ̊C in the dark for 20 minutes. The cells were 
centrifuged at 1200rpm for 5 minutes. After discarding the supernatant, the cells 
were resuspended in RPMI and this wash step repeated twice. 0.5x106 of each 
cell type were transferred to fresh FACS tubes in 0.5mL RPMI and used to set 
compensation limits for subsequent cell sorting. The remaining cells were fused 
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using the protocol described above. The fused cells were resuspended in 1mL 
RPMI/10%FCS and sorted, as described above, according to single or dual 
fluorescence. 
 
2.10.3 Antibodies used for flow cytometry/FACS 
The primary antibodies used were mouse anti-human CD81 (1.0µg/106 cells; BD 
Biosciences), mouse anti-human CD64 [10.1] (1.0µg/106 cells), mouse anti-
human CD32 [AT10] (1.0µg/106 cells; both from Abcam, Cambridge, UK) and 
rabbit anti-human SR-B1 (1/100; Novus Biologicals, Cambridge, UK). Isotype 
controls were mouse IgG1, ƙ isotype control (1.0µg/106 cells; Biolegend, London, 
UK), rabbit IgG isotype control (1/100; Novus Biologicals) and PerCP-Cy5.5-
conjugated mouse IgG1 (20 µL/106 cells; BD Biosciences). Secondary antibodies 
were FITC rat anti-mouse IgG (1.0µg/106 cells) and DyLight 488 Donkey anti-
rabbit IgG (1.0µg/106 cells; both from Biolegend). Fluorescence-conjugated 
primary antibodies were PerCP-Cy5.5-conjugated mouse anti-human CD16 and 
FITC-conjugated mouse anti-human CD14 (both used at 20 µL/106 cells; BD 
Biosciences). 
 
2.11 Statistical analyses 
Data were tested for normality using the D’Agostino and Pearson test. Analyses 
for statistical significance used Student t-test for parametric data or Mann-
Whitney U-test for non-parametric data. Analyses of correlation used Pearson r 
correlation coefficient for parametric data or Spearman rank correlation test for 
non-parametric data.  In all cases, p <0.05 was considered statistically significant.  
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3.0 Results: Replication of HCV in fused patient monocytes 
 
3.1 Introduction 
Many groups have reported that HCV associates with PBMCs in patients with 
chronic HCV infection, including monocytes, however whether this virus is viable, 
or replicates in these cells, has remained controversial [112, 116, 118, 132, 138, 
271-275]. At least some of this controversy stems from technical challenges 
inherent in detecting low level viral replication with techniques such as negative 
strand PCR and immunofluorescence (reviewed in [108]). We hypothesised that 
detectable viral replication would occur if monocyte-associated HCV was 
transferred to a more permissive environment. The Huh7.5 cell line was chosen 
as this is highly permissive to the HCV replicon and cell culture HCV strains [276, 
277]. Polyethylene glycol (PEG) causes fusion of cell membranes by exclusion 
of water molecules and is widely used in production of hybridomas for monoclonal 
antibody synthesis [278]. Previous work in our group found an increase in 
detectable HCV RNA over time after PEG-mediated fusion of patient monocytes 
with Huh7.5 cells, up to 7 days after fusion, suggesting viral replication in the 
fused cells. This work, performed by Dr Alia Javaid, established optimal fusion 
conditions which were used in fusion experiments described in this chapter 
(detailed in Chapter 2). This chapter describes the further development of this 
work, including development of a sensitive and specific PCR assay for HCV copy 
number quantification, fusion of monocytes infected with diverse viral genotypes 
and further proof of HCV replication by indirect immunofluorescence and drug 
inhibition. Viral replication after fusion implies presence of viable HCV in patient 
monocytes, and the biological significance of this as a mechanism for relapse 
after antiviral therapy is explored. 
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3.2 Development of a PCR assay for HCV quantification 
Initial experiments demonstrating an increase in HCV RNA after fusion by real-
time PCR used SYBR Green chemistry, a fluorescent dye which intercalates with 
double-stranded DNA and generates a fluorescence signal proportional to the 
amount of specific PCR product generated. These experiments quantified HCV 
RNA relative to beta actin expression. This PCR assay was useful in initial 
experiments, and demonstrated proof-of-principle in the fusion technique. 
However, quantification using SYBR Green is potentially limited at low copy 
number by non-specific product, such as primer dimer formation. Quantification 
of HCV RNA relative to B actin expression does not give a measure of viral 
replication which is easily comparable to other replication assays. To allow 
accurate quantification of HCV copy number in further fusion experiments, a 
sensitive and specific quantitative real time PCR assay was developed.  
 
To enhance sensitivity for detection of low-level viral RNA, a one-step reverse 
transcription-quantitative PCR (RT-qPCR) assay was employed using a 
commercial kit dedicated to detection of viral nucleic acids (details in chapter 2). 
To ensure specificity of PCR product amplification and detection, TaqMan 
chemistry using a commercial HCV primer and probe set was used (see chapter 
2). The addition of the target-specific probe diminishes the occurrence of non-
specific product causing a false positive signal, compared to use of SYBR Green 
reaction chemistry.  
 
Serial dilutions of a known copy number standard in each PCR reaction are 
required for reliable quantification of HCV copy number. An RNA standard was 
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therefore synthesised by transcription of JFH-1 RNA from a plasmid containing 
JFH-1 under a T7 promoter element (see chapter 2). The quantification range for 
the assay was 10-108 HCV copies per reaction and the RNA standard amplified 
with comparable efficiency to samples from fusion experiments, thus was suitable 
for quantification of HCV RNA in the experimental samples (Fig 3-1 A, B). 
Estimates of the intra-assay and inter-assay variation of the RT-qPCR assay 
were generated using standard RNA and expressed as percentage coefficient of 
variation for copy number (%CV) [279]. Intra-assay variation was calculated from 
results of PCR triplicates of the RNA standard dilution series in a single PCR 
experiment. Inter-assay variation was calculated from PCR duplicates of the RNA 
standard dilution series in 10 independent PCR experiments. The mean intra-
assay variation was 25.5%CV and the inter-assay variation was 20.6%CV (Fig. 
3-1 C). Intra-assay variation was similar for two separate experimental samples, 
where over 20 PCR replicates were performed per sample in a single PCR 
experiment (16.1%CV and 19.0%CV) (Fig 3-1 D). This degree of variation was 
deemed to be acceptable.  
 
Normalisation of PCR data is performed to control for differences between 
experimental samples, such as quantity of input RNA or efficiency of reverse 
transcription. When quantifying expression of cellular mRNA, results are usually 
normalised to expression of one (or more) reference genes which are stably 
expressed throughout the experimental conditions under investigation. However, 
quantification of viral RNA represents a rather different situation as viral RNA 
production does not necessarily bear any relation to expression of cellular mRNA. 
In these circumstances, standard practice [280] is to normalise viral RNA to 
112 
Template RNA per reaction (ng)
C
t
 v
a
lu
e
10- 1 0 10 - 5 100 105
0
10
20
30
40 Standard RNA
Fusion RNA
B
.
HCV RNA copies/reaction
C
t 
v
a
lu
e
100 101 102 103 104 105 106 107 108
0
10
20
30
40
A
.
Slope = -3.40 
Slope = -3.16 
number of input cells (if known) or total input RNA, measured using a robust 
method [279]. We chose to express HCV RNA as ‘copies per microgram total 
RNA’ as quantification of RNA is more accurate than cell counts in this 
experimental model as this approach avoids the problems associated with cell 
death in the traumatic fusion process. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-1. Validation of the RT-qPCR assay used for HCV quantification. A, standard curve 
obtained using serial dilutions of a HCV RNA standard. A quantification range of 10 – 108 copies 
per reaction was obtained. B, serial dilutions of RNA from a capture-fusion experiment were run 
in a PCR reaction alongside serial dilutions of the RNA standard. The difference between slopes 
was not significant (standard -3.40 ± 0.04, fusion -3.12 ± 0.18, p = 0.072), indicating comparable 
reaction efficiency between standard and experimental samples. Graphs A and B show mean ± 
s.d. of PCR triplicates per RNA dilution. C, intra-assay and inter-assay variation of the PCR assay, 
expressed as percentage coefficient of variation (%CV) of the HCV RNA copy number [3]. Intra-
assay variability was calculated from PCR triplicates of the RNA standard dilution series shown 
in A. Inter-assay variability was calculated from serial dilutions of RNA standard run in 10 separate 
PCR reactions. D, intra-assay variation was further defined using experimental samples. 22 
replicates of two samples of capture-fusion RNA were measured in a single PCR assay. Graph 
shows mean ± s.d. with intra-assay variation expressed as %CV for each sample. 
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3.3 HCV replication can be detected in monocytes from patients infected 
with diverse viral genotypes 
To establish whether the fusion technique could be used to identify viable HCV 
RNA in monocytes of patients infected with diverse viral genotypes, CD14(+) 
monocytes were isolated from 8 patients infected with genotype (G)1 HCV and 6 
patients with G3 HCV. Details of HCV subtype were not collected at the time of 
sampling and was not available retrospectively. HCV RNA was quantified at 
various times after fusion of these monocytes with Huh7.5 cells. An increase in 
HCV RNA was observed in the majority of samples tested (12 of 14), up to 7 days 
after fusion, suggesting viral replication. No increase in viral RNA was seen in 
patient monocytes cultured alone, or in monocytes co-cultured with Huh7.5 cells, 
without the fusion step, indicating that fusion is required for replication to occur 
(Fig 3-2). In most experiments the cultured cells reached confluence by day 7 
after fusion, most likely due to replication of unfused Huh7.5 cells. Fused cells 
did not survive passage, and so culture periods longer than 7 days after fusion 
were not studied. 
 
Prolonged PEG exposure is cytotoxic, and it is possible that fusion-related 
cytotoxicity could cause an artefactual increase in HCV RNA after fusion due to 
a relative reduction in cellular RNA. Cell viability experiments performed at 
various times after fusion confirmed a degree of PEG-induced cytotoxicity, 
however viability of fused cells increased over the incubation period, mirroring the 
rise in viral RNA seen. This suggested that PEG-induced cytotoxicity was not a 
significant contributor to the observed rise in HCV RNA (Figure 3-3). 
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p = 0.006 
A. p = 0.041 
Genotype 3 
B. 
C. 
Figure 3-2. HCV replication occurs in patient-derived monocytes fused with Huh7.5 
cells. A, B; 14 independent experiments demonstrating an increase in HCV RNA copy number 
after fusion in patients with chronic genotype 1 (subtype unknown) (A; N = 8) or genotype 3 
(B; N = 6) HCV infection. C, no evidence of HCV replication was seen when monocytes from 
3 of these patients were cultured alone or with Huh7.5 cells, without fusion. p values were 
calculated using Mann-Whitney U test. 
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3.4 Alternate strategies to detect HCV replication 
An increase in HCV RNA was seen in the majority of patient monocytes after 
fusion with Huh7.5 cells, suggestive of viral replication. Rather than the 
logarithmic increases in HCV RNA observed in propagation of cell culture HCV 
strains, we observed a 2-10 fold increase in viral RNA over 7 days after fusion, 
suggestive of low level viral replication (Fig 3-2 A,B). Further evidence of HCV 
replication was sought by using alternate techniques to demonstrate the 
presence of viral RNA or protein production in fused cells.  
 
3.4.1 Indirect immunofluorescence 
To complement the results demonstrating increased HCV RNA in fused cells over 
time after fusion, fused cells were examined for HCV protein production by 
**  
***  
***  
***  
Figure 3-3. Effect of cell fusion on viability of patient-derived monocytes and Huh7.5 
cells. An equal number of patient-derived monocytes and Huh7.5 cells were either fused or 
cultured together without fusion, in biological triplicates. Cell viability was measured after 
various lengths of time using a luminescent ATP quantification assay. Luminescence was 
measured in quadruplicate for each sample. Graph shows mean luminescence ± s.e.m., 
corrected for background. ** p = <0.01; *** p = <0.0001. Graph shows results from a single 
representative experiment. p values calculated using Mann-Whitney U test. 
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indirect immunofluorescence. Five days after fusion, cells were fixed and stained 
for the viral NS5A protein and albumin (a Huh7.5 cell marker). Huh7.5 cells 
infected with the HCV cell culture strain JFH-1, and uninfected Huh7.5 were 
included as positive and negative controls, respectively. In these experiments, 
viral NS5A appeared to co-localise in the cytoplasm with albumin, a Huh7.5 cell 
marker. However, in subsequent experiments including monocytes from 
uninfected donors fused with Huh7.5 as a negative control, NS5A staining was 
also identified. We speculated that this might be due to the high affinity of 
monocytic receptors, particularly FcR, for antibody binding. A number of alternate 
strategies and protocol variations were employed in an attempt to reduce this 
non-specific staining, including attempts to detect viral NS3, core and NS5A 
proteins and a variety of fixing and blocking steps (including use of Fc blockers; 
experiments performed in conjunction with Dr Meleri Jones, data not shown). 
Despite these measures, we were unable to eliminate non-specific staining, 
presumably due to antibody binding to Fc receptors on monocytes within the 
fused cells, and so were unable to conclusively demonstrate HCV protein 
production in the fusion model. 
 
3.4.2 Detection of protein production by Western blot 
Attempts were made to detect HCV NS3, core and NS5A proteins in fused cells 
by western blotting. Using a replicon containing cell line, HCV proteins could be 
detected from cell lysates using this technique (ranging from 10-50 µg total 
protein), but could not be detected in cell lysates from fused cells (Westen blot 
experiments performed by Dr Meleri Jones, data not shown). 
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3.4.3 Huh7-J20 reporter cell line 
A novel reporter cell line to detect and quantify HCV replication in cell culture has 
recently been described (Huh7-J20), consisting of Huh7 cells which stably 
express a fluorescent marker fused to secreted alkaline phosphatase (SEAP) via 
a sequence which is recognised and cleaved by HCV NS3/4A serine protease. 
In the presence of HCV replication and free HCV NS3/4 within the cellular 
cytoplasm, the recognition site is cleaved by NS3/4A and SEAP released into the 
supernatant, where it can be detected and quantified. The Huh7-J20 reporter cell 
line has been used to sensitively quantify replication of cell culture HCV (HCVcc) 
strains [281].  
 
The Huh7-J20 cell line was investigated to see if it could be used as an alternate 
detection technique for HCV replication in the fusion assay. Huh7-J20 cells were 
kindly supplied by Dr Arvind Patel (Centre for Virus Research, University of 
Glasgow). First, a serial dilution of positive control placental alkaline phosphatase 
was run in the SEAP detection assay to establish its linear range and sensitivity 
(Fig 3-4A). Huh7-J20 cells were then infected with JFH-1 at 3 separate dilutions, 
corresponding to concentrations detected by the reporter cell line in published 
work [281]. After 72 hours, supernatants were harvested for SEAP quantification. 
In parallel, total RNA was extracted from the infected Huh7-J20 cells for 
quantification of HCV RNA by RT-qPCR. A dose-dependent increase in SEAP 
was seen in supernatants from Huh7-J20 cells infected with increasing 
concentrations of JFH-1, and this mirrored a dose-dependent increase in HCV 
RNA detected from the cells by RT-qPCR (Fig 3-4 B, C). However, the lowest 
infectious dose of JFH-1 that was used produced HCV RNA levels approximately 
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10-fold greater than the highest yields achieved after cell fusion. To determine 
whether this assay detected replication in the fusion assay, patient monocytes 
were fused with Huh7-J20 cells. At various times after fusion, supernatants were 
removed to assay for SEAP and in parallel total RNA was extracted from the cells 
and HCV RNA quantified by RT-qPCR. Although an increase in HCV RNA was 
seen over time after fusion by RT-qPCR, no change above background was seen 
using the SEAP assay (data not shown). Thus whilst the Huh7-J20 reporter cell 
line could detect and quantify replication of ccHCV, it was not suitable for use as 
a tool to detect HCV replication after fusion of patient monocytes with Huh7.5 
cells.  
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Figure 3-4. Detection of JFH-1 replication by the Huh7-J20 cell line. A. Serial dilutions of 
placental alkaline phosphatase (ALP) positive control confirmed that luminescence was 
proportional to alkaline phosphatase over a wide linear range. B, SEAP activity detected as 
relative light units (RLU) 72 hours after infection of Huh7-J20 cells with JFH-1 at a range of 
infectious doses. ALP was included as a positive control at a dilution of 1/40. C shows the 
corresponding HCV RNA yield measured by RT-qPCR from Huh7-J20 cells infected with various 
doses of JFH-1 for 72 hours, after the supernatants had been removed to assay for SEAP. Graphs 
show mean ± sd of biological triplicates. Graphs each show results from a single representative 
experiment. R2 calculated using linear regression analysis. 
 
 
3.5 Enhancement of HCV replication by isolation of monocyte subsets for 
fusion  
Although a consistent increase in HCV RNA was seen after fusion of monocytes 
from most patients with chronic HCV, the level of replication remained relatively 
low and close to the quantification limit of the PCR assay. Human monocyte 
subpopulations can be categorised according to CD14 and CD16 expression 
[282]. Phenotype and function of these subpopulations is poorly characterised, 
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however one report has suggested that HCV infects both CD14+CD16++ and 
CD14++CD16++ cells, but not CD14+CD16- cells [271]. If so, isolation of the 
CD14+CD16+ subpopulation for fusion might enhance viral replication by 
enriching the population of infected monocytes for fusion. Total PBMCs from a 
patient with chronic HCV infection were labelled with fluorescence-conjugated 
anti-CD14 and anti-CD16 monoclonal antibodies. CD14+CD16- and 
CD14+CD16+ monocyte subsets were isolated by fluorescence activated cell 
sorting (FACS). Each cell population was fused with Huh7.5 cells and HCV RNA 
compared after 3 and 5 days. Due to the small number of cells in each population, 
further time points after fusion were not analysed. There was no significant 
difference in HCV RNA obtained 3 or 5 days after fusion of the CD14+CD16+ 
cells compared to CD14+CD16- cells (Fig. 3-5). Given that isolation of monocyte 
subpopulations for fusion did not significantly enhance HCV RNA replication, all 
further fusion experiments were performed using total monocytes. 
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Figure 3-5. Separation of monocyte subsets did not enhance HCV replication after fusion. 
CD14+CD16+ or CD14+CD16- monocytes were isolated from total PBMCs from a patient with 
chronic HCV infection by FACS. Each subpopulation was fused with Huh7.5 cells and HCV RNA 
quantified 3 and 5 days after fusion. Graph shows mean ± sd of biological triplicates from a single 
experiment. 
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3.6 HCV replication in fused cells is inhibited by antiviral drugs 
 
Inhibition of viral replication with a reduction of HCV RNA provides valuable 
confirmation of viral replication. Monocytes isolated from patients with chronic G1 
HCV infection were fused with Huh7.5 cells and then cultured in the presence of 
interferon α-2a (IFN) or the HCV protease inhibitor telaprevir. HCV RNA was 
quantified and compared with untreated cells at various time points after fusion. 
By day 7 after fusion, both antiviral drugs significantly reduced detectable HCV 
RNA compared to untreated cells, suggesting inhibition of viral replication (Figure 
3-6). 
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Figure 3-6. Inhibition of HCV replication in fused patient monocytes with antiviral drugs. 
Monocytes from 5 patients with chronic G1 HCV were fused with Huh7.5 cells, and cultured in the 
presence or absence of either interferonα-2a (IFN; patients A and B) or telaprevir (patients C, D 
and E) for up to 7 days. By 7 days after fusion significantly less HCV RNA was obtained from drug 
treated than untreated cells from all patients. Due to a low yield of monocytes, only day 7 data for 
IFN treated fused cells was available for patient B. Graphs show mean ± s.e.m of single 
independent experiments. All p values are for comparisons of drug treated and untreated cells at 
day 7 after fusion and were calculated using Mann-Whitney U test. 
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3.7 Viable HCV in patient monocytes at the end of treatment as a predictor 
of relapse  
Previous work in our group has demonstrated that when patients treated with 
pegIFN/ribavirin for chronic HCV infection relapse, this occurs rapidly after the 
end of treatment. Detectable viraemia is seen within a week of treatment 
cessation and viral load returns to pre-treatment levels within 4-6 weeks (Dania 
Shoeb, unpublished data). This is compatible with a model in which HCV persists 
in a sanctuary site during treatment, with rapid emergence and re-establishment 
of infection after withdrawal of therapy. Monocytes have been implicated as a 
sanctuary site for viral relapse in patients co-infected with HIV and HCV [146]. 
Given our findings that monocytes harbour viable HCV during chronic HCV mono-
infection, we hypothesised that monocytes may also act as a sanctuary site 
during treatment of mono-infected patients and may be associated with or 
responsible for relapse. This section describes experiments performed to test the 
hypothesis that the presence of viable HCV in patient monocytes at the end of 
therapy, detected using the fusion technique, predicts relapse in patients treated 
for chronic HCV infection.  
 
3.7.1 Predicting relapse in G3 HCV after treatment with pegylated 
interferon and ribavirin 
Patients with chronic G3 HCV infection who fail pegIFN/ribavirin treatment most 
often respond to therapy initially, but then relapse once treatment is withdrawn. 
This is in contrast to G1 HCV infection, where the more common pattern of 
treatment failure is primary non-response or partial response to pegIFN and 
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ribavirin (discussed in more detail in Chapter 1). Due to the higher rate of 
treatment failure due to relapse, patients with G3 HCV were selected for these 
experiments.  
 
PBMCs were taken from 18 sequential patients attending their end of treatment 
visit. All patients had completed a standard course of 24 weeks pegIFN/ribavirin 
treatment for chronic G3 HCV. CD14+ monocytes were isolated and fused with 
Huh7.5 cells. HCV RNA was quantified in unfused monocytes and at 3, 5 and 7 
days after fusion, in duplicate or triplicate, depending on the number of 
monocytes obtained. Treatment outcome information was obtained for each 
patient 6 months after the end of treatment, either relapse or sustained virological 
response (SVR).  
 
Patient demographics are shown in Table 3-1, according to treatment outcome. 
Participants were predominantly female in both groups. Relapsers were older 
with slightly greater fibrosis scores than patients with SVR. Two of the patients 
who relapsed (33%) had biopsy-confirmed cirrhosis whilst none of the patients 
with SVR were cirrhotic. Pre-treatment viraemia did not differ between the groups. 
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SVR (N = 12) Relapse (N = 6) p value 
Female:Male 
 
8:4 4:2  
Age (years) 
 
41.5 (28 – 50) 54.5 (41 – 63) 0.019 
Pre-treatment  
viral load (IU/mL) 
 
4.16x105 (6.95x104 
– 1.45x107) 
2.23x105 (1.18x104 
– 6.93x106) 
0.815 
Fibrosis score 
 
1 (0 – 3) 3.5 (1 – 6) 0.041 
 
Table 3-1. Baseline characteristics of patients submitting end-of-treatment monocytes, 
according to ultimate treatment outcome. Fibrosis score was expressed using the Ishak 
scoring system. Values are given as median (range). SVR, sustained virological response. P 
values were calculated using Student’s t-test. 
 
 
HCV RNA obtained from fused cells was compared between patients with SVR 
and those with relapse. Results were compared at baseline (unfused monocytes) 
and 5 days after fusion to determine whether or not viral replication (as evidenced 
by an increase in HCV RNA) occurred. The change in HCV RNA from day 0 to 
day 5 after fusion was significantly greater in patients who relapsed than patients 
with SVR (expressed as % change to normalise for variability in baseline HCV 
RNA between samples; Fig 3-7A). HCV RNA increased from day 0 to day 5 after 
fusion in fused monocytes from patients who relapsed, although this did not reach 
statistical significance in this small number of samples. Similarly, HCV RNA 
decreased after fusion in fused monocytes from patients who achieved SVR, 
although again this did not reach statistical significance (Fig 3-7B, C). 
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Figure 3-7. Fusion of end of treatment monocytes according to treatment outcome. End-of-
treatment monocytes from patients with G3 HCV treated with pegIFN/ribavirin were fused with 
Huh7.5 cells and HCV RNA quantified at Day 0 and Day 5 post-fusion. The percentage change 
in HCV RNA from Day 0 to Day 5 post-fusion was significantly greater amongst fused monocytes 
from relapsers than from patients with SVR (A). HCV RNA declined over time after fusion of 
monocytes from patients who achieved SVR (B; N = 12), and increased after fusion of monocytes 
from patients who relapsed (C; N = 6), although these changes did not reach statistical 
significance in this small cohort of patients. P values were calculated using Mann Whitney U test. 
 
 
3.7.2 Predicting relapse in G1 HCV after treatment with sofosbuvir and 
ribavirin 
Sofosbuvir is a nucleotide analogue inhibitor of HCV RNA-dependent RNA 
polymerase which has shown potent anti-HCV activity in clinical trials and has 
recently been licensed for treatment of chronic HCV (discussed in more detail in 
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chapter 1). Clinical trials of sofosbuvir in chronic G1 HCV have shown high 
efficacy when this drug is combined with pegIFN and ribavirin [205, 206, 238], 
but a significant rate of relapse when given with ribavirin alone [235].  
 
To investigate whether monocytes could act as a sanctuary site for HCV during 
sofosbuvir and ribavirin treatment, stored, end of treatment PBMCs were kindly 
supplied by Dr Shyam Kottilil (NIH, Bethesda) from 8 patients with G1 HCV who 
had received sofosbuvir/ribavirin in a clinical trial, with differing treatment 
outcomes (4 patients who achieved SVR and 4 who relapsed). CD14+ monocytes 
were isolated and fused with Huh7.5 cells. As these patients had not received 
interferon, the monocyte yield was generally high and sufficient cells were 
obtained to measure HCV RNA up to 7 days after fusion. HCV RNA yield over 
time after fusion was compared between patients with SVR and those who 
relapsed. Regardless of treatment outcome the yield of HCV RNA decreased 
over time after fusion, with no significant difference between samples from 
patients with SVR and relapse after sofosbuvir/ribavirin therapy (Fig 3-8). This 
suggests absence of viable HCV associated with monocytes at the end of 
treatment, and that HCV sequestration in monocytes during sofosbuvir/ribavirin 
therapy is not a mechanism for relapse in these patients. 
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SVR (N = 4) A 
Relapse (N = 4) B 
C 
p = 0.33 
D 
p = 0.62 
Figure 3-8. Absence of viable HCV in monocytes at the end of treatment in patients with 
G1 HCV treated with sofosbuvir and ribavirin. CD14+ monocytes were isolated from end 
of treatment PBMCs from 4 patients with SVR and 4 patients who relapsed after sofosbuvir 
and ribavirin treatment in a clinical trial. After fusion with Huh7.5 cells, HCV RNA was 
quantified at days 0, 3, 5 and 7 post-fusion and compared between patients with SVR (A) and 
relapse (B). There was no significant difference in the change in HCV RNA from day 0 to day 
5 (C) or day 0 to day 7 after fusion (D) between patients with different treatment outcomes. 
Graphs each show mean ± s.e.m. of 4 independent experiments. P values were calculated 
using Mann Whitney U test. 
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3.8 Discussion 
This chapter builds on previous work from our group, in which a technique for 
fusion of patient-derived monocytes with Huh7.5 cells was developed and 
optimised as a means to detect HCV replication. Development of a highly 
sensitive and specific quantitative real time PCR technique allowed quantification 
of low level HCV RNA copy number. This was used to document an increase in 
HCV RNA over time after fusion, as well as inhibition of this increase by antiviral 
drugs, both of which are suggestive of HCV replication after fusion.  
 
Technical difficulties in detection of HCV RNA at low copy number have long been 
recognised as a challenge to investigation of extrahepatic HCV replication using 
other techniques, such as negative strand PCR or core antigen assay [283]. 
These techniques were not attempted in view of technical difficulty and poor 
sensitivity (for example, the sensitivity of negative strand PCR has been reported 
by various authors to be 10-1000 fold less than that of the positive strand assay; 
reviewed in [108]), as even after cell fusion the level of HCV replication remained 
low. Instead, presence of replicating virus has been strongly suggested by 
increase in viral RNA over time which was inhibited by treatment of the fused 
cells with antiviral drugs. Together, these data suggest that the fusion technique 
complements existing literature on detection of HCV in extrahepatic sites and 
support the presence of replication competent HCV RNA associated with 
monocytes from patients with chronic HCV infection.  
 
Attempts to use alternate techniques to demonstrate and quantify HCV 
replication after fusion (Western blotting, indirect immunofluorescence and the 
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Huh7-J20 reporter cell line) were unsuccessful. The most likely explanation is 
that these techniques were insufficiently sensitive to detect HCV RNA in the 
fusion model. Using Western blotting, HCV proteins could be detected in extracts 
from replicon cells, which support high level viral replication, but the signal was 
lost when the cell extracts were diluted to a level approximating the HCV yield 
seen in the fusion experiments. Detection of HCV proteins by indirect 
immunofluorescence in fused cells was complicated by persistent non-specific 
background staining, attributed to high avidity of monocytes for antibody binding. 
The Huh7-J20 cell line has been noted to be less permissive for HCV replication 
than the parent cell line [281], which may have a significant impact on 
comparatively low-level replication seen after fusion. Alternatively, as this cell line 
has been reported to be as sensitive as RT-qPCR for detection of HCVcc [281], 
it is possible that virus transferred to Huh7-J20 cells by cell fusion is masked from 
the SEAP reporter construct, for example in an alternate intracellular 
compartment. At present, the low level of HCV replication after fusion has 
precluded investigation of its subcellular localisation but this represents an area 
for further study.  
 
Attempts were made to enhance HCV replication after fusion, in particular by 
isolating the CD14+CD16+ monocyte subpopulation which has been suggested 
to be preferentially infected with HCV [271]. Following fusion, no difference was 
seen in the yield of HCV RNA from CD14+CD16+ or CD14+CD16- monocytes. 
These discordant findings could be explained by differences in the detection 
systems used. The paper reporting absence of positive strand HCV RNA in 
CD14+CD16- monocytes used a sensitive in situ hybridisation technique to detect 
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HCV RNA in patient monocytes [271], but it is difficult to establish how sensitive 
this assay was in comparison to the RT-qPCR assay used in the fusion 
experiments. It is possible that viable HCV RNA present at a very low level in 
CD14+CD16- monocytes may not have been detected by this in situ hybridisation 
technique. Even if present at lower levels initially, following fusion with Huh7.5 
cells, replication of viable HCV present in this subpopulation may have “caught 
up” with that of virus in CD14+CD16+ cells, especially if other blocks to viral 
replication in fused cells created a ceiling for replication. The very small number 
of monocytes obtained in each subpopulation after cell sorting meant that no 
unfused monocyte RNA was available for HCV RNA quantification to explore this 
possibility further. 
 
PEG has been used to induce cell fusion for over 3 decades [278] and is 
established as a method of combining cell characteristics in generation of 
hybridomas. The method by which PEG induces cell membranes to fuse is 
incompletely understood, but is thought to involve exclusion of water molecules 
from membranes at areas of close contact [278]. Cell fusion techniques have 
been employed by others to investigate extrahepatic HCV replication [284]. 
However, cell fusion has not previously been used to facilitate replication of 
patient-derived HCV. We found that transfer of HCV associated with patient 
monocytes to Huh7.5 cells by cell fusion facilitated replication. Whether this was 
due to removal from an environment rich in restriction factors, or transfer to an 
environment containing permissive factors, or both, has not been established. 
The presence of dominant restriction factors has been excluded as the primary 
block on HCV replication in certain non-permissive human or murine cells [284], 
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however data on monocytes is lacking. The Huh7 hepatoma cell line is uniquely 
permissive for HCV replication, especially Huh7.5 cells which were generated by 
curing a highly permissive Huh7 subclone [276]. The factors underlying the 
permissiveness of Huh7.5 to HCV replication are not fully understood, but are 
thought to include defective innate anti-viral signalling (in particular RIG-I 
signalling) [285] and presence of the liver-specific microRNA miR-122, which 
appears critical for efficient HCV replication [55].  
 
The observation that HCV replication occurs after fusion of patient monocytes 
with Huh7.5 cells implies that monocytes of patients with chronic HCV infection 
harbour viable HCV. Whether this monocyte-sequestered virus may be 
responsible for relapse after cessation of antiviral therapy had not previously 
been examined in HCV mono-infected patients. Relapse was the predominant 
mechanism of treatment failure amongst patients with G3 HCV treated with 
pegIFN/RBV and also amongst patients with G1 HCV treated with 
sofosbuvir/RBV. The presence of viable HCV in end-of-treatment monocytes 
appeared to be associated with relapse amongst G3 patients treated with 
IFN/RBV, but not G1 patients treated with sofosbuvir and ribavirin. Whether this 
discrepancy is due to genotypic differences or to the treatment regimen would 
require further study of patients with G1 HCV treated with pegIFN/RBV, and 
patients with G3 infection treated with sofosbuvir/RBV. This may be difficult to 
achieve in practice as the standard of care for G1 patients moves away from 
pegIFN/RBV alone to regimens containing new antiviral agents, and as interferon 
is recommended together with sofosbuvir/RBV  for patients with G3 infection 
[155]. It is interesting to note that although no indication of viable HCV RNA was 
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found in monocytes from patients treated with sofosbuvir and ribavirin, the 
amount of HCV RNA detected by the PCR assay was considerably higher than 
that detected from G3 patients treated with pegIFN/RBV. The reasons for this 
could be multifactorial, relating to storage of samples, some differences in 
reagents used (G1 experiments were performed at the NIH laboratories in 
Bethesda, although the extracted RNA was shipped to London for HCV 
quantification). Genotypic differences are also possible, although less likely as 
this was not observed amongst patients infected with chronic HCV of different 
genotypes. It is possible that IFN treatment may have enhanced uptake and 
degradation of non-viable HCV virions or RNA fragments by monocytes and other 
immune cells and following IFN-free therapy, this viral detritus remains 
detectable. Although these results suggest that monocytes may act as a 
sanctuary site in G3 patients treated with IFN/ribavirin, the lack of viable HCV 
associated with monocytes of patients who relapsed after sofosbuvir/RBV 
therapy suggests that other mechanisms are involved in relapse after therapy 
and other sanctuary sites may be as, or more, important. Alternatively, it remains 
possible that sofosbuvir-resistant HCV does persist in monocytes of patients who 
relapsed at the end of therapy, but this virus is poorly replication-competent and 
so could not be detected in the fusion model, which supports low-level viral 
replication at best. 
 
Sequencing of sequestered virus in monocytes and comparison with viral 
sequences present in serum before treatment/after relapse would provide further 
insights into the role of HCV RNA detectable in end of treatment monocytes in 
relapse. Unfortunately, extensive attempts to sequence HCV RNA from 
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monocytes of G3 patients at the end of treatment and after fusion unsuccessful, 
most likely due to the relatively low yield of HCV RNA obtained (experiments 
performed by Dr Jenny Waters). With the development of novel sequencing 
technologies, it should be possible to investigate this further in the near future. 
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4.0 Results: Development of a “capture-fusion” model to study replication 
of patient-derived HCV 
4.1 Introduction 
Our observation that patient monocyte-associated HCV could be induced to 
replicate in culture, and inhibited with antiviral drugs, led us to question whether 
this model could be used to assess patient-specific responses to novel antiviral 
therapies. However there are several practical limitations to the use of patient-
derived monocytes for this purpose. For example, a relatively large volume of 
blood is required from each patient, the yield of cells is relatively low, and sample 
storage and opportunities to share samples between laboratories are limited. For 
these reasons we sought an approach which would enable use of patient serum 
instead of monocytes. This chapter describes development of a “capture-fusion” 
assay, in which virus from patient serum is captured by a monocytic cell line 
before fusion with Huh7.5 cells and quantification of HCV RNA. 
 
4.2 Investigation of candidate monocytic cell lines 
HCV infection or association with a number of monocytic cell lines has been 
reported [123, 286, 287]. The monocytic cell lines THP-1 and Monomac 1 were 
selected for initial evaluation for their ability to capture HCV from patient serum. 
 
4.2.1 Comparison of HCV capture by THP-1 and Monomac-1 cells 
THP-1 is a human monocytic cell line derived from peripheral blood of a 1 year 
old male infant with acute monocytic leukaemia [265] that has been used to study 
replication of another Flavivirus, Dengue virus, in vitro [288]. MonoMac 1 is a 
human monocytic cell line derived from the peripheral blood of a patient with 
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acute peripheral monoblastic leukaemia [289], which has been used as a model 
system for HIV replication [290]. It has previously been reported that uptake of 
HCV immune complexes into another monocyte cell line (U937) was enhanced 
by pre-exposure of the cells to a combination of PMA and IFNγ [123]. In initial 
experiments, THP-1 and MonoMac-1 cells were pre-stimulated with PMA and 
IFNγ. Empirically determined concentrations of PMA/IFNγ were used, based on 
published work [123]. Cells were cultured in the presence or absence of 
PMA/IFNγ for 24 hours before thorough washing. After 24 hours of exposure to 
PMA/IFNγ, THP-1 cells became adherent to the bottom of the well and no further 
proliferation was seen. In contrast, MonoMac 1 cells remained in suspension but 
aggregated in large clusters. After removal of stimulants, the cells were exposed 
to patient serum for 24 hours, then washed again and HCV RNA measured at 
various times. Viral association with both THP-1 and MonoMac 1 cells was 
significantly enhanced by stimulation (Fig. 4-1). However, HCV RNA detectable 
by RT-qPCR declined over time after exposure, implying absence of viral 
replication in these cells regardless of PMA/IFNγ stimulation (Fig 4-1). As the 
MonoMacs aggregated after PMA/IFNγ stimulation, this made them unsuitable 
for downstream fusion experiments. Further experiments were therefore 
performed with THP-1 cells only.  
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Figure 4-1. HCV does not replicate in monocytic cell lines, but viral association is 
enhanced by pre-stimulation with PMA/IFNγ. THP-1 (A) or MonoMac1 cells (B) were cultured 
with PMA (200ng/mL)/IFNγ (10ng/mL) or in the absence of stimulants for 24 hours, then incubated 
with HCV (+) patient serum for 24 hours. HCV RNA was quantified from the cells up to 5 days 
after HCV exposure. Graphs show mean ± s.d. of single representative experiments. P values 
were calculated using Mann Whitney U test.  
 
 
 
4.2.2 IFNγ enhances HCV association with THP-1 
IFNγ is a cytokine component of the innate antiviral immune response, and would 
be expected to prime intracellular antiviral responses and potentially inhibit 
subsequent HCV infection of monocytes. However, IFNγ has also been reported 
to potentiate uptake of HCV immune complexes into monocytic cells [123]. HCV 
uptake/association with THP-1 was compared after no stimulation, PMA alone, 
IFNγ alone or PMA with IFNγ. The combination of PMA and IFNγ led to greatest 
association of HCV with the cells (Fig. 4-2). Given these findings, stimulation with 
both PMA and IFNγ was used in all further experiments. 
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Figure 4-2. Association of patient-derived HCV with THP-1 was enhanced by pre-
stimulation with PMA and IFNγ. THP-1 cells were incubated with PMA (200ng/mL), IFNγ 
(10ng/mL) PMA (200ng/mL) and IFNγ (10ng/mL) or no stimulants for 24 hours, prior to incubation 
with HCV (+) patient serum for 24 hours then quantification of HCV RNA. Graph shows mean ± 
sem of results from 3 independent experiments. P value was calculated using Student’s t-test. 
 
 
4.2.3 Patient-derived HCV is internalised into THP-1 cells 
Pre-treatment of THP-1 with PMA/IFNγ enhanced HCV RNA association after 
exposure to patient serum. To investigate whether the HCV RNA was internalised 
into THP-1, PMA/IFNγ-stimulated THP-1 cells were treated with trypsin at various 
times after exposure to patient serum (experiments performed in conjunction with 
laboratory technician Joseph Davidson-Wright). Viral internalisation occurred 
between 1 and 4 hours after exposure to serum, as by 4 hours a proportion of 
viral RNA could not be removed by trypsin. The proportion of internalised virus 
did not increase significantly between 4 and 24 hours of infection, indicating that 
uptake was close to maximal by 4 hours after exposure (Fig. 4-3). These 
experiments suggested that a minority of HCV RNA was internalised 
(approximately 20% at 24 hours after exposure), whilst the majority remained at 
the cell surface. 
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Figure 4-3. Internalisation of HCV RNA by pre-stimulated THP-1 cells. THP-1 cells were 
incubated with PMA (200ng/mL) and IFNγ (10ng/mL) for 24 hours, before exposure to HCV (+) 
patient serum. Cells were treated with trypsin at 1, 4 or 24 hours after infection and HCV RNA 
quantified immediately after. p = 0.029 for the comparison between trypsin treated cells at 1 hour 
and 24 hours after infection. Graph shows mean ± s.d. of a single representative experiment. P 
value was calculated using Mann Whitney U test. 
 
 
4.3 Replication of patient-derived HCV associated with THP-1 after fusion 
with Huh7.5 cells 
Analogous to the experiments on fused patient monocytes (chapter 3), we 
hypothesised that patient-derived HCV associated with THP-1 cells was viable 
and could be induced to replicate by transfer to a more permissive environment, 
by fusion with Huh7.5 cells. Again, we sought evidence of HCV replication by viral 
RNA accumulation after fusion, inhibition with antiviral drugs, and demonstration 
of HCV protein production. 
 
4.3.1 HCV RNA accumulation after fusion suggests viral replication 
To investigate whether patient-derived HCV RNA associated with THP-1 would 
replicate after fusion with Huh7.5 cells, THP-1 were stimulated with PMA/IFNγ for 
24 hours before thorough washing and incubation with patient serum for 24 hours. 
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After further washing, these cells were fused with Huh7.5. The hybrid cells were 
maintained in culture for up to 5 days before quantification of HCV RNA. As 
controls, Huh7.5 cells and PMA/IFNγ stimulated THP-1 cells were independently 
incubated with serum from the same patient for 24 hours, then washed thoroughly 
and maintained in culture in parallel with the fused cells. An increase in HCV RNA 
was seen over time after fusion, which was not observed in HCV-exposed 
unfused THP-1 or Huh7.5 cells (Fig. 4-4), suggesting that replication of HCV RNA 
occurred after capture from patient serum by THP-1 cells and fusion with Huh7.5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-4. Replication of patient-derived HCV after fusion of HCV-exposed THP-1 with 
Huh7.5 cells. THP-1 were pre-stimulated with PMA 200ng/mL/IFNγ 10ng/mL before exposure to 
patient serum for 24 hours then fusion with Huh7.5. In parallel, stimulated THP-1 and Huh7.5 cells 
were exposed to patient serum and maintained in culture without fusion. HCV RNA was quantified 
from the cells up to 5 days after fusion. Graph shows mean ± s.e.m of a results from a single 
representative experiment. p = 0.019 for the comparison between fused THP-1/Huh7.5 at day 0 
and day 5 after fusion, calculated using Mann Whitney U test.  
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4.3.2 Antiviral drugs inhibit HCV replication after fusion 
Although an increase in HCV RNA was observed after fusion of pre-stimulated, 
HCV-exposed THP-1 with Huh7.5, the rise was modest. To provide further 
evidence that this rise reflected low-level replication of patient-derived HCV, the 
hybrid cells were treated with antiviral drugs after fusion. Initial experiments 
compared HCV RNA 5 days after fusion where the hybrid cells had been cultured 
in the presence or absence of interferon α-2a (IFN), or the cyclophillin inhibitor 
alisporivir. HCV RNA yield 5 days after fusion was significantly reduced by IFN 
or alisporivir treatment (Fig. 4-5), suggesting inhibition of viral replication by 
antiviral drugs in the fused cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-5. HCV yield 5 days after fusion of HCV-exposed THP-1 with Huh7.5 is reduced by 
treatment with antiviral drugs. Fused cells were treated with IFN 100IU/mL, alisporivir 1.0µM, 
or no drugs for 5 days after fusion prior to quantification of HCV RNA. Graph shows mean ± 95% 
CI of results from 2 independent experiments, expressed as percentage of untreated cells to 
normalise for differences in RNA yield between samples. P values were calculated using 
Student’s t-test. 
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4.3.3 Indirect immunofluorescence 
To provide further evidence to support HCV replication after fusion using a 
technique other than PCR, fused cells were examined for HCV protein production 
by indirect immunofluorescence. Hybrid cells were fixed and stained for the viral 
NS5A protein and albumin (a Huh7.5 cell marker) 5 days after fusion. Huh7.5 
cells infected with the HCV cell culture strain JFH-1 and uninfected Huh7.5 were 
included as positive and negative controls, respectively. In these experiments, 
viral NS5A appeared to co-localise in the cytoplasm with albumin, a Huh7.5 cell 
marker, suggesting viral replication in fused cells. However, similar to 
experiments using patient-derived monocytes in cell fusion (see chapter 3), a high 
level of non-specific background staining was seen when uninfected THP-1 fused 
with Huh7.5 were used as a negative control. Again, this was thought to be due 
to the high affinity of monocytic receptors, particularly FcR, for antibody binding. 
As the level of HCV replication detectable by RT-qPCR was higher in experiments 
using patient-derived monocytes in fusion than THP-1, and strategies to eliminate 
background staining had been unsuccessful in those experiments, further 
attempts to eliminate background staining in THP-1 fusion experiments were not 
made. 
 
4.3.4 Exclusion of contamination by laboratory HCV strains by sequencing 
To exclude contamination by laboratory strains, particularly the high-replicating 
G2 strain JFH-1, a 265-base region of the HCV 5’UTR from capture-fusion 
experimental RNA was cloned and sequenced. Details of the methods used are 
given in Section 2.6.8. Briefly, cDNA derived from RNA samples from 2 separate 
capture-fusion experiments using G1a donor serum was amplified by PCR using 
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a high-fidelity reverse transcriptase and PCR primers designed specific to the 
reference G1a strain H77. Small aliquots of the PCR product were run on a 1% 
agarose gel. Although no bands was seen in the experimental samples, a band 
was present in the positive control reaction and the lack of visible band in the 
experimental samples was thought to be likely to be due to low level of PCR 
product present. A second round of PCR was not performed due to concerns 
regarding introduction of contamination. After purification and concentration of 
the PCR reaction product, this was introduced into TOPO vectors and 
subsequently into E.coli by chemical transformation. Using ampicillin selection, 
colonies of E coli containing the vector were grown on agar plates. Multiple (over 
50) bacterial colonies were obtained per plate, and 10 colonies (2 from each of 5 
agar plates) were isolated and further amplified by growth in ampicillin-containing 
broth. The resulting DNA was isolated, purified and quantified, then subjected to 
an Eco-R1 digest to confirm presence of an appropriately-sized insert, 
representing the cloned HCV 5’UTR sequence. Of the 10 clones, 7 contained a 
265-base insert which was visible after electrophoresis on a 1% agarose gel. It 
was not possible to check the orientation of the PCR product within the plasmid 
by restriction enzyme analysis as no suitable single cut site in the plasmid and 
product could be identified. Therefore each sample containing an appropriately-
sized insert on Eco-R1 digestion was sent for Sanger sequencing (performed by 
Source Bioscience, Nottingham, UK) using both T3 and T7 primers. Sequences 
obtained were aligned with the 5’UTR of the G1a reference sequence H77 and 
JFH-1 (obtained from the European HCV Database) using BioEdit Sequence 
Alignment Editor software. Once the correct orientation was established, all 
seven  clones aligned with the 5’UTR region of the G1a reference strain H77, but 
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not with JFH-1. These results confirmed that output HCV RNA from capture-
fusion experiments reflected replication of the input virus, rather than 
contamination by infectious laboratory strains. 
 
4.4 Quantifiable replication of most viral isolates in the capture-fusion 
assay 
A total of 81 viral isolates were tested in the experiments described in this chapter 
and in chapter 5. Clinical characteristics of participants are summarised 
according to genotype in Table 4-1, and listed in full in Appendix 1. HCV RNA 
could be detected at quantifiable levels (>10 copies/reaction) after fusion in 65 
(80%) (Fig 4-6). Of the remaining 16 samples, 10 were archived (3 to 7 years old) 
and may have degraded during storage. Six other samples produced HCV RNA 
levels above the level of detection but below the level of quantification in repeated 
experiments. 
 
Genotype (N) 1 (29 ) 2 (3) 3 (35) 4 (8) 5 (3) 6 (3) 
Number of  
participants 
with data 
available 
26 
(G1a:G1b 
20:6) 
3 
27 
(G3a:G3b 
23:4) 
3 0 3 
M:F 18:8 3:0 16:9 0:3  2:1 
Age (median, 
range) 
57 (34-69) 
53.5 (49-
59) 
52 (23-
75) 
47  
(44–48) 
 
51.5 
(41-62) 
ALT (median, 
range) 
59 (12-280) 
127 (22-
253) 
109 (29-
254) 
50  
(36–88) 
 
80.5 
(14-
147) 
Viral load (x106 
IU/mL; median, 
range) 
6.28 (4.2-
7.19) 
6.30 
(5.41-
6.46) 
6.23 
(41.9-7.1) 
5.45  
(3.65 – 
5.79) 
5.39 
(4.22-
6.24) 
6.22 
(5.97-
6.38) 
Fibrosis score 3 (1-6) 6 (0-6) 5 (1-6) 0  1 
 
Table 4-1. Summary of clinical characteristics of patients with chronic HCV who donated 
serum samples for capture-fusion experiments. Total number of participants per genotype is 
given in the top row. The second row refers to the number of participants for whom clinical data 
was available. Full clinical information was not available for 3 G1 samples supplied by The Royal 
Free Hospital, 8 G3 samples supplied by Janssen Virology, 5 G4 samples supplied by Dr Hadeel 
Gamal (Cairo) and 3 G5 samples supplied by King’s College Hospital. Viral load was available for 
all samples. M:F, male:female; ALT, alanine aminotransferase. 
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4.4.1 Diverse viral genotypes replicate in the capture-fusion assay 
Initial experiments were performed using serum from donors infected with G1 and 
G3 HCV, as these genotypes predominate in the UK. To investigate whether HCV 
of all known viral genotypes would replicate in the capture-fusion model, serum 
samples were obtained from patients infected with less common viral genotypes 
(2, 4, 5 and 6). Samples were tested in the capture-fusion assay, as described in 
Section 4.3.1, and HCV RNA quantified 5 days after fusion. Although the level of 
replication varied from patient to patient, there were no consistent differences 
between genotypes and HCV RNA from isolates of all genotypes could be 
quantified 5 days after fusion (Fig. 4-6). 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-6. HCV RNA can be detected 5 days after fusion in most capture-fusion 
experiments. HCV RNA was quantified 5 days after fusion in capture-fusion experiments using 
serum from 58 donors infected with diverse HCV genotypes. Samples which were above the limit 
of detection but below the level of quantification at day 5 are in grey. Each point represents mean 
HCV RNA from at least 4 biological replicates per patient sample. 
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To confirm replication of patient-derived isolates of different genotypes in the 
assay, fused cells were treated with a range of concentrations of telaprevir.  A 
dose-dependent reduction in viral RNA was seen in capture-fusion experiments 
with all viral genotypes except G3, which is known to be poorly sensitive to 
telaprevir. Representative examples are shown in Figure 4-7. 
  
147 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-7. Telaprevir inhibited replication of patient-derived HCV of diverse viral 
genotypes in the capture-fusion assay. In separate experiments, THP-1 cells pre-stimulated 
with PMA/IFNγ were exposed to serum from patients with HCV genotypes 1-6 prior to fusion with 
Huh7.5. All G1 samples were from donors infected with G1a. Fused cells were treated in 
quadruplicate with a range of telaprevir doses for 5 days before HCV RNA quantification. HCV 
RNA in drug treated wells was calculated as a percentage of that in untreated wells, and dose-
response curves constructed for each experiment. These were used to calculate a 50% inhibitory 
concentration for telaprevir (IC50) for each experiment. Each graph shows mean ± s.e.m. for an 
experiment using serum from a single donor infected with each genotype. 
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4.4.2 HCV replication is independent of clinical features and is consistent 
for a given sample 
HCV RNA yield in the assay varied between samples, but did not relate to donor 
viral load, fibrosis score or disease activity (Fig. 4-8 A-C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-8. HCV RNA yield in the capture-fusion assay is independent of donor clinical 
features. Replication in the capture-fusion assay did not correlate with donor viral load (A), 
fibrosis score (B) or ALT (C). Replication is given as mean HCV RNA measured at day 5 post-
fusion for each patient. Data are given for all patients where viral load, fibrosis score and ALT 
were available at the time of sampling. Fibrosis score was measured histologically using the 
Ishak scoring system. Correlations and p values were calculated using Pearson r correlation 
coefficient for parametric data or Spearman rank correlation test for non-parametric data. 
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To address whether the variability in HCV RNA levels seen at day 5 after fusion 
was due to experimental variation or viral characteristics, capture-fusion 
experiments were repeated for a number of patients where sufficient serum was 
available. Variation in HCV RNA yield at day 5 post-fusion was low between 
repeat experiments, indicating that differences in viral replication between patient 
samples was influenced by viral characteristics more than experimental variability 
(Fig. 4-9). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-9. Low variation in HCV RNA yield in repeat capture fusion experiments using the 
same donor serum sample. To measure consistency of HCV RNA yield at day 5 after fusion, 
capture-fusion experiments were repeated using 15 serum samples where sufficient sample was 
available. Graph shows mean ± s.e.m of at least 4 biological replicates per fusion. 
 
 
4.5 Release of infectious virions after fusion 
The experiments described above showed that patient-derived HCV associated 
with THP-1 cells pre-stimulated with PMA/IFNγ. Evidence suggestive of low-level 
viral replication was seen after these cells were fused with Huh7.5 cells, 
specifically an increase in HCV RNA which could be inhibited with antiviral drugs. 
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Further experiments were performed to investigate whether this model supported 
full cycles of viral replication with production and release of infectious virions into 
the supernatant. 
 
As viral replication occurred at low level within the fusion model, it was expected 
that any virions released into the supernatant would be present at very low copy 
number. Therefore, supernatants from multiple wells (1mL supernatant per well, 
total volume 10-20 mL) were collected and concentrated by centrifugation on a 
sucrose gradient (details in chapter 2). Direct RT-qPCR analysis of concentrated 
supernatant confirmed the presence of small amounts of HCV RNA. A method to 
test infectivity of the supernatant was sought, to establish whether the presence 
of HCV RNA equated to presence of infectious virions. Unlike cell culture 
produced HCV, patient-derived strains do not infect Huh7.5 cells (Fig. 4-4). 
However it is possible that after cell fusion, viral replication in the fused cells may 
have selected for a strain capable of de novo infection of Huh7.5. To investigate 
whether capture-fusion supernatants contain infectious virions, a further cycle of 
capture-fusion experiments was performed, using concentrated supernatant in 
place of patient serum. In two independent experiments using concentrated 
supernatants from capture-fusion experiments with serum from a G1 and a G3 
donor, an increase in viral RNA was seen after fusion of THP-1 cells infected with 
the concentrated supernatant indicating replication of viable HCV (Fig. 4-10A, B). 
Sufficient concentrated supernatant was available from the original G3 capture-
fusion experiment to also inoculate directly onto Huh7.5 cells for 24 hours. The 
cells were then washed thoroughly and HCV RNA quantified up to 5 days after 
infection. In this single experiment, there was a small but significant increase in 
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HCV RNA quantifiable from Huh7.5 exposed to concentrated supernatant (Fig 4-
10B), suggesting that virions present in the capture-fusion supernatant may have 
successfully entered fresh Huh7.5 cells and established replication, albeit at very 
low level.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-10. Infectious virions are released into capture-fusion supernatants. Results of 
experiments using concentrated supernatants from 2 separate capture-fusion experiments, one 
using a serum from a G1 HCV infected donor (A) and the other from a G3 HCV infected donor 
(B). Concentrated supernatant was applied to pre-stimulated THP-1 cells for 24 hours, before 
fusion with Huh7.5 and quantification of HCV RNA immediately after fusion and after 3 and 5 days 
in culture. (B) also shows results of inoculation of concentrated supernatant directly onto fresh 
Huh7.5 cells for 24 hours. After washing, HCV RNA was quantified immediately then 3 and 5 days 
after infection. In (A), p = 0.045 for comparison between day 0 and day 5 post-fusion. In (B), p = 
0.018 for the comparison between fused cells at day 0 and day 5 post-fusion, and p = 0.014 for 
the comparison between infected Huh7.5 at day 0 and day 5 post-infection. Graphs show mean 
± s.e.m. Graphs each show results from a single capture-fusion experiment. P values were 
calculated using Mann-Whitney U test. 
 
 
4.6 Mechanisms underlying HCV entry and replication in the capture-
fusion assay 
The experiments above showed that patient-derived HCV could be “captured” 
from patient serum by pre-stimulated THP-1 and induced to replicate following 
fusion with Huh7.5 cells. Full replicative cycles appeared to occur, with release 
of infectious virions into the supernatant. Although in the majority of experiments 
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the level of HCV RNA detectable after cell fusion was above the quantification 
limit of the sensitive PCR assay and could clearly be inhibited with antiviral drugs, 
the low level of viral replication made studies on the mechanisms underlying viral 
entry and replication difficult. To address this, HCV pseudoparticles (HCVpp) 
were employed to study entry of HCV into THP-1 cells and capture-fusion 
experiments were performed using cell culture HCV (HCVcc) in an attempt to 
achieve high level replication after fusion. 
 
4.6.1 Cell culture HCV (HCVcc) does not replicate in the capture-fusion 
assay 
The capture-fusion assay was performed using infectious supernatants 
containing the HCV cell culture strain JFH-1. JFH-1 replicates to high levels in 
Huh7.5 cells [28, 99], and would facilitate mechanistic studies in contract to the 
low-level replication seen using patient-derived HCV. THP-1 were stimulated with 
PMA/IFNγ then incubated with JFH-1, the infectivity of which had previously been 
titrated on Huh7.5 cells (see chapter 2). After 24 hours incubation, JFH-1 
associated with both unstimulated and PMA/IFNγ stimulated THP-1. Unlike 
infection with patient-derived HCV, PMA/IFNγ did not significantly enhance 
association of JFH-1 with THP-1 (Fig. 4-11A). When THP-1 were incubated with 
JFH-1 then fused with Huh7.5 cells, a decline in HCV RNA was seen up to 5 days 
after fusion, implying a lack of JFH-1 replication in fused cells. This was seen 
whether THP-1 were stimulated with PMA/IFNγ prior to JFH-1 exposure or not 
(Fig. 4-11B). Furthermore, indirect immunofluorescence found no evidence of 
HCV protein production in THP-1 exposed to JFH-1 before or after fusion with 
Huh7.5 (data not shown).  
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Figure 4-11. PMA/IFNγ stimulation did not enhance association of JFH-1 with THP-1 or 
replication after fusion with Huh7.5. A. THP-1 cells, treated with PMA (200ng/mL) and IFNγ 
(10ng/mL) or with no stimulants for 24 hours, were incubated with JFH-1 (0.5 MOI (multiplicity of 
infection) per cell) for 24 hours, before quantification of HCV RNA (A). These THP-1 were then 
fused with Huh7.5 cells and HCV RNA quantified immediately after fusion, and after 3 and 5 days 
(B).  P = 0.111 mean ± 95% CI. Graph shows results from a single representative experiment. P 
value was calculated using Mann Whitney U test. 
 
 
4.6.2 HCV pseudoparticles (HCVpp) do not infect THP-1 
HCVpp comprise functional HCV envelope glycoproteins assembled with a 
luciferase reporter onto retroviral or lentiviral core particles [88]. They are not 
capable of replication but have been used extensively to study entry of HCV into 
hepatocytes (reviewed in [291]). In experiments performed by Dr Jenny Waters 
infection of THP-1 cells by HCV pseudoparticles could not be achieved (data not 
shown). These data suggest that viral entry mechanisms in monocytes may differ 
from those in hepatocytes. 
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4.7 Patient-derived HCV does not utilise classical entry receptors for 
attachment/entry to THP-1 
Entry of HCVcc and HCVpp into hepatocytes is dependent upon CD81, SR-B1 
and the tight junction proteins claudin-1 and occludin (see for example [22, 26, 
30, 32, 37, 38]). Neither HCVpp nor HCVcc infected THP-1 and PMA/IFNγ 
treatment of THP-1 enhanced association of patient-derived HCV but not HCVcc, 
suggesting that HCV entry into monocytes may use different receptors, perhaps 
scavenger receptors such as Fcγ receptors. We investigated expression of these 
receptors on THP-1 cells and their potential role in uptake of patient-derived HCV 
in the capture-fusion model.  
 
4.7.1 THP-1 expression of CD64, but not classical HCV entry receptors, is 
upregulated by PMA/IFNγ 
Association of patient-derived HCV, although not HCVcc, with THP-1 cells was 
enhanced by pre-stimulation of THP-1 with PMA/IFNγ.  To examine whether 
PMA/IFNγ pre-stimulation upregulated expression of classical HCV entry 
receptors or FcγR on THP-1 cells, mRNA expression of CD81, SR-B1, LDL-R, 
CD64 (FcγIR), CD32 (FcγIIR) and CD16 (FcγIIIR) was measured by real time 
PCR before and at various times after stimulation of THP-1 cells with PMA and 
IFNγ. Claudin-1 and occludin mRNA was not detected in unstimulated or 
stimulated THP-1 cells (data not shown). This was expected, as these cells do 
not form tight junctions. CD16 mRNA was not detected either before or after 
PMA/IFNγ stimulation (data not shown). CD81, SR-B1 and LDL-R mRNA was 
expressed by THP-1 cells at baseline but expression declined over 24 hours after 
PMA/IFNγ stimulation (Fig 4-12 A-C). CD32 and CD64 were expressed at 
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baseline but only expression of CD64 increased after PMA/IFNγ stimulation (Fig 
4-12 D, E). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-12. Expression of CD64, but not of other candidate receptors for HCV entry, is 
increased by PMA and IFNγ stimulation of THP-1 cells. mRNA expression of classical HCV 
entry receptors CD81 (A), SR-B1 (B) and LDL-R (C) and of Fcγ receptors CD32 (FcγIIR, D) and 
CD64 (FcγIR, E) on THP-1 cells over 24 hours after stimulation with PMA (200ng/mL) and IFNγ 
(10ng/mL). mRNA is expressed relative to GAPDH and to unstimulated cells. CD16 (FcγRIII), 
claudin-1 and occludin mRNA could not be detected in stimulated or unstimulated cells. Graphs 
show mean ± s.e.m. of results from 2 independent experiments. P values were calculated using 
Student’s t-test. 
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Protein expression is regulated at multiple levels. To confirm that the observed 
increase in CD64 mRNA expression translated into an increase in receptor 
expression, cell surface CD81, SR-B1, CD32 and CD64 were quantified by flow 
cytometry. Receptor expression was compared on unstimulated THP-1 and after 
stimulation with PMA or PMA and IFNγ for 24 hours. CD81 and CD32 surface 
expression was not significantly increased by treatment with either PMA or 
PMA/IFNγ (Fig 4-13 A, B). CD64 expression, however, increased after PMA 
treatment and a synergistic effect of PMA and IFNγ stimulation was observed (Fig 
4-13 C). Technical problems made quantification of SR-B1 expression by flow 
cytometry difficult as the only commercially available antibody was a polyclonal 
rabbit anti-human SR-B1. The isotype control for this antibody gave a high 
background signal which made it difficult to detect a true increase in protein 
expression. However, no clear increase in SR-B1 was seen after either PMA or 
PMA/IFNγ stimulation, in keeping with the results of the mRNA expression 
experiments and further suggesting that SR-B1 was not significantly upregulated 
by PMA or PMA/IFNγ treatment. CD64 was the only candidate receptor tested 
which was upregulated at both the mRNA and cell surface level by treatment with 
PMA/IFNγ. Given that PMA/IFNγ also enhanced association of patient-derived 
HCV with THP-1 cells, this suggested that CD64 might play a role in attachment 
or entry of patient-derived HCV into THP-1.  
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Figure 4-13. Expression of CD64, but not CD81 or CD32, is upregulated on THP-1 by PMA 
and IFNγ. THP-1 cells were incubated with PMA 200ng/mL, PMA 200ng/mL and IFNγ 10ng/mL 
or with no stimulants for 24 hours before fixation and staining with antibodies to CD81, SR-B1, 
CD16, CD32, CD64 or isotype controls. Receptor expression was quantified by flow cytometry. 
Grey histograms show receptor expression, clear histograms show isotype control. 
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4.7.2 Blocking CD64 reduces HCV replication after fusion  
To investigate the role of CD64 in THP-1 attachment/entry of patient-derived HCV 
which replicated after fusion with Huh7.5 cells, PMA/IFNγ stimulated THP-1 were 
incubated with anti-CD81 or anti-CD64 blocking antibodies at a range of 
concentrations prior to exposure to patient serum. Association of patient-derived 
HCV with stimulated THP-1 was not significantly reduced by blocking of CD64 or 
CD81 (which is classically associated with HCV entry into hepatocytes) (Fig 4-
14A). However HCV yield after fusion was reduced when THP-1 cells were pre-
incubated with CD64 blocking antibodies before infection and fusion with Huh7.5 
cells, but not when the THP-1 were pre-incubated with anti-CD81 antibodies (Fig. 
4-14B, C). Taken together, these results suggest that uptake of patient-derived 
HCV into THP-1 cells may be mediated at least in part by CD64. Uptake via this 
receptor permits replication to occur after fusion with Huh7.5 cells. Blocking of 
CD64 does not abrogate association of HCV with THP-1 cells, suggesting that 
additional receptor(s) may play a role, however this does not appear to be via the 
classical CD81 pathway associated with HCV entry into hepatocytes. 
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Figure 4-14. CD64 blocking does not reduce attachment of patient-derived HCV to THP-1 
but does reduce replication after fusion with Huh7.5 cells. A, pre-stimulated THP-1 were 
incubated with anti-CD81 or anti-CD64 blocking antibodies at a range of concentrations for 1 hour, 
prior to exposure of the cells to HCV (+) patient sera for 24 hours then quantification of HCV RNA. 
Graph shows mean ± sem of 3 independent experiments. B, in a further experiment, pre-
stimulated THP-1 were incubated with anti-CD81 or anti-CD64 antibodies (5µg/mL), prior to 
incubation with patient serum then fusion with Huh7.5 cells. HCV RNA was quantified immediately 
after fusion. C, in one further experiment, pre-stimulated THP-1 were incubated with anti-CD64 
antibody (5µg/mL), prior to incubation with patient serum then fusion with Huh7.5 cells. HCV RNA 
was quantified immediately, then at 3 and 5 days after fusion. D, control experiment to confirm 
efficacy of the CD81 blocking antibody. Huh7.5 cells were incubated in the presence or absence 
of anti-CD81 blocking antibody (5µg/mL) for 1 hour before infection with the HCV cell culture 
strain JFH-1. HCV RNA was quantified 72 hours after infection and expressed as a percentage 
of cells infected in the absence of blocking antibody. P value was calculated using Mann-Whitney 
U test. 
 
 
4.7.3 Anti-HCV antibodies do not enhance uptake of HCVcc into THP-1 
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complexes may play a role in viral uptake into monocytes. This hypothesis may 
explain why cell culture-derived virus (JFH-1) is not active in the ‘capture-fusion’ 
model. To examine this we assayed JFH-1 infectivity after incubation with sera 
from patients with past HCV infection. Sera were available from a panel of donors 
who had cleared HCV infection. These HCV RNA (-), anti-HCV IgG (+) sera were 
screened for reactivity to JFH-1 protein using an established ELISA technique 
[270] (Chapter 2). Samples with the highest reactivity to JFH-1 were used for 
subsequent experiments. In 2 independent experiments, JFH-1 was incubated 
with each serum at a range of dilutions, before incubation with PMA/IFNγ 
stimulated THP-1 cells for 24 hours and then fusion with Huh7.5. Incubation with 
sera containing anti-HCV antibodies did not enhance JFH-1 association with 
THP-1 cells or replication after fusion with Huh7.5 (Fig. 4-15). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-15. JFH-1 association with THP-1 and replication after fusion was not enhanced 
by anti-HCV antibodies. JFH-1 was incubated with HCV (-), anti-HCV (+) sera from 2 patients, 
which were reactive to JFH-1, at a range of dilutions before incubation with THP-1 cells. The THP-
1 were then fused with Huh7.5 cells and HCV RNA measured at various times after fusion. Graphs 
show mean ± sem for each individual experiment. 
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4.7.4 Cell fusion does not trigger expression of interferon stimulable 
genes 
We hypothesised that the fusion process permits transfer of HCV to Huh7.5 cells 
without triggering induction of interferon and innate antiviral responses. However 
the fused cells remain interferon sensitive, as exogenous interferon inhibited 
replication of interferon sensitive viral strains (Fig. 4-5 and Chapter 5). We 
compared expression of the interferon stimulable gene MxA in fused cells with 
and without HCV exposure and with and without interferon treatment. We found 
that MxA expression is not induced by cell fusion and is low in infected cells, but 
can be upregulated by exogenous interferon (Fig. 4-16A). Furthermore, priming 
of Huh7.5 cells with interferon significantly reduced HCV replication after fusion 
(Fig. 4-16B). These data suggest that at least one of the mechanisms underlying 
the capture-fusion replication process is delivery of virus to hepatocytes without 
triggering an intracellular innate immune response. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-16. The fusion process does not trigger expression of the interferon stimulable 
gene MxA, but MxA expression remains inducible by exogenous IFN. A, fused HCV-infected 
THP-1/Huh7.5, fused uninfected THP-1/Huh7.5 or unfused Huh7.5 were cultured for 5 days in 
the presence or absence of IFNα-2a (100 IU/mL). MxA mRNA was quantified by PCR and 
expressed relative to GAPDH and uninfected, unfused, untreated Huh7.5. Results are shown on 
a logarithmic scale. B, Untreated Huh7.5 cells or Huh7.5 pre-treated with 100 IU/mL IFNα-2a for 
1 hour were fused with THP-1 cells infected with patient serum. HCV RNA was quantified 
immediately and at 3 and 5 days after fusion. Each graph shows mean ± s.e.m. of a single 
representative experiment. 
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4.7.5 Fusion with THP-1 does not render Huh7.5 more permissive to HCV 
replication 
It is conceivable that the process of cell fusion results in release of factor(s) which 
enhance permissiveness of Huh7.5 to HCV entry and/or replication. To establish 
whether this was the case, an equal number of PMA/IFNγ pre-stimulated THP-1 
cells and Huh7.5 cells were stained with the fluorescent membrane dyes DiI 
(THP-1) or DiO (Huh7.5) prior to fusion. After fusion, dual labelled cells were 
sorted by fluorescence activated cell sorting (FACS) to identify the fused THP-
1/Huh7.5 population and cultured overnight. In parallel, an equivalent number of 
dye-labelled Huh7.5 and THP-1 cells were cultured together without fusion. The 
fused or co-cultured cells were infected with the HCV cell culture strain JFH-1 
and HCV RNA quantified after 72 hours. No enhancement of JFH-1 replication 
was seen in the fused cells compared to the co-cultured cells (Fig. 4-17), 
excluding fusion-induced enhancement of Huh7.5 permissiveness as a 
mechanism underlying replication after fusion. 
 
 
 
 
 
 
 
Figure 4-17. Fusion with THP-1 does not render Huh7.5 cells more permissive to HCV 
replication. Pre-stimulated THP-1 and Huh7.5 were stained with fluorescent membrane dyes 
and prior to fusion. After fusion, dual-labelled cells were isolated by FACS and infected with JFH-
1 at 0.5 MOI/cell (fused THP/Huh7.5). An equal number of labelled, unfused THP-1/Huh7.5 
(cocultured THP/Huh7.5) were also infected at the same multiplicity of infection. After 72 hours 
HCV RNA was quantified. Graph shows mean ± s.d. of biological quadruplicates in a single 
experiment. 
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4.8 Enhancement of HCV replication in the capture-fusion model  
Similar to HCV replication seen after fusion of patient-derived monocytes with 
Huh7.5 cells, the level of replication of patient-derived HCV in the capture-fusion 
assay was low, often near the limit of quantification of the sensitive RT-qPCR 
assay. In an effort to improve consistency and reliability of results, attempts were 
made to enhance HCV replication after fusion. 
 
4.8.1 Activation of the sonic hedgehog signalling pathway 
Others have shown that upregulation of the hedgehog signalling pathway 
enhances replication of cell culture produced HCV (HCVcc) [292]. However, we 
found no enhancement of replication of patient-derived HCV after treatment of 
fused cells with the hedgehog agonist SAG (data not shown). Osteopontin, a 
profibrogenic extracellular matrix protein and cytokine, is upregulated by 
activation of the hedgehog signalling pathway and also enhances replication of 
HCVcc [293, 294]. Osteopontin treatment of fused THP-1/Huh7.5 cells showed a 
trend towards enhanced replication of patient-derived HCV at the highest 
concentrations used (Fig 4.18A), although this was not statistically significant. 
Others have reported that OPN-mediated enhancement of HCV replication is 
greater in Huh7 cells than in Huh7.5 as baseline OPN levels are higher in Huh7.5 
cells [293]. Where fusion experiments were performed with Huh7 cells, HCV RNA 
yield was enhanced by OPN in 2 out of 3 patient samples tested (Fig 4-18B). 
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Figure 4-18. Effect of osteopontin (OPN) treatment on HCV replication in fused cells. A, 
mean ± sem of results from 2 independent experiments where prestimulated, HCV-exposed THP-
1 fused with Huh7.5 cells were treated with osteopontin (OPN) at a range of concentrations for 5 
days after fusion, before quantification of HCV RNA. B shows results from a further 3 independent 
experiments in which prestimulated, HCV-exposed THP-1 were fused with Huh7 cells then 
cultured in the presence or absence of OPN (1000ng/mL) for 5 days before quantification of HCV 
RNA. p values were calculated using Mann-Whitney U test. 
 
 
4.9 Discussion 
Following our demonstration that patient-derived HCV replicates after fusion of 
patient monocytes with Huh7.5 cells, we hypothesised that monocytic cell lines 
could be used to transmit virions from patient serum samples to Huh7.5 cells and 
induce viral replication in a similar manner. The monocytic cell line THP-1 was 
readily available in the laboratory and was evaluated in these experiments. 
Alternate monocytic cell lines were either found to be unsuitable for use in this 
assay due to proliferation and clumping in culture (MonoMac1) or were 
subsequently evaluated and found to provide no additional benefit in terms of 
HCV yield over THP-1 (U937, experiments performed by Dr Meleri Jones, data 
not shown).  
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Replication of HCV derived from patient serum after “capture” by pre-stimulated 
THP-1 cells and fusion with Huh7.5 was demonstrated by accumulation of HCV 
RNA over time after fusion, inhibition of RNA accumulation by antiviral drugs, and 
demonstration of HCV protein production. The vast majority of patient samples 
could be induced to replicate after fusion, regardless of viral genotype, although 
analysis of uncommon viral genotypes (particularly G5 and G6) was limited as 
these genotypes are very rare in the UK. Of the samples which did not replicate 
in the assay, some may have been due to degradation of archived viral RNA, but 
a few freshly taken samples did not replicate in repeated capture-fusion 
experiments. Amongst samples which did replicate, the levels of replication were 
consistent in repeated capture-fusion experiments for a given sample. These 
findings suggest that most viral isolates will replicate in this assay, but replication 
levels vary between samples and this is predominantly determined by intrinsic 
viral characteristics, rather than experimental variation. 
 
Establishing whether patient-derived HCV underwent full replicative cycles in the 
capture-fusion model, with release of infectious virions into the supernatant, 
proved challenging. This was partly due to the low level of viral replication seen 
(and therefore extremely low levels in experimental supernatants), and also as 
patient-derived viral strains do not directly infect cultured cell lines, making the 
use of standard viral infectivity assays impossible. To address the issue of low 
viral yield supernatants were concentrated on a sucrose gradient. In an attempt 
to establish whether the concentrated supernatants contained infectious virions, 
the capture-fusion assay was employed again to assay viral replication, using 
concentrated supernatant in place of patient serum. In 2 separate experiments, 
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HCV from concentrated supernatant appeared to accumulate over time after 
capture by THP-1 and fusion with Huh7.5. Interestingly, accumulation of HCV 
RNA was also seen after exposure of naïve Huh7.5 cells to concentrated 
supernatants, although at a lower level than that seen in the fused cells. This 
raises the possibility of generation or selection of a viral strain adapted for 
replication in this culture environment. Unfortunately in a single round of 
experiments the HCV RNA levels achieved were too low for cloning and 
sequencing of the viral product, but it is possible that this might be enhanced by 
further round of replication in the capture-fusion assay and this remains an area 
for future work. 
 
Association of HCV from patient serum with THP-1 was greatly enhanced by pre-
treatment of cells with PMA and IFNγ. A proportion of virus (approximately 20%) 
appeared to be internalised into the cells, as this was resistant to trypsin 
treatment of the cells from 4 hours after exposure to patient serum. However, we 
found no evidence to support replication of HCV within THP-1. In keeping with 
the findings of others, we were unable to infect THP-1 with cell culture produced 
HCV (JFH-1), or with HCVpp [122]. This made further study of HCV entry into 
THP-1 difficult, as it was reliant on relatively low-level HCV association with the 
cells, further confounded by sample-sample variability. In addition, JFH-1 was not 
efficiently transmitted in the capture-fusion assay, complicating investigation of 
mechanisms underlying replication following fusion of THP-1 with Huh7.5. HCV 
protein production could not be reliably detected in fused cells, most likely due to 
non-specific antibody binding by THP-1 cells. This means that more detailed 
investigation, such as subcellular localisation of HCV replication, was not 
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achievable. The development of sensitive fluorescence-emitting constructs which 
can be used to track HCV replication within the cell in real time may help to 
address this [295], and these have recently been obtained in the lab. 
 
The enhancement of HCV association with THP-1 cells by PMA and IFNγ was 
marked and consistent. This was initially unexpected, as IFNγ is a component of 
the innate anti-viral immune response, and as such might be reasonably 
expected to reduce viral association or persistence/replication after fusion. 
However, others have described enhancement of Fcγ receptor (FcγR) expression 
on monocytic cell lines by IFNγ [123, 296-298]. We speculated that as patient-
derived HCV associated with THP-1 cells after PMA/IFNγ treatment, but cell 
culture produced strains did not, FcγR may be upregulated by PMA/IFNγ and 
may be responsible for this association. Previously, CD32 (FcγIIR) was shown to 
be upregulated on U937 cells after PMA/IFNγ, and this was associated with 
increased attachment of HCV-Ig complexes to these cells [123]. Upon exposure 
of THP-1 to PMA/IFNγ, we found no change in CD32 expression, but expression 
of CD64 (FcγIR) was enhanced at the mRNA and cell surface level, more so by 
PMA/ IFNγ than by PMA alone. Interestingly, pre-exposure to CD64 blocking 
antibodies did not reduce HCV association with stimulated, unfused THP-1, but 
a reduction was seen after the fusion step had been performed, and less HCV 
RNA accumulation was seen after fusion where THP-1 had been exposed to 
CD64 blocking antibodies before incubation with patient sera. However, entry of 
JFH-1 into THP-1 and replication of JFH-1 after fusion could not be enhanced by 
pre-incubation with patient sera containing anti-HCV antibodies. This suggests 
that although CD64 may play a role in uptake of patient-derived virus and 
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replication after fusion, other receptors are also involved. Alternatively, the range 
of mechanisms by which patient-derived virus interacts with THP-1 may be 
different from those of JFH-1 at a number of levels which are not fully explored in 
these experiments. Other candidate receptors which warrant further investigation 
are the lectins L-SIGN and DC-SIGN, which have been implicated in attachment 
of HCVcc to B cells [130] and also in protection of HCV virus-like particles from 
lysosomal degradation after uptake into THP-1 cells [299]. The role of exosomes 
in transfer of cellular material, including viral RNA, is gaining increasing 
recognition, and this represents another potential mechanism for viral infection of 
cells [300-302].  
 
A major limiting factor in these experiments, especially in attempts to explore 
mechanisms underlying the success of the ‘capture-fusion’ strategy, is the very 
low level of viral replication observed in this model. The Huh7 cell line and its 
derivatives, including Huh7.5 cells, are unique amongst hepatoma cell lines in 
their permissiveness to replication of highly adapted HCV replicons and cell 
culture strains. Replication depends on acquisition of cell culture adaptive 
mutations, and with the exception of the highly atypical viral strain JFH-1, viral 
strains without adaptive mutations cannot be propagated in tissue culture [28, 90-
92, 99]. The properties conferred by such mutations, and why they permit 
replication in this cell line, is incompletely understood. The Huh7.5 cell line was 
derived from Huh7 by identification of a highly permissive Huh7 subclone which 
was cured of HCV replicon infection with interferon [276]. The attributes of the 
Huh7.5 line which make it more permissive to HCV replication are incompletely 
understood, but are thought to include defective RIG-I signalling [285]. Clearly, 
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however, these cells remain responsive to exogenous interferon, demonstrated 
both by the method by which they were generated and response to IFN in 
capture-fusion experiments. In a limited number of experiments we conducted 
using Huh7 cells, we found overall lower levels of HCV RNA than in experiments 
using Huh7.5 cells, suggesting the difference in permissiveness extend to 
patient-derived HCV in the capture-fusion model as well as to the highly adapted 
replicon and atypical HCVcc strains. 
 
Both enhancement and inhibition of HCV replication by the profibrogenic 
extracellular matrix protein and cytokine osteopontin (OPN) have been reported 
in published literature [293, 303]. Interestingly, OPN has also been reported to 
enhance replication of HIV in primary monocyte-derived macrophages [304]. Our 
observations suggest that OPN may enhance replication of patient-derived HCV 
in the capture-fusion model, particularly when less permissive cell lines are used, 
but some viral strains may be more susceptible than others. Whether OPN 
“boosting” is likely to be a useful strategy to enhance viral replication in the 
capture-fusion assay will require a more detailed understanding of the 
interactions between OPN and HCV which facilitate replication.  
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5.0 Results: validation of the “capture-fusion” assay to measure drug 
sensitivity of patient-derived HCV 
 
5.1 Introduction 
We have demonstrated that patient-derived HCV of diverse viral genotypes can 
be induced to replicate in the capture-fusion model, and can be inhibited with 
antiviral drugs, suggesting that this assay could be used to assess patient-
specific sensitivity to current and novel antiviral therapies. At present, in vitro 
models to test HCV drug sensitivity are limited to the genotype (G)1-based 
replicon system [73] and G2-based HCV cell culture strains [28]. Whilst these 
models have allowed considerable advances in the study of HCV replication and 
development of direct-acting antiviral drugs, they are highly adapted, replicate 
only in specific cell lines, and the extent to which they predict behaviour of HCV 
in vivo is uncertain. Recent development of G3a and G4a replicons has extended 
the range of genotypes which can be tested [97, 98], and chimeric variants of 
JFH-1 have been described [101, 305]. However, these techniques remain 
impractical for establishing the drug sensitivity of an individual patient’s HCV, as 
defining the drug sensitivity of a single viral isolate requires subcloning the gene 
for each DAA target and insertion into a subgenomic replicon [306-308]. 
Furthermore, difficulty in generating replicons with more than one modified locus 
precludes testing of sensitivity to combinations of DAAs using this technique. For 
G1 HCV some viral motifs associated with resistance to protease inhibitors have 
been identified [309] but for other genotypes there is no clear association 
between viral sequence and drug response [104, 200, 246]. This chapter 
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presents the work performed to validate the capture-fusion assay as a tool to 
screen individual patient responsiveness to current and novel antiviral therapies. 
 
5.2 Telaprevir and alisporivir inhibit HCV replication in a genotype-specific 
manner  
We investigated whether replication of patient-derived HCV in the capture-fusion 
model could be inhibited by antiviral compounds. Telaprevir, a HCV NS3 protease 
inhibitor, potently inhibits G1 HCV but has little effect against G3 HCV in clinical 
trials [184, 186, 199]. Conversely, the cyclophillin inhibitor alisporivir is clinically 
more efficacious against G2 and G3 HCV than G1 and G4 [217]. The ability of 
the capture-fusion system to accurately reflect these clinical differences in 
sensitivity was evaluated using serum samples from G1a (N = 9) and G3 (N = 5) 
infected donors. THP-1 cells infected with the sera were fused with Huh7.5 cells, 
and the fused cells treated with telaprevir or alisporivir at a range of 
concentrations for 5 days before quantification of HCV RNA. Dose-response 
curves were constructed and used to calculate a 50% inhibitory concentration 
(IC50) for each experiment. Individual patient-derived HCV sensitivity to a wide 
range of telaprevir/alisporivir doses is shown in Figure 5-1.  
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Figure 5-1. Genotype-specific responses to telaprevir or aliporivir treatment in the capture-
fusion assay. Each graph shows results of a single capture-fusion experiment using serum from 
a G1a or G3 HCV infected donor, where the fused cells were treated with a range of doses of 
telaprevir or alisporivir for 5 days after fusion, prior to quantification of HCV RNA. Graphs show 
mean ± s.e.m. of biological quadruplicates.  
 
Based on the sensitivity of diverse viral genotypes to an extensive range of drug 
concentrations, five drug doses (nil, 0.05, 0.1, 0.5 and 1.0µM) were selected for 
use in further experiments. This allowed each capture-fusion drug inhibition 
experiment to be performed in biological quadruplicates and the resulting HCV 
RNA measured in a single PCR run. Dose response curves could be constructed 
for all viral isolates which replicated to quantifiable levels in the assay.  Pooled 
results from 14 donors (9 with G1a HCV and 5 with G3 HCV) are shown in Figure 
5-2. Results are normalised to untreated cells to account for variability in 
replication seen in the capture-fusion assay between samples from different 
donors. G1 samples were significantly more sensitive to telaprevir than G3 
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samples (Figure 5-2A, B), but significantly less sensitive to alisporivir (Figure 5-
2C, D). Telaprevir and alisporivir IC50s for each sample according to HCV 
genotype are shown in Figure 5-2E-F. 
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Figure 5-2. Genotype-specific sensitivity of patient-derived HCV to telaprevir or alisporivir 
in the capture-fusion assay. HCV derived from serum from 9 G1a and 5 G3 donors was treated 
with varying concentrations of telaprevir or alisporivir in capture-fusion assays, and HCV RNA 
measured after 5 days. G1a patient-derived HCV was more sensitive to telaprevir than G3 (A-B), 
but less sensitive to alisporivir (C-D). Comparison of individual IC50 values showed telaprevir IC50 
was 0.042 ± 0.003 for G1 samples versus 0.117 ± 0.015 μM for G3, p = 0.001 (E). Conversely, 
alisporivir IC50 was 0.139 ± 0.013 for G1 samples versus 0.044 ± 0.007 μM for G3, p =0 .004 (F). 
Graphs show mean ± s.e.m. P values were calculated using Mann-Whitney U test. 
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To exclude drug-induced cytotoxicity as a cause of the observed reduction in 
HCV RNA, cell viability was assessed after exposure to the range of 
concentrations of telaprevir and alisporivir used in the drug inhibition 
experiments. Exposure to higher doses of alisporivir caused some loss of viability 
(up to 25%) but this was insufficient to fully account for inhibition of HCV 
replication in alisporivir treated samples. Telaprevir exposure did not lead to 
significant cytotoxicity (Figure 5-3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-3. Viability of fused cells treated with telaprevir (A) or alisporivir (B). Pre-stimulated 
THP-1 cells were exposed to HCV infected serum, fused with Huh7.5 cells then cultured for 5 
days in the presence of telaprevir or alisporivir at various concentrations. Cell survival was 
measured using a luminescent cell viability assay and is expressed as a percentage of untreated 
fused cells. Graphs show mean ± s.d. of results from single experiments *** p <0.001, calculated 
using Student’s t test. 
 
 
Initial experiments evaluating the capture-fusion assay as a replication model for 
all HCV genotypes had suggested that replication of less common viral genotypes 
could also be inhibited by antiviral drugs, specifically telaprevir, in the assay (see 
chapter 4). Telaprevir and alisporivir sensitivity of a small number of samples of 
other viral genotypes was measured and IC50 values calculated for each sample 
(Figure 5-4). G2 isolates were sensitive to both telaprevir and alisporivir, whilst 
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G4 strains showed a similar alisporivir response to G1, which is in keeping with 
clinical trial data [217]. Interestingly, some G4 isolates appeared to be poorly 
sensitive to telaprevir, consistent with the findings of a small clinical trial 
evaluating telaprevir for G4 HCV [198]. However replication of other G4 isolates 
was inhibited by telaprevir in the capture-fusion assay, suggesting potential 
differing susceptibility to telaprevir amongst G4 strains. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-4. Sensitivity to telaprevir and alisporivir can be estimated in patient-derived HCV 
of all viral genotypes. Graphs show telaprevir (A) or alisporivir (B) sensitivity in individual 
experiments using serum from patients with genotype 2, 4, 5 or 6 HCV infection. 
 
 
5.3 Genotypic and phenotypic resistance to direct-acting antivirals can be 
detected in the capture-fusion assay 
Treatment failure in patients receiving telaprevir, pegylated interferon (pegIFN) 
and ribavirin (RBV) therapy is characterised by an initial response to therapy 
followed by on-treatment virological breakthrough associated with acquisition of 
resistance associated variants (RAVs). To explore whether genotypic and clinical 
telaprevir resistance could be detected as a loss of telaprevir sensitivity in the 
capture-fusion assay, pre-treatment and post-breakthrough serum samples were 
obtained from two patients with G1 HCV who initially responded to treatment with 
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telaprevir, pegIFN and RBV but experienced virological breakthrough by 
treatment week 12. Sequencing of the first ~200 amino acids of viral NS3 to 1% 
frequency by pyrosequencing did not identify any known telaprevir resistance 
associated variants (RAVs) at baseline, but the telaprevir resistance-associated 
mutations V36M/R155K were found at breakthrough (samples were kindly 
supplied, with sequencing results, by Dr Tanzina Haque and Mr Malcolm 
McCartney, Department of Virology, Royal Free Hospital, London). Telaprevir 
sensitivity of the pre-treatment and post-breakthrough samples for each patient 
was assessed in the capture-fusion assay and demonstrated a loss of telaprevir 
sensitivity in the resistant strains (Figure 5-5).  
 
 
 
Figure 5-5. Loss of clinical response to telaprevir and acquisition of genotypic resistance 
correlates with drug sensitivity in the capture-fusion assay. Telaprevir sensitivity of pre-
treatment and post-breakthrough sera from 2 patients (A and B) who initially responded but then 
broke through treatment with telaprevir, pegIFN and RBV was measured in the capture-fusion 
assay. Each graph shows mean ± s.e.m. of a single capture-fusion experiment using pre-
treatment serum, and a single capture-fusion experiment using post-breakthrough serum from 
each patient.  
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Pre- and post-treatment serum was obtained from one further patient with G1 
HCV with a poor clinical response to telaprevir, pegIFN and RBV therapy (circa 
1 log10 reduction in viral load at treatment week 4). No telaprevir resistance 
associated mutations were identified pre-treatment, although V36M/R155K 
mutations were present at treatment failure (again measured to 1% frequency by 
454 pyrosequencing). This strain demonstrated poor telaprevir sensitivity in the 
capture-fusion assay both before and after telaprevir exposure (Fig. 5-6A). We 
identified 2 further patients with G1 HCV and a similar poor clinical response to 
telaprevir, pegIFN and RBV although deep sequencing of the NS3 region of these 
viral isolates was not available. Pre-treatment sera from these individuals was 
also poorly sensitive to telaprevir in the capture-fusion assay (Fig. 5-6B, C). This 
raises the possibility that viral phenotypic sensitivity to telaprevir, as assessed by 
the capture-fusion assay, may be more predictive of telaprevir treatment 
response than genotypic sensitivity, at least when assayed using the techniques 
described.   
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Figure 5-6. Failure to respond to telaprevir-containing treatment correlates with poor pre-
treatment telaprevir sensitivity in the capture-fusion assay. Telaprevir sensitivity of pre-
treatment and post-failure sera from 1 patient (A) and pre-treatment sera from 2 further patients 
(B, C) who failed to respond to treatment with telaprevir, pegylated interferon and ribavirin was 
measured in the capture-fusion assay. 
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5.4 Interferon sensitivity in the capture-fusion assay correlates with 
response to interferon in G1 HCV 
Interferon sensitivity is thought to be an important determinant of virological 
breakthrough and acquisition of resistance to novel antiviral drugs, especially in 
patients who have previously failed to respond to interferon-based therapy. 
Whether host or viral factors dominate response to interferon treatment is 
unclear. Archived pre-treatment serum samples from 4 patients with G1 HCV who 
responded to pegIFN and RBV treatment and 4 patients with a null response to 
therapy were used to examine whether interferon sensitivity of patient-derived 
HCV in the capture fusion assay correlated with response to treatment. Pre-
treatment HCV from patients who responded to therapy was more sensitive to 
interferon in the capture-fusion assay than pre-treatment virus from patients with 
a null response (Figure 5-7). 
 
 
  
 
 
 
 
 
Figure 5-7. Interferon sensitivity in the capture-fusion assay correlates with response to 
interferon-based therapy. Archived pre-treatment sera from patients who did (A, N = 4) or did 
not (B, N = 4) respond to pegIFN and RBV were used in capture-fusion experiments. Fused cells 
were treated with interferonα-2a at a range of doses for 5 days prior to HCV quantification. Graphs 
show mean ± s.e.m. of pooled results from all 4 experiments in each group. 
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5.5 Ribavirin sensitivity in the capture-fusion assay correlates with 
relapse after interferon and ribavirin therapy in G3 HCV 
In contrast to G1, the predominant mode of treatment failure in patients with G3 
HCV infection is relapse. Relapse rates are higher in patients who receive 
suboptimal ribavirin dosing and some investigational treatment regimens without 
ribavirin [310, 311]. Archived pre-treatment sera from 10 cirrhotic G3 patients 
treated with pegIFN and RBV, 4 with sustained virological response (SVR) and 6 
who relapsed, were used to investigate whether pre-treatment interferon or 
ribavirin sensitivity in the capture-fusion assay correlated with treatment outcome. 
No difference in interferon sensitivity was seen, but pre-treatment HCV from 
patients with SVR was more sensitive to ribavirin in the assay than virus from 
patients who relapsed (Fig. 5-8). 
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Figure 5-8. Pre-treatment ribavirin sensitivity in the capture-fusion assay correlates with 
treatment response in cirrhotic G3 patients treated with interferon/ribavirin. Using archived 
pre-treatment sera from 10 cirrhotic G3 patients who relapsed (N = 6) or achieved SVR (N = 4) 
following pegIFN and RBV treatment, interferon (A, B) and ribavirin (C, D) sensitivity was 
measured in the capture-fusion assay. Pre-treatment sera from patients with SVR were 
significantly more sensitive to ribavirin, but not interferon, than sera from relapsers (E, F). Graphs 
A-D show mean ± s.e.m. of pooled results from all experiments in each group. Graphs E and F 
show mean ± s.e.m. of IC50 values calculated from each experiment. P values were calculated 
using Mann-Whitney U test. 
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5.6 Sensitivity to telaprevir in the capture-fusion assay correlates with 
clinical response  
Although telaprevir is poorly effective in G3 HCV, a subgroup of patients (~30%) 
do show some antiviral response [199]. To establish if the capture-fusion assay 
could be used to distinguish patients with telaprevir-sensitive G3 HCV, pre-
treatment serum samples were obtained (blinded to virological response) from 
eight patients with G3 HCV who had been treated with telaprevir monotherapy in 
a clinical trial. Using the capture-fusion assay, telaprevir sensitivity of each 
sample was determined. Telaprevir sensitivity measured in the capture-fusion 
assay correlated well with clinical response. In contrast, a biochemical 
phenotyping assay, in which the viral NS3 was subcloned and enzymatic activity 
assessed in the presence and absence of telaprevir using fluorescence 
resonance energy transfer cleavage, correlated poorly with clinical outcome [104] 
(samples and results of the biochemical assay kindly supplied by Gaston Picchio, 
Janssen Virology) (Figure 5-9). Three samples with the greatest telaprevir 
sensitivity in the capture-fusion assay corresponded to the three patients who 
had shown a clinical response to telaprevir monotherapy before acquiring 
resistant viral strains. These results indicate that the capture-fusion assay may 
be useful to predict individual patient response to telaprevir, and to distinguish 
patients with G3 infection who may respond to telaprevir therapy from those who 
will not. 
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Figure 5-9. Correlation between pre-treatment telaprevir sensitivity and response to 
telaprevir in 8 patients with G3 HCV. Clinical response to telaprevir monotherapy is shown on 
the y-axes, and could be predicted by the capture-fusion assay (A), but not by a biochemical 
phenotyping assay (B). Graphs show IC50 values from individual experiments using serum from 
8 G3 HCV infected donors prior to telaprevir treatment. P values were calculated using Spearman 
rank correlation test. 
 
 
 
 
5.7 Use of the capture-fusion assay to investigate anti-HCV activity of a 
novel antiviral drug 
To further explore the range of antiviral drugs for which patient-derived HCV 
sensitivity could be investigated using the assay, the novel antiviral agent SB 
9200 was supplied by SpringBank Pharmaceuticals.  
 
SB 9200 is a host-targeting antiviral compound which, at the time of writing, is in 
Phase 1 clinical trials for treatment of chronic HCV infection. Its precise 
mechanism of action is not fully elucidated but it is thought to involve activation 
of components of the innate antiviral immune response, including the double 
stranded RNA helicase RIG-I and the pattern recognition receptor NOD-2. It is a 
broad spectrum antiviral, with activity demonstrated against HCV, HBV, 
respiratory syncytial virus and norovirus [312]. 
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The dose range of SB 9200 used in capture-fusion experiments was established 
by treating HCV replicon cells with various concentrations of SB 9200 for 5 days, 
before quantification of HCV RNA and construction of a dose-response curve. 
Inhibition of the HCV replicon was demonstrated over the range 0-10µM SB 9200, 
and so the doses selected for use in the capture-fusion assay were 0, 0.01, 0.1, 
1.0 and 10µM. 
 
To demonstrate that SB 9200 was effective against diverse HCV genotypes in 
the capture-fusion assay, serum samples from donors infected with G1 (N = 6), 
G2 (N = 2), G3 (N = 7), G4 (N = 3) and G6 (N = 2) HCV were used in capture-
fusion experiments. Fused cells were treated with SB 9200 for 5 days before 
quantification of HCV RNA. Isolates of all viral genotypes tested were sensitive 
to SB 9200 in the capture-fusion assay (Fig 5-10), although G3 isolates were 
significantly more sensitive to SB 9200 than G1 samples. Single samples were 
available from a G1 patient who did not respond to telaprevir (telaprevir sensitivity 
in the capture-fusion assay shown in Fig 5-6C) and from a G3 patient who had 
repeatedly relapsed after pegIFN and RBV therapy. Both of these samples were 
sensitive to SB 9200 in the capture-fusion assay (Fig. 5-10 F, G). 
 
Together, these results suggest that SB 9200 may be a useful host-targeting anti-
HCV agent with pan-genotypic antiviral activity and may be effective against viral 
strains which are poorly responsive to other antiviral agents. The capture-fusion 
assay may be a useful tool to identify genotypic range and efficacy of novel anti-
HCV drugs at the early stages of clinical development. 
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Figure 5-10. Sensitivity of patient-derived HCV to SB 9200 in the capture-fusion assay. 
Serum samples from donors chronically infected with HCV G1 A, N = 5); G2 (B, N = 2); G3 (C, N 
= 7); G4 (D, N = 3) or G6 (E, N = 2) were used in separate capture-fusion experiments. After 
fusion, cells were treated with a range of concentrations of SB 9200 for 5 days before 
quantification of HCV RNA and construction of dose-response curves. SB 9200 IC50 for each 
sample is shown in F. In addition, the capture-fusion assay was used to measure SB 9200 
sensitivity of HCV from a patient with G1 HCV who had failed to respond to telaprevir, pegIFN 
and RBV (G) and from a patient with G3 HCV who had relapsed on 3 occasions after pegIFN and 
RBV therapy (H). Graphs show mean ± s.e.m. 
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5.8 Discussion 
The work presented in this chapter demonstrates that replication of HCV in the 
capture-fusion assay can be inhibited by antiviral drugs in a manner that reflects 
both genotype-specific and patient-specific drug response. This assay represents 
the first replication system for HCV where drug responsiveness of individual 
patient-derived HCV can be tested in vitro, and where drug efficacy can readily 
be tested in genotypes other than G1 (replicon) or G2 (cell culture HCV strains).  
 
50% inhibitory concentrations (IC50) for a given drug often vary in published 
literature, which may be due to experimental differences such as the assay used 
(e.g. cell culture based or enzymatic), the time of exposure to the drug or the 
range of drug concentrations employed. IC50 values obtained in telaprevir or 
alisporivir inhibition experiments using serum from G1 donors in the capture 
fusion assay are comparable to IC50 values obtained in the replicon system (G1b) 
[313, 314], further supporting the validity of the capture-fusion assay as tool to 
screen drug sensitivity of patient-derived HCV. 
 
A very limited number of genotype 4, 5 and 6 isolates were available for testing 
in the assay, as these genotypes (especially G5 and G6) are rare in the UK. Very 
little clinical data is available for these viral genotypes and there is no published 
data on clinical efficacy of telaprevir in G5 or G6 HCV. A small clinical trial 
suggested that G4 HCV is poorly sensitive to telaprevir [315], but divergent 
responses to protease inhibitors have been observed amongst isolates of the 
same genotype [199, 246], which could not reliably be predicted by presence of 
resistance-associated motifs [104, 200]. The results obtained in the capture-
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fusion assay suggest that there may be strain-specific differences in telaprevir 
sensitivity amongst G4 isolates, whilst at least some G5 isolates may respond 
well and some G6 isolates may respond poorly to telaprevir. The results of our 
blinded study where three of eight G3 samples which showed a clinical response 
to telaprevir were accurately identified in the capture-fusion assay suggests that 
this assay may represent a valuable screening tool to identify which non-G1 
infected patients may benefit from protease inhibitor therapy. However, 
correlating viral sensitivity in the capture-fusion assay with sustained clinical 
response to therapy will require further work. 
 
Notably, we identified a single patient with a poor therapeutic response to 
telaprevir whose virus was phenotypically resistant to telaprevir in the absence of 
any detectable telaprevir resistance associated variant (RAV) by deep 
sequencing of the viral NS3 region. Two further patients were subsequently 
identified who also failed to respond to telaprevir therapy with phenotypically 
resistant virus pre-treatment, although viral NS3 sequencing was not available 
for these samples. It is possible that a pre-existing RAV was present at <1% 
frequency and so was not detected by 454 sequencing, and was subsequently 
selected during treatment. Alternatively, these results raise the possibility of novel 
resistant variants to telaprevir which may exist in the population and may lie 
outside the classical resistance associated regions. Further work will be required 
to delineate this region and large-scale studies will be needed to identify the 
frequency with which these variants occur. 
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The predictive value of pre-existing resistance associated variants (RAVs) on 
outcome of telaprevir treatment is unclear. Pre-existing RAVs conferring low-level 
telaprevir resistance have been identified by population sequencing in up to 3% 
of treatment-naïve or pegIFN/ribavirin treatment-experienced individuals, but 
their presence does not appear to influence the outcome of subsequent 
telaprevir-containing treatment, except in the context of a poor interferon 
response [259, 262]. In clinical trials the number of participants with primary 
failure of telaprevir-containing therapy (as distinct from virological breakthrough) 
has not been reported [184, 186]. However, in a large series of cirrhotic, 
treatment-experienced G1 patients treated with telaprevir, pegIFN and RBV, 10% 
failed to respond to triple therapy [251]. Therefore, primary non-response to 
telaprevir-based therapy may become a significant issue as protease inhibitor 
use becomes more widespread, particularly in patients who have previously 
failed treatment with pegIFN and ribavirin. A phenotyping assay such as the 
capture-fusion assay may be of value to identify these patients pre-treatment.  
 
SB 9200, a novel antiviral in early phase clinical trials for treatment of HCV, is 
thought to exert its antiviral effects primarily through activation of RIG-I signalling, 
although NOD2 has also been implicated [312]. The fact that clear inhibition of 
HCV replication by SB 9200 was seen in the fusion model was interesting, given 
that the RIG-I pathway is defective in Huh7.5 cells [285]. This implies that the role 
of NOD2 activation in the mechanism of action of SB 9200 is greater than 
previously appreciated, or that it activates part of the RIG-I signalling pathway 
downstream of the defect present in Huh7.5 cells. 
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The clinical response to pegIFN and ribavirin therapy for HCV is influenced both 
by host characteristics, such as IL28B genotype [165, 166] and baseline 
interferon stimulable gene (ISG) expression [179, 181], and viral genotype. 
Overall, with the exception of the interferon sensitivity determining region (ISDR) 
in the HCV NS5A, were an accumulation of mutations is associated with higher 
rates of SVR in G1b HCV [163], host factors are thought to dominate interferon 
responsiveness. In an assessment of viral interferon sensitivity in the capture-
fusion assay in eight patients with extreme responses to therapy, we found 
reduced interferon sensitivity in patients who showed no clinical response to 
treatment. The archival samples analysed could not be correlated with IL28B 
genotype and insufficient samples were available to assess ribavirin sensitivity. 
Although the number of samples analysed was very small, these findings suggest 
viral characteristics may play a role in determining outcome of interferon-based 
therapy. Further studies will be needed to investigate the complex interactions 
between host characteristics, especially IL28B genotype, viral interferon 
sensitivity and clinical outcome.  
 
The mechanisms by which ribavirin exerts its antiviral effects in treatment of 
chronic HCV remain uncertain, but it remains an important component of 
treatment, even the emerging era of interferon-free treatment regimens [316]. 
Amongst patients with G3 HCV cirrhosis, we noted a reduced pre-treatment 
response to ribavirin in patients who relapsed when compared to patients who 
achieved SVR and these data suggest that ribavirin sensitivity may be an 
important determinant of response in this genotype. Whether this finding extends 
to non-cirrhotic patients, relapse in patients infected with other genotypes, or 
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relapse following treatment with ribavirin in combination with drugs other than 
interferon, will require further investigation. 
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6.0 Discussion and Further Work 
This project aimed to investigate factors that influence response to antiviral 
treatment amongst patients with chronic HCV infection. In this work, we have 
modified a fusion assay (previously developed in the group) to use cell culture 
monocytes to “capture” HCV from sera of patients infected with diverse viral 
strains. In the majority of samples viral replication is seen after fusion of HCV-
exposed monocytes with hepatoma cells, and can be inhibited by antiviral drugs. 
We have undertaken work to validate this “capture-fusion” approach as an assay 
to screen patient sensitivity to antiviral drugs, and to investigate mechanisms 
underlying HCV infection of monocytes and the role this may play in relapse after 
antiviral therapy. We have demonstrated that drug sensitivity in the capture-
fusion assay reflects genotypic patterns of treatment response, as well as 
genotypic and clinical drug resistance. Furthermore, our work suggests that HCV 
may utilise CD64 to enter monocytes, and both pre-treatment ribavirin sensitivity 
and persistent HCV harboured in monocytes at the end of interferon and ribavirin 
therapy may be implicated in relapse.  
 
The most significant limitations of the capture-fusion approach are the low level 
of viral replication achieved, and the short period for which replication can be 
sustained (up to seven days) as the fused cells do not survive passage. HCV 
RNA could only be detected and quantified using a sensitive PCR assay. Other 
methods to detect viral replication (detection of protein production by indirect 
immunofluorescence or western blot, and alternative replication detection 
systems, such as the SEAP reporter cell line J20) were unsuccessful, most likely 
due to insufficient sensitivity. Negative strand PCR, widely used by others to 
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confirm HCV replication, was not attempted as its sensitivity is 10-1000-fold lower 
than that of positive strand PCR, and so would have been unlikely to have yielded 
positive results. Low level replication precluded detailed study of the mechanisms 
underlying replication in the hybrid cells, which in turn made it difficult to develop 
strategies to enhance replication. Empirical use of techniques found to enhance 
viral replication of the HCV cell culture strain JFH-1 met with varying success.  
 
To demonstrate HCV replication, monocyte fusion experiments and capture-
fusion experiments relied on accumulation of HCV RNA over time, and dose-
dependent reduction in HCV RNA following treatment with antiviral drugs. 
Although the inability to demonstrate HCV replication with any other technique 
than PCR is a significant limitation of this work, the PCR assay used was 
demonstrated to be highly sensitive, with a lower limit of detection of 10 copies 
and low intra- and inter-assay variation. Over the course of this project, many 
monocyte fusion and capture-fusion experiments were performed using samples 
from a large number of patients, infected with diverse HCV genotypes. The extent 
to which HCV RNA increased over time after fusion was highly variable between 
samples and in some cases little increment was seen, implying viral turnover or 
very low level replication only. However, the vast majority of fusion experiments 
yielded quantifiable HCV RNA 5 days after fusion, and the results were 
remarkably consistent when experiments were repeated using the same sample. 
Regardless of the level of HCV RNA accumulation seen after fusion, viral RNA 
levels were consistently reduced in a dose-dependent manner by exposure to 
antiviral drugs, and this correlated with known genotypic and clinical drug 
sensitivity. Together, these findings strongly suggest that low level viral 
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replication occurs in the capture-fusion system. The level of replication seen in 
the current assay is sufficient to allow testing of drug response in most samples, 
but is a significant limitation to the use of the assay to study replication of patient-
derived HCV in the hybrid cells. 
 
Use of digital PCR may allow more precise quantification of HCV RNA in the 
capture-fusion model. This novel technique relies on distribution of the sample 
nucleic acid into thousands of individual PCR reactions. Each reaction will receive 
a target molecule, yielding a positive result, or no target, yielding a negative 
result. The fraction of negative reactions is used to generate absolute 
quantification of target nucleic acid in the sample, without the need for a reference 
standard. A Poisson distribution model corrects for the possibility that some 
reactions receive more than 1 input copy of target nucleic acid. Target detection 
occurs with increased sensitivity and specificity compared to real time PCR, as 
partitioning of samples reduces competition and background DNA. The increased 
precision of quantification of low copy number target offered by digital PCR would 
enhance the reliability of HCV RNA detection in the capture-fusion assay. This 
may represent a useful option for future studies, as the technology becomes more 
widely available. 
 
6.1 The capture-fusion assay as a tool to study drug sensitivity of patient-
derived HCV 
The recent advances in in vitro model systems to study HCV replication have 
permitted enormous progress in understanding of the HCV life cycle and 
development of novel direct-acting antiviral therapies (DAAs). However a system 
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permitting the study of patient-derived HCV is still lacking. Patient-derived HCV 
does not infect hepatoma cells in culture, and the reasons for this remain poorly 
understood. The replicon and HCVcc systems (JFH-1) are based on highly 
adapted viruses replicating within an immortalised liver cell line [28, 73, 99]. 
Infection of primary monocyte/macrophages and T cells by patient-derived viral 
strains has been described [119, 124, 126], as well as chronic infection of 
transformed B and T cell lines in vitro using patient-derived virions [128, 129, 
317]. Hepatocyte-like cells derived from human embryonic stem cells or induced 
pluripotent stem cells support JFH-1 replication, but their use as a replication 
system for patient-derived HCV has not yet been reported [318, 319]. Attempts 
to use primary human hepatocytes (PHH) have been hampered by poor 
proliferation, limited viability in culture and restricted availability of cells [107].  
 
In this work, we have developed a model in which patient-derived HCV of all viral 
genotypes will replicate. For the majority of viral isolates, replication occurs at a 
sufficient level and for a sufficient duration to permit testing of sensitivity to 
antiviral drugs. It is possible that minor viral strains are selectively associated with 
monocytes, or that monocyte-associated virus has undergone adaptive mutations 
which render it un-representative of the patient’s viral quasispecies. Due to the 
low level of viral replication obtained, we were unable to perform extensive 
sequencing studies to investigate this. However the consistency between drug 
sensitivity seen in the assay, known genotype-specific responses to antiviral 
drugs and individual patient responses to drug therapy, implies that any viral 
selection or adaptive mutations are not significant for purposes of determining 
drug sensitivity.  
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The clinical response to pegIFN/RBV therapy for patients with HCV is dominated 
by viral genotype, host single nucleotide polymorphisms (SNPs) upstream of the 
IL28B gene [165, 166], and baseline host expression of interferon stimulable 
genes (ISG) [178, 179]. In an assessment of pre-treatment viral interferon 
sensitivity in eight patients with diverse responses to pegIFN/RBV therapy, we 
found reduced viral interferon sensitivity in patients who showed no clinical 
response. The archival samples analysed could not be correlated with IL28B 
genotype and insufficient samples were available to assess ribavirin sensitivity or 
ISG expression. Further studies will be needed to investigate the complex 
interactions between host IL28B genotype, interferon responsiveness, viral 
interferon sensitivity and clinical outcome. 
 
We have demonstrated that sensitivity of patient-derived HCV can be determined 
to several antiviral agents with widely differing mechanisms of action in the 
capture-fusion system. Antiviral therapy for HCV is rapidly evolving to include 
multi-drug combinations of DAAs. Although in clinical trials cure rates with these 
combination therapies are high [228, 240, 247, 320], rates of treatment failure in 
real-world settings are likely to be greater. To avoid development of ‘multi-drug 
resistant’ HCV strains, careful selection of ‘second line’ regimens will be required. 
Identification of the most effective treatment regimens in this scenario would be 
facilitated by phenotyping assays. Combinations of DAAs have not been tested 
as yet in the capture-fusion assay, and establishing its ability to predict treatment 
outcome to combination therapy is an important area for further work. 
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For the protease inhibitor telaprevir, our assay accurately identified viruses with 
known resistant variants and, of interest, we identified a single patient with wild 
type protease sequence and a poor therapeutic response to telaprevir whose 
virus was phenotypically resistant to telaprevir. These data suggest that novel 
resistant variants to telaprevir may exist and lie outside the classical resistance 
associated regions. Further work will be required to delineate this region and 
identify the frequency of these variants. In a blinded study using the capture-
fusion assay, we distinguished three G3 samples which had shown some 
response to telaprevir monotherapy in a clinical trial, from five samples with no 
telaprevir response [199]. These three samples could not be distinguished by 
genotyping, or by a commercial biochemical phenotyping assay [104]. Together, 
these findings suggest there may be patient-specific variability in response to 
DAA-based therapy which cannot be predicted by current genotyping or 
phenotyping assays. Future optimal treatment regimens may need to be patient-
specific, especially in patients who have already failed therapy, emphasising the 
need for a reliable phenotyping assay. 
 
6.2 Relapse after antiviral therapy 
We explored the possibility that monocytes play a role in relapse after anti-viral 
treatment by acting as a sanctuary site for HCV during therapy. An association 
between HCV detectable in monocytes at the end of therapy and relapse has 
been reported in patients co-infected with HIV and HCV [146], although patients 
co-infected with HIV may demonstrate increased replication of HCV in 
monocytes/macrophages compared to HCV mono-infected patients [271].  
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In patients with genotype (G)3 HCV, the viral genotype most prone to relapse 
following pegylated interferon and ribavirin (pegIFN/RBV) therapy, we found an 
association between viable HCV RNA in end-of-treatment monocytes and 
relapse after treatment. However, when we studied end-of-treatment monocytes 
from G1 HCV-infected patients treated with the HCV nucleoside polymerase 
inhibitor sofosbuvir and ribavirin, we found no evidence of viable HCV RNA in any 
sample, regardless of treatment outcome. Whether this reflects genotypic 
differences in treatment response or therapeutic differences in targeting of 
extrahepatic virions remains to be investigated.  
 
Using the capture-fusion model, we have also demonstrated that impaired viral 
ribavirin sensitivity pre-treatment was associated with relapse following 
pegIFN/RBV therapy in a cohort of cirrhotic patients with G3 HCV. One possible 
explanation for these findings is that ribavirin plays a critical role in treatment of 
extrahepatic HCV. Poorly ribavirin sensitive virus may be sequestered in 
extrahepatic sites (such as monocytes) during treatment, where it could 
conceivably be relatively protected from the effects of exogenous interferon if the 
level of turnover or viral replication is low. With regards to sofosbuvir/ribavirin 
therapy, the lack of apparent viable HCV RNA associated with end-of-treatment 
monocytes could be attributable to acquisition of adaptive mutations conferring 
reduced susceptibility to sofosbuvir in the poorly ribavirin-sensitive virions 
sequestered in extrahepatic sites during therapy. These resistance-associated 
variants (RAVs) often have compromised replicative fitness [207], which may 
explain why replication was not seen after fusion of end-of-treatment monocytes 
with Huh7.5 cells. Further investigation will be required to explore this hypothesis, 
199 
including sequencing of viral strains from pre-and post-treatment serum and 
monocytes and phenotyping in chimeric replicons. 
 
6.3 HCV infection of monocytes 
Further work employing the capture-fusion assay would be greatly assisted by 
enhancement of viral replication in the assay. Strategies reported by others to 
boost HCV replication in Huh7.5 cells, including treatment with the sonic 
hedgehog pathway agonist SAG and the cytokine osteopontin [292, 293], had 
limited and variable effect in the capture-fusion model. It is likely that successful 
and robust enhancement of replication in this assay will require greater 
understanding of the mechanisms permitting viral replication after fusion of 
infected monocytes with hepatoma cells. In common with others, we were unable 
to infect THP-1 cells with cell culture HCV (HCVcc; JFH-1) [122]. More recently, 
THP-1 have been successfully transfected with modified JFH-1 RNA [321]. This 
technique may assist in establishing a greater level of replication in the capture-
fusion assay, and help break the cycle of low level replication impeding 
investigation of mechanisms underlying viral replication in the fusion model, 
which in turn limits development of strategies to boost replication. Further 
understanding of extrahepatic HCV entry and replication may ultimately assist in 
development of treatment strategies to prevent relapse after antiviral therapy. 
 
Our work has suggested a role for Fcγ receptor I (CD64) in attachment of patient-
derived HCV RNA to THP-1, which then replicates after fusion with Huh7.5. 
However, CD64 blocking did not completely abrogate HCV replication after 
fusion, and so this is unlikely to be the sole means of uptake. Although we 
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demonstrated that a proportion of HCV RNA is internalised into THP-1 cells after 
incubation with patient serum, further work is needed to establish whether viral 
internalisation is required for replication after fusion. One hypothesis is that HCV 
is protected from degradation after uptake into monocytes by specific 
mechanisms, perhaps by segregation within intracellular compartments. This 
virus may then replicate after transfer to an environment rich in permissive factors 
for HCV replication. In support of this hypothesis, others have demonstrated that 
HCV virus-like particles were protected from lysosomal degradation after DC-
SIGN mediated uptake into dendritic cells or L-SIGN-mediated uptake into THP-
1 cells [299]. Targeting to a non-lysosomal compartment appeared to be ligand-
dependent, so whether this pathway is relevant to uptake of patient-derived 
virions into THP-1 cells remains to be established.  A series of experiments 
involving L-SIGN blocking and/or knockdown, fusion after trypsin treatment of 
HCV-exposed THP-1 and use of recently described fluorescent constructs which 
allow intracellular localisation of HCV replication [295] may help test this 
hypothesis. 
 
Alternatively, it is possible that internalisation of HCV into monocytes is not 
required for replication after fusion with Huh7.5. The fusion process may bypass 
any blocks in entry of patient-derived HCV into Huh7.5 cells, and “loading” of 
monocytes with HCV may result in bulk delivery of virus into the cell which 
overwhelms innate antiviral immune responses, permitting low level viral 
replication to occur. In support of this hypothesis, cytoplasmic sensing of dsRNA 
by retinoic acid inducible gene-I (RIG-I) is defective in Huh7.5, permitting 
enhanced HCV replication relative to the parent cell line (Huh7) in which RIG-I 
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function is intact [285]. Furthermore, we have demonstrated that the process of 
cell fusion of HCV-infected monocytes with Huh7.5 cells does not trigger 
expression of interferon stimulable genes, although their expression remains 
inducible by exogenous interferon.  
 
Whether transfer of internalised or surface-bound HCV into Huh7.5 is more 
important for replication after fusion, it appears that viral replication is facilitated 
by transfer to a more permissive environment. Cell fusion studies have previously 
been used to exclude dominant restriction factors as the limitation on HCV 
replication in non-liver cells [284]. A number of host factors are required for HCV 
replication which are present in Huh7.5 cells, including phosphatidylinositol 4-
kinase type III-α (PI4KIII-α) [63, 64] and the liver-specific micro-RNA miR-122 
[55]. The importance of these factors in HCV replication after fusion could be 
explored by knockdown in Huh7.5 cells before fusion. Ectopic expression in THP-
1 cells of critical permissive factors for replication after fusion might permit 
replication of patient-derived HCV in these cells, dispensing with the need for cell 
fusion and potentially enhancing the viability of the system for high-throughput 
screening of patient-derived HCV sensitivity to antiviral therapies.  
 
6.4 Extrahepatic HCV replication 
Extrahepatic replication of HCV has long been controversial. Over recent years, 
particularly with advances in technology with increased sensitivity to detect very 
low amounts of viral RNA and non-structural proteins, a consensus view has 
emerged that HCV probably does turn over or replicate at very low levels in 
extrahepatic sites, including PBMCs [112-116]. It has been suggested that such 
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low level replication permits the virus to evade intracellular innate antiviral 
detection mechanisms [139]. The work presented in this thesis lends support to 
this hypothesis by using an entirely novel technique to detect the presence of 
viable HCV RNA in patient-derived monocytes. We were unable to demonstrate 
significant HCV replication within monocytes or THP-1 cells, but the 
demonstration of replication after fusion with Huh7.5 cells strongly supports the 
presence of viable HCV RNA associated with these cells. 
 
The presence of viable HCV in patient-derived monocytes has potential 
significance in several aspects of HCV infection, including establishment of 
chronic HCV infection, reinfection of the graft after orthotopic liver transplantation 
and relapse after antiviral therapy. HCV has been successfully transmitted to a 
chimpanzee by transfusion of PBMC from an infected individual [322] and to 
immunodeficient mice by transfusion of human PMBCs from an HCV-infected 
donor [323]. Following orthotopic liver transplantation, reinfection of the graft is 
universal amongst HCV-infected recipients. The primary source of reinfection 
appears to be serum-derived virus but reinfection from PBMCs has been 
implicated [144] and graft infection is also described amongst recipients who are 
serum HCV RNA negative [145]. The source of infection in these patients has not 
been clearly identified, but reinfection by HCV sequestered in 
monocytes/macrophages or other PBMCs is a possibility and this warrants further 
investigation. 
 
In this work, we have not investigated whether HCV replication occurs after fusion 
of other PBMCs with Huh7.5 cells. HCV replication has been reported in patient-
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derived B and T lymphocytes as well as monocytes/macrophages [116, 132, 133, 
324]. T cells can be infected with patient-derived HCV in vitro [124], whilst B cells 
can be used to infect hepatoma cells with cell culture-produced HCV (HCVcc) 
[130]. Although this work has focussed on monocytes/macrophages, extrahepatic 
replication in other PBMCs may also be clinically important. 
 
6.5 Concluding remarks 
The work in this thesis has demonstrated that viable HCV RNA resides within 
patient-derived monocytes. By fusing these cells with the replication-permissive 
cell line Huh7.5, low level viral replication can be induced. Although the level of 
replication is low, it is sufficient to be detected using a sensitive PCR assay and 
can be reproducibly inhibited by antiviral drugs. Pre-stimulated THP-1 can be 
infected with HCV derived from patient-serum, and low level replication of this 
virus was seen after fusion of infected THP-1 with Huh7.5 cells. This could be 
inhibited by a range of antiviral drugs with diverse mechanisms of action in a 
genotype-specific and patient-specific manner. 
 
HCV infection of monocytes has implications for several clinical aspects of 
chronic HCV infection, including relapse after therapy. A limiting factor of our viral 
replication model is low level viral replication in the fused cells and this has 
hampered our attempts to investigate mechanisms underlying HCV entry into 
monocytes and replication after fusion. Our work in this area continues as the 
biology of HCV replication in extrahepatic sites has implications for relapse after 
antiviral therapy, which remains important clinically in the emerging era of DAA 
therapy. Greater understanding of mechanisms underlying replication in fused 
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monocytes:hepatocytes may allow refinement of the capture-fusion technique to 
enhance is suitability as a high-throughput screening tool for antiviral drug 
sensitivity. In turn, this may help tailor antiviral therapy to the individual to achieve 
the ultimate treatment goal in HCV: a cure for all. 
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Appendix A 
 
Sample Subtype Age 
(Years) 
Gender VL 
(IU/mL) 
ALT Fibrosis 
score 
Ethnicity Treatment status 
SER101 1a 69 M 15488166 43 5 White British prev NR, subsequent 
SVR with telaprevir 
SER102 1a     61 F 15849 12 1 White British previous NR, SVR in 
alisporivir trial 
SER103 1a 67 M 1318257 82 2 White British naïve 
SER104 1b 63 F 1778279 50 2 White - 
other 
background 
naïve (subsequent 
relapse) 
SER105 1a 54 M 1332903 96 1 White British NRx2  
SER106 1a 45 M 3000000 126 1 White British naïve 
SER107 1a 57 M 2701351 54 2 White British naïve 
SER108 1a 34 M 3636300 62 N/A White other relapse in PI/NS5B 
trial 
SER109 1b 53 M 207337 66 N/A White other naïve (subsequent 
relapse) 
SER110 1b 59 M 851857 51 6 White British naïve 
SER111 1a 57 M 7075272 56 2 White British naïve (subsequent 
SVR in 
sofosbuvir/5855/RBV 
trial) 
SER112 1a 38 M 3356395 67 3 White other naïve 
SER113 1a 56 F 1548816 280 1 White British naïve 
SER114 1a 58 M 300333 24 3 Other prev NR; 
breakthrough on 
IFN/RBV/boceprevir 
SER115 1a 61 M 2470464 131 N/A White British prev relapse; 
subsequent SVR 
with telaprevir 
SER116 1b 64 M 417312 71 6 White British naïve, SVR on 
Abbvie trial 
SER117 1a 44 F 742292 38 1 Asian or 
Asian British 
- Pakistani 
previous partial 
responder to 
IFN/RBV 
SER118 1b 63 M 494740 90 4 White British naïve, subsequent 
relapse 
IFN/RBV/telaprevir 
SER119 1a 59 F 2042201 168 6 White British naïve 
SER120 1a 46 M 5186029 99 5 White British NR to IFN/RBV and 
to 
IFN/RBV/danoprevir 
SER121 1a 63 F 1243820 18 6 White British NR to IFN/RBV and 
to IFN/RBV/telaprevr 
SER122 1a 55 M 3890451 47 2 White British relapse, subsequent 
SVR with telaprevir 
SER123 1b 51 F 5495409 30 2 Asian or 
Asian British 
- 
Bangladeshi 
SVR 
SER124 1a 54 M 3467369 167 4 White British SVR 
SER125 1a 45 M 794328.2 56 3 White - 
other 
background 
NR 
SER126 1a 58 F 14125375 33 4 White British NR 
 
Table A-1. Clinical features of patients with genotype 1 HCV who supplied serum samples 
for use in capture-fusion experiments. VL, viral load; ALT, alanine transaminase; NR, non-
response to previous treatment with pegylated interferon and ribavirin; SVR, sustained virological 
response; PI, protease inhibitor; NS5B, antiviral drug targeting HCV NS5B; IFN, pegylated 
interferon; RBV, ribavirin; N/A, not available. 
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Sample Subtype Age 
(Years) 
Gender VL 
(IU/mL) 
ALT Fibrosis 
score 
Ethnicity Treatment status 
SER201 2b 53 M 1636987 154 N/A White 
British 
naïve 
SER202 2 49 M 2884032 100 6 Black - 
other 
NR 
SER203 2b 59 M 258301 253 N/A White 
British 
naive, subsequent 
SVR 
SER204 2 54 M 2436479 22 6 White 
British 
naïve 
 
Table A-2. Clinical features of patients with genotype 2 HCV who supplied serum samples 
for use in capture-fusion experiments. VL, viral load; ALT, alanine transaminase; NR, non-
response to previous treatment with pegylated interferon and ribavirin; SVR, sustained virological 
response; N/A, not available. 
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Sample Subtype Age 
(Years) 
Gender VL 
(IU/mL) 
ALT Fibrosis 
score 
Ethnicity Treatment 
status 
SER301 3a 47 M 12589254 140 1 White British naïve 
(subsequent 
SVR) 
SER302 3a 58 M 5888437 72 4 White British relapse 
SER303 3a 43 M 2290868 153 5 Asian or 
Asian British - 
Pakistani 
naïve 
(subsequent 
relapse) 
SER304 3a 40 M 3890451 152 5 Asian or 
Asian British - 
Pakistani 
relapse 
SER305 3a 58 F 12384588 99 N/A Asian or 
Asian British - 
Pakistani 
naïve 
(subsequent NR 
to IFN/RBV) 
SER306 3a 24 M 170663 101 3 Asian or 
Asian British - 
Pakistani 
naïve 
(subsequent 
SVR) 
SER307 3a 26 M 282092 165 2 Other naïve 
(subsequent 
SVR) 
SER308 3a 53 M 2879840 88 2 White British naïve 
SER309 3a 41 F 3598151 51 1 Asian - Other naïve 
(subsequent 
SVR) 
SER310 3a 58 M 177526 168 5 White British naïve 
(subsequent 
relapse) 
SER311 3a 58 M 4168694 117 2 White British naïve 
SER312 3a 23 M 15586 114 N/A Asian or 
Asian British - 
Pakistani 
naïve, 
subsequent 
SVR 
SER313 3a 40 F 282608 109 N/A Asian - Other naïve 
(subsequent 
SVR) 
SER314 3b 42 M 197106 161 2 Other naïve 
SER315 3a 61 F 1699009 76 6 White British discontinued Rx 
- 
decompensation 
SER316 3a 54 M 5970686 171  Asian - other relapse 
SER317 3a 53 F 149882 29 1 White British relapse 
SER318 3b 75 M 3715352 66 6 Asian or 
Asian British - 
Bangladeshi 
relapse 
SER319 3a 38 F 177828 58 5 Asian - other SVR 
SER320 3b 59 F 281838 91 5 Asian or 
Asian British - 
Pakistani 
SVR 
SER321 3b 53 M 1621810 43 4 Asian or 
Asian British - 
Bangladeshi 
SVR 
SER322 3a 58 M 1153109 179 6 White British Relapse 
SER323 3a 48 M 4134234 216 6 Asian or 
Asian British - 
Pakistani 
Relapse 
SER324 3a 49 F 1945911 52 6 Asian or 
Asian British - 
Pakistani 
Relapse 
SER325 3a 52 M 366120 254 5 Asian or 
Asian British - 
Pakistani 
SVR 
SER326 3a 46 M 546020 151 4 White British SVR 
SER327 3a 56 F 1776799 47 6 Other SVR 
 
Table A-3. Clinical features of patients with genotype 3 HCV who supplied serum samples 
for use in capture-fusion experiments. VL, viral load; ALT, alanine transaminase; NR, non-
response to previous treatment with pegylated interferon and ribavirin; SVR, sustained virological 
response; IFN, pegylated interferon; RBV, ribavirin; N/A, not available. 
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Sample Subtype Age 
(Years) 
Gender VL 
(IU/mL) 
ALT Fibrosis 
score 
Ethnicity Treatment status 
SER40
1 
4 44 F 618730 88 N/A Black or Black 
British - African 
Previous NR 
SER40
2 
4 47 F 4555 50 0 Black - other Previous NR 
SER40
3 
4 48 F 283015 36 0 White - other naive 
 
Table A-4. Clinical features of patients with genotype 4 HCV who supplied serum samples 
for use in capture-fusion experiments. VL, viral load; ALT, alanine transaminase; NR, non-
response to previous treatment with pegylated interferon and ribavirin; N/A, not available. 
 
 
Sample Subtype Age 
(Years) 
Gender VL ALT Fibrosis 
score 
Ethnicity Treatment status 
SER601 6 33 F 564798 N/A N/A Asian - other naive 
SER602 6 41 M 2398833 14 N/A Asian - other Naïve 
(subsequent 
SVR) 
SER603 6k 62 M 939746 147 1 Other - Chinese naïve  
 
Table A-5. Clinical features of patients with genotype 6 HCV who supplied serum samples 
for use in capture-fusion experiments. VL, viral load; ALT, alanine transaminase; SVR, 
sustained virological response to treatment; N/A, not available. 
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Appendix B. Communications arising from this research 
Development and Validation of a “Capture-Fusion”
Model to Study Drug Sensitivity of Patient-Derived
Hepatitis C
Morven E. Cunningham, Alia Javaid, Jenny Waters, Joseph Davidson-Wright, Joshua L.C. Wong,
Meleri Jones, and Graham R. Foster
Emerging therapies for chronic hepatitis C viral (HCV) infection involve inhibition of viral
enzymes with drug combinations. Natural, or treatment-induced, enzyme polymorphisms
reduce efficacy. We developed a phenotyping assay to aid drug selection based on viral
transfer from monocytes to hepatocytes. We studied HCV in monocytes from infected
patients and developed a model in which patient-derived HCV is “captured” by the cell
line THP-1 and replication assessed after fusion to hepatoma cells. We found that mono-
cytes from HCV-infected patients harbor virus that replicates when cells are fused to hepa-
tocytes. THP-1 cells incubated with infected sera capture HCV, which replicates when
fused to hepatocytes. Inhibitable replication of all HCV genotypes was achieved (42 of 52
isolates). We measured sensitivity of telaprevir (TVR) and alisporivir (AVR) in different
genotypes, and showed differences in 50% inhibitory concentration (IC50) correlating with
clinical response (TVR IC50 for genotype (G)1 was 0.042 6 0.003 vs. 0.117 6 0.015 lM
for G3, whereas AVR IC50 for G1 was 0.139 6 0.013 vs. 0.044 6 0.007 lM for G3). We
tested TVR-resistant viral isolates and identified changes in IC50. One patient with a poor
clinical response to TVR and wild-type viral sequence showed reduced TVR sensitivity in
our assay. We studied samples from a 2-week TVR monotherapy study in which 5 of 8
patients with G3 HCV did not respond whereas 3 of 8 patients did. The “capture-fusion”
assay correctly identified responders. Conclusion: The capture-fusion model represents a
promising new technique that may help identify appropriate treatment strategies for
patients with chronic HCV infection. (HEPATOLOGY 2015;61:1192-1204)
See Editorial on Page 1112
T
herapy for patients infected with hepatitis C
virus (HCV) is rapidly evolving, and inter-
feron (IFN) and ribavirin (RBV) are being
replaced by direct-acting antiviral (DAA) agents.1
Drugs against the viral nonstructural protein 3 of
HCV (NS3) protease (telaprevir [TVR] simeprevir,
and boceprevir) and nonstructural protein 5B of HCV
(NS5B) polymerase (sofosbuvir; SOF) have been
licensed, and new protease, nonstructural protein 5A
of HCV (NS5A), and polymerase inhibitors are in
clinical trials. In combination with IFN, most drugs
increase the proportion of patients who respond. This
has led to attempts to avoid IFN-related side effects by
combining drugs of different classes in IFN-free regi-
mens. Distinct viral strains respond differently, for
Abbreviations: Abs, antibodies; AVR, alisporivir; DAA, direct acting antiviral; DMEM, Dulbecco’s modified Eagle medium; DMSO, dimethyl sulfoxide; FCS,
fetal calf serum; G, genotype; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; JFH-1, Japanese fulminant hepatitis type 1; HCV, hepatitis C virus; IC50, 50%
inhibitory concentration; IF, immunofluorescence; IFN, interferon; IL, interleukin; mRNA, messenger RNA; NS3, nonstructural protein 3 of the hepatitis C virus;
NS5A, nonstructural protein 5A of the hepatitis C virus; NS5B, nonstructural protein 5B of the hepatitis C virus; PBMCs, peripheral blood mononuclear cells;
PEG, polyethylene glycol; Peg-IFN, pegylated IFN; PI3K/Pi4K, phosphatidylinositol 3- and 4-kinase; PMA, phorbol 12-myristate 13-acetate; PS, penicillin/strepto-
mycin; RBV, ribavirin; RT-qPCR, reverse-transcription quantitative polymerase chain reaction; SOF, sofosbuvir; SR-B1, scavenger receptor class B type 1; SVR, sus-
tained virological response; TVR, telaprevir; WT, wild type.
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example, genotype (G)1b strains respond well to prote-
ase inhibitors combined with non-nucleotide polymer-
ase inhibitors or NS5A inhibitors,2,3 but G1a strains
require additional drugs.4 Some G1a strains do
respond to protease plus non-nucleoside drugs,5 but
their characteristics are undefined. IFN-free SOF is
effective for G2 HCV and has some efficacy in G1,
but less so in G3.6
Development of DAAs was facilitated by in vitro
HCV replication systems (the G1 replicon and
replication-permissive G2 strain, Japanese fulminant
hepatitis type 1 [JFH-1])7,8 that allowed high-
throughput screening. Subgenomic replicons based
around G3a and G4a have extended the range of geno-
types that can be studied,9,10 and chimeric variants have
been used to analyze resistance-associated variants.
These systems are of limited value in analysis of a
patient’s viral sensitivity—defining drug sensitivity of a
viral isolate requires subcloning each DAA target gene
and insertion into a replicon. Difficulty in generating
replicons with more than one modified locus precludes
studies of multidrug combinations. In human immuno-
deficiency virus infection, viral phenotyping assays
enabled selection of optimal regimens, although pro-
gress in genotypic resistance testing has reduced their
value. For G1 HCV, some viral motifs associated with
protease inhibitor treatment failure have been identi-
fied,11 but for other genotypes there is no association
between sequence and response,12 indicating that, in the
short term, viral phenotyping assays may be useful in
identifying optimal regimens for less-responsive viral
strains. Although recently presented data indicate that
emerging drug regimens cure over 90% of patients with
G1 HCV,13,14 the proportion of patients who fail may
be higher in practice. To avoid development of
“multidrug-resistant” HCV strains, careful selection of
“second-line” regimens will be required. Identification
of the most effective treatment regimens in this scenario
would be facilitated by phenotyping assays.
Association of HCV with extrahepatic sites, such as
peripheral blood mononuclear cells (PBMCs), is estab-
lished, although extrahepatic viral replication remains
controversial.15-20 Here, we describe a “capture-fusion”
technique in which patient-derived HCV is “captured”
by monocytes and transferred to hepatocytes using cell
fusion. This allows analysis of patient-derived virus
from all genotypes and drug sensitivity and treatment
response can be predicted. This new assay may be
helpful in determining optimal drug combinations and
be of particular value in patients who have failed
“first-line” regimens.
Materials and Methods
Cells, Reagents, and Clinical Material. Huh7.5
cells (kindly provided by C.M. Rice, Rockefeller Insti-
tute, New York, NY) were maintained in Dulbecco’s
modified Eagle medium (DMEM) with glutamine, 10%
fetal calf serum (FCS), and 1% penicillin/streptomycin
(DMEM/10% FCS/PS). THP-1 cells21 were maintained
in RPMI with glutamine, 10% FCS, and 1% PS.
PBMCs and sera were obtained from consenting
patients with chronic HCV infection.
Stimulants/inhibitors used were phorbol 12-
myristate 13-acetate (PMA; Sigma-Aldrich, Dorset,
UK), IFN-c (Invitrogen, Paisley, UK), and wortman-
nin (Sigma-Aldrich).
TVR and alisporivir (AVR) were kindly supplied by
Janssen Virology (Baar, Switzerland) and Novartis
Pharma AG (Basel, Switzerland), respectively. IFN-a-
2a was from Cambridge Bioscience (Cambridge, UK)
and RBV from Sigma-Aldrich. Ethical approval for the
study was given by London-City Research Ethics
Committee, and informed consent obtained from all
patients. The study was conducted in accord with the
Declaration of Helsinki.
Fusion of Patient Monocytes. PBMCs were sepa-
rated from whole blood by centrifugation on Ficoll-
Paque (GE Healthcare, Buckinghamshire, UK). The
PBMC layer was washed twice before positive selection
of CD141 cells by magnetic separation (Milteyi Bio-
tec, Surrey, UK), according to manufacturer’s instruc-
tions. For fusion optimization experiments, CD141
cells were incubated with DiI and Huh7.5 cells with
DiO (Life Technologies, Paisley, UK) before incuba-
tion with polyethylene glycol (PEG) 1500 (Roche
Diagnostics, Burgess Hill, UK). Cells were fixed with
4% paraformaldehyde (PFA) and enumerated by flow
Address reprint requests to: Graham R. Foster, Ph.D., F.R.C.P., Blizard Institute, Queen Mary University of London, 4 Newark Street, London E1 2AT, UK.
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cytometry (FACSCanto II; BD Biosciences, Oxford,
UK).
For all subsequent fusion experiments, Huh7.5 cells
and CD141 cells (1:1) were incubated with PEG at
37C for 2 minutes, then prewarmed medium
(DMEM) added dropwise and the cells washed by
centrifugation. Fused cells were seeded into six-well
plates (5 3 105 cells/mL) and maintained at 37C.
Stimulation and Infection of THP-1 Cells.
THP-1 cells were seeded into six-well plates (106 cells/
mL) and maintained for 18 hours, with or without
IFN-c (10 ng/mL) and PMA (200 ng/mL). Cells were
washed thrice and medium replaced with RPMI/2%
FCS and patient serum (1 HCV IU/cell). After incu-
bation (37C for 18-24 hours), supernatant was
removed and cells washed. Adherent cells were
removed by scraping and combined with Huh7.5 cells
(1:1). Cell fusion was performed as described above.
Fused cells were seeded into six-well plates (105 cells/
mL) and maintained at 37C with or without drugs
for up to 7 days. In selected experiments, supernatants
were pooled from non-drug-treated wells and concen-
trated by filtration through a 0.45-lm filter, then 10
mL was layered on 4 mL of 20% sucrose. Supernatants
were centrifuged (24,000g) for 2 hours and the pellet
resuspended in 1 mL of RPMI. For capture-fusion
experiments using concentrated supernatant, 1 3 106
prestimulated THP-1 cells were incubated with 1 mL
of concentrated supernatant for 24 hours before
fusion.
Drug Inhibition Assays. Fused cells were rested
overnight before the addition of drugs. TVR and AVR
were diluted from 20-mM stock solutions in dimethyl
sulfoxide (DMSO). Each drug concentration was
tested in quadruplicate. Drug dilution mix alone
(RPMI/2% FCS/0.5% DMSO) was added to control
wells. Media and drug were refreshed at day 3. Viral
RNA was calculated as a percentage of that in
untreated wells. Dose-response curves were constructed
and used to estimate the 50% inhibitory concentration
(IC50) of drug using Prism 4.0 software (GraphPad
Software, Inc., La Jolla, CA).
Cell Viability Assays. Cell viability was measured
using the Cell Titer-Glo assay (Promega, Southamp-
ton, UK) and a FLUOstar Optima plate reader (BMG
Labtech, Aylesbury, UK), according to the manufac-
turer’s instructions.
Quantification of HCV RNA and Gene Expres-
sion. Total RNA was extracted with TRIzol (Invitro-
gen) and quantified using RiboGreen (Invitrogen),
according to the manufacturer’s instructions. Comple-
mentary DNA was synthesised using Moloney murine
leukemia virus reverse transcriptase (Promega) and
diluted (1:10) for amplification by quantitative poly-
merase chain reaction (qPCR; QuantiTect SYBR Green
PCR kit; Qiagen, Hilden, Germany). For primers and
cycling conditions, see the Supporting Information.
Target messenger RNA (mRNA) was normalized to
glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
or b-actin expression, which were confirmed to be sta-
bly expressed in these experiments (GeNorm; Primer-
Design, Southampton, UK).
For HCV copy number quantification, one-step
reverse-transcription PCR (RT-qPCR) using the Quan-
tiTect Virus Kit (Qiagen) and TaqMan Gene Expres-
sion Assay HCV primer and probe (Applied
Biosystems, Paisley, UK) was performed. Serial dilu-
tions of an RNA standard were included in each PCR
run and results expressed relative to total sample RNA.
Fluorescence-Activated Cell-Sorting Analysis.
Cells were incubated with primary antibody (Ab) or
appropriate isotype control in 1% bovine serum albu-
min/10% FCS for 30 minutes. Alexa Fluor 488 sec-
ondary Abs were used to detect bound primary Ab
and quantified on a FACSCanto II flow cytometer
(BD Biosciences). Data were analyzed using FlowJo
software (TreesStar, Ashland, OR).
Statistical Analysis. Data were tested for normal-
ity using the D’Agostino’s and Pearson’s test. Statistical
analyses used the Student t test for parametric data or
Mann-Whitney’s U test for nonparametric data, with
P < 0.05 considered significant.
Results
Identification of Replication-Competent HCV in
Patient-Derived Monocytes by Fusion With Huh7.5
Cells. We examined CD14(1) monocytes from
patients with chronic HCV infection (N 5 4) and
found low levels of HCV that did not increase during
cell culture (7 days), implying a lack of viral replica-
tion (data not shown). We then fused patient-derived
monocytes with Huh7.5 cells using PEG. Dye-labeled
cells were used to determine optimal fusion conditions.
Fusion of 40% of CD14(1) monocytes with Huh7.5
cells was achieved using optimized conditions (see
Materials and Methods; Fig. 1A). Monocytes from
patients infected with diverse viral genotypes were
fused to Huh7.5 cells and maintained in culture for
up to 21 days. HCV RNA increased progressively up
to 7 days after fusion, but declined thereafter (Fig.
1B). In these preliminary experiments, HCV RNA was
quantified relative to beta-actin expression. To confirm
reliable detection of low-level HCV RNA and quantify
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Fig. 1. Detectable HCV RNA increases after fusion of patient-derived monocytes with Huh7.5 cells, and this can be inhibited with antiviral
drugs. (A) Fluorescence-activated cell-sorting plot showing PEG-mediated fusion of patient monocytes and Huh7.5 cells. Huh7.5 cells were
stained with DiO and CD14(1) monocytes with DiI. After PEG fusion, the percentage of cells expressing both dyes was enumerated by flow
cytometry. Figures refer to percentage of total cells. (B) monocytes from 7 patients with chronic HCV were fused with Huh7.5 and HCV RNA quan-
tified at various times up to 21 days after fusion. Not all time points are available for all samples as a result of limited cell numbers. Results
are expressed as fold change from unfused monocytes and normalized to beta-actin expression. (C) Mean 6 standard error of the mean (SEM)
of five further experiments where monocytes from HCV patients were either fused or cocultured with Huh7.5 cells and HCV RNA quantified up to
7 days after fusion. P 5 0.038 at 3 days and P 5 0.015 at 5 days postfusion for the comparison between fused and unfused cells. (D) Mean
6 SEM of two further experiments where fused patient monocytes were cultured with or without 100 IU/mL of IFN-a-2a. P 5 0.031 for the com-
parison between treated and untreated cells at day 7 postfusion. (E) Mean 6 SEM of three further experiments where fused G1 patient mono-
cytes were cultured with or without TVR 0.5 lM. P 5 0.0001 at 5 days and P 5 0.0002 at 7 days postfusion for the comparison between
treated and untreated cells. (F) Mean 6 SEM of two further experiments where fused patient monocytes were cultured with or without the PI3K/
PI4K inhibitor, wortmannin, 0.5 lM for 5 days after fusion. P 5 0.014 for the comparison between treated and untreated cells. (C-E) HCV cop-
ies/lg total RNA as a percentage of day 0 postfusion to normalize for differences in HCV-RNA yield between individual patient samples. (F) HCV
copies/lg total RNA as a percentage of untreated cells at day 5 postfusion.
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HCV-RNA copy number, a one-step RT-qPCR assay
was employed (see Materials and Methods) with a
quantification range of 10-108 HCV copies per reac-
tion (Supporting Fig. 1). Rather than logarithmic
increases in HCV RNA observed in propagation of
cell-culture HCV strains, we typically observed a 2- to
10-fold increase in viral RNA over 7 days after fusion,
suggesting low-level replication (Fig. 1C). Treatment
of fused cells with antiviral drugs abolished this
increase (Fig. 1D,E). Treatment of fused cells with
wortmannin, a phosphatidylinositol 3- and 4-kinase
(PI3K/PI4K) inhibitor, also reduced replication after
fusion (Fig. 1F). Contamination by laboratory HCV
strains was excluded by viral sequencing (data not
shown). Attempts to demonstrate HCV replication
using less-sensitive techniques (western blotting and
indirect immunofluorescence [IF]) were unsuccessful,
most likely because of the low level of viral replication
(data not shown). Together, these results indicate that
viable HCV is associated with monocytes of patients
with chronic HCV infection. Fusion of infected
monocytes with Huh7.5 cells permits sufficient viral
replication to be detected by a sensitive PCR assay.
Association of Patient-Derived HCV With THP-1
Cells Is Enhanced by PMA and IFN-c, but Is Inde-
pendent of CD81. Patient-derived HCV in fused
cells can be inhibited with antiviral drugs, allowing
identification of patient-specific responses to antiviral
therapies. Given the limitations of working with
patient monocytes, we examined whether cultured
monocytes could be used to capture HCV from
patient serum. After incubation of the monocytic cell
line, THP-1, with patient serum, we found little asso-
ciation of HCV with THP-1 cells. Others report that
PMA and IFN-c pretreatment enhances HCV uptake
into monocytic cell lines.22 Stimulation of THP-1
with PMA/IFN-c enhanced the association of patient-
derived HCV (Fig. 2A), and trypsin treatment of
virus-loaded THP-1 cells after 4 hours reduced viral
levels, indicating that virus was internalized between 1
and 4 hours after infection (Fig. 2B).
HCV entry into hepatocytes is dependent upon
CD81, scavenger receptor class B type 1 (SR-B1),
claudin, and occludin.23 Neither mRNA nor cell-
surface expression of CD81 or SR-B1 was enhanced
by PMA/IFN-c treatment of THP-1 (Supporting Fig.
Fig. 2. Association of patient-derived HCV with THP-1 is enhanced by PMA/IFN-c, but is independent of CD81. (A) THP-1 cells were cultured
for 24 hours with PMA 200 ng/mL, IFN-c 10 ng/mL, PMA 200 ng/mL and IFN-c 10 ng/mL or no stimulants before incubation with patient
serum. HCV RNA was measured 24 hours after infection. P 5 0.026 for the comparison between unstimulated and PMA/IFN-c-stimulated cells.
(B) THP-1 cells prestimulated with PMA/IFN-c were treated with trypsin at various times after incubation with patient sera. P 5 0.029 for the
comparison between trypsin treatment 0 and 24 hours postinfection. (C) PMA/IFNc-stimulated THP-1 cells were incubated in the presence or
absence of anti-CD81 blocking Ab (5 lg/mL) for 1 hour before infection with patient-derived HCV. HCV RNA was quantified after 24 hours.
Graph shows mean 6 standard error of the mean of two independent experiments. P 5 0.09 for the comparison between antibody treated and
untreated cells.
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2). Claudin-1 and occludin were not expressed by
these cells. Blocking Abs to CD81 did not reduce
HCV association with stimulated THP-1 (Fig. 2C),
although JFH-1 entry into Huh7.5 cells was inhibited
(Supporting Fig. 3). These data suggest that HCV
association with THP-1 is independent of CD81 and
other receptors are associated with HCV entry into
hepatocytes.
Accumulation of Patient-Derived HCV Occurs
After Capture Fusion. Accumulation of HCV RNA
was observed after Huh7.5 fusion to PMA/IFN-c-
stimulated, HCV-exposed THP-1 cells, compared to
HCV-exposed, PEG-treated Huh7.5, THP-1, or
Huh7.5 alone (Fig. 3A). HCV-RNA accumulation
after fusion was significantly greater when THP-1 were
prestimulated, particularly when IFN-c was added to
PMA stimulation (Fig. 3B). To examine the potential
antiviral effects of IFN-c, we studied expression of the
IFN-inducible gene MxA. MxA expression was not
induced by cell fusion and was low in fusions with
HCV-infected monocytes, even when the monocytes
had been pretreated with PMA/IFN-c, but could be
up-regulated by subsequent treatment with IFN-a
(Fig. 3C). Priming of Huh7.5 cells with IFN-a signifi-
cantly reduced HCV replication after fusion (Fig. 3D).
Thus, addition of IFN-c increases uptake of virus by
monocytes, but fusing IFN-c-exposed cells does not
lead to induction of antiviral genes in fused cells.
However, direct stimulation of Huh7.5 cells with the
more potent antiviral IFN, IFN-a, does reduce HCV
replication. These data suggest PMA/IFN-c treatment
of THP-1 is important for HCV capture, but does
not trigger induction of innate antiviral responses,
although the cells are still able to induce antiviral
genes.
To establish whether full replication cycles occurred
in the fused cells with release of infectious virus, super-
natants from capture-fusion experiments were col-
lected, concentrated, and applied to Huh7.5 cells or to
stimulated THP-1 cells in a fresh capture-fusion cycle.
HCV RNA accumulated over time in fused cells and
to a much lesser extent in Huh7.5 cells (Fig. 3E).
These data suggest that HCV undergoes replicative
cycles with release of infectious virions in the capture-
fusion model.
HCV RNA Accumulation Occurs After Fusion in
Isolates From All Viral Genotypes and Can Be
Inhibited by Antiviral Drugs. Fifty-two viral isolates
of genotypes 1-6 were tested in this capture-fusion
assay and HCV RNA could be quantified (>10 copies
per reaction) after fusion in 42 (81%). Median viral
yield was 63 copies/lg total RNA (range, 14-354)
equivalent to median 19 HCV copies per fused cell
(range, 4-106). Of the remaining 10 samples, seven
were archival (3-7 years old) and may have degraded
during storage. Three samples produced detectable
HCV RNA below the quantification limit in repeated
experiments. HCV-RNA yield varied between samples,
but did not relate to viral load or disease activity (Sup-
porting Fig. 4), and was consistent in repeated experi-
ments for a given sample (Supporting Fig. 5),
suggesting that replicative fitness in this model is influ-
enced by intrinsic viral characteristics. TVR exposure
after fusion caused a dose-dependent reduction in
HCV RNA in isolates from all genotypes except G3,
known to be poorly TVR sensitive (Fig. 3F). Experi-
ments with alternative inhibitors confirmed that sensi-
tivity of G3 HCV could also be studied (see below).
Drug Sensitivity of Patient-Derived HCV in the
Capture-Fusion Model Reflects Genotypic Patterns of
Response to Antiviral Drugs. We observed that G3
HCV was poorly inhibited by TVR in the capture-
fusion assay (Fig. 3F). TVR inhibits G1, but has little
effect against G3 HCV.24-26 Conversely, the cyclophil-
lin inhibitor, AVR, is more efficacious against G2 and
G3 than G1 and G4.27 THP-1 cells exposed to sera
from G1- and G3-infected donors were fused with
Huh7.5, then treated with TVR or AVR for 5 days
before quantification of HCV RNA. Dose-response
curves were constructed and used to calculate an IC50.
Figure 4 shows pooled results from 14 donors,
normalized to untreated cells. Dose-response curves
were constructed for all isolates which reached quanti-
fiable levels (Supporting Fig. 6 shows absolute values
for representative patients). Drug-induced cytotoxicity
was excluded by measuring cell viability after drug
exposure. TVR had no effect on cell survival. The
minor effects of doses of AVR >0.1 lM were insuffi-
cient to account for the reduction in HCV RNA (Sup-
porting Fig. 7). G1 samples were significantly more
sensitive to TVR and less sensitive to AVR than G3
(Fig. 4A-D). Individual TVR and AVR IC50s for each
sample are shown in Fig. 4E,F. G2 isolates were sensi-
tive to TVR and AVR, whereas G4 strains showed a
similar AVR response to G1 (in keeping with clinical
trial data). Some G4 isolates were poorly sensitive to
TVR, consistent with clinical trial findings.28 However,
other G4 isolates were inhibited by TVR in the assay,
suggesting differing TVR susceptibility amongst G4
strains (Supporting Fig. 8).
Drug Sensitivity in the Capture-Fusion Assay
Reflects Phenotypic Treatment Response. To explore
whether clinical TVR resistance could be detected in
the capture-fusion assay, pretreatment and post-
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Fig. 3. Replication of patient-derived HCV occurs after capture by prestimulated THP-1 and fusion with Huh7.5 cells and can be inhibited by
telaprevir. A. Mean 6 standard error of the mean (SEM) of two independent experiments where HCV RNA was quantified from PMA/IFN-c-stimu-
lated, HCV-exposed THP-1 fused with Huh7.5 cells, from HCV-exposed THP-1 and Huh7.5 cells without fusion, and from HCV-exposed Huh7.5
cells treated with PEG (fusion protocol). P 5 0.019 for the comparison between HCV RNA in fused THP-1/Huh7.5 at days and 5 postfusion.
Results are shown as percentage of HCV RNA in cells at day 0. (B) Representative of two independent experiments where THP-1 cells were cul-
tured with PMA 200 ng/mL, PMA 200 ng/mL and IFN-c 10ng/mL or no stimulants for 24 hours before infection with patient-derived HCV and
fusion with Huh7.5 cells. HCV RNA was quantified up to 5 days after fusion. P 5 0.005 and P 5 0.015 for the comparison between unstimu-
lated and PMA/IFN-c-stimulated THP-1 at days 3 and 5 postfusion, respectively. (C) PMA/IFNc-treated THP-1 fused with Huh7.5 (labeled fused
THP-1/Huh7.5), PMA/IFN-c-treated, HCV-exposed THP-1 fused with Huh7.5 (labeled fused THP-1/Huh7.5 1 HCV), or unfused Huh7.5 (labeled
Huh7.5) were cultured for 5 days in the presence or absence of IFN-a-2a (100 IU/mL). MxA mRNA was quantified by PCR and expressed rela-
tive to GAPDH expression and uninfected, unfused, untreated Huh7.5. Results are shown on a logarithmic scale. (D) Huh7.5 cells were pre-
treated with IFN-a-2a (100 IU/mL) before fusion with prestimulated, HCV-infected THP-1. HCV RNA was quantified up to 5 days after fusion. (E)
Mean 6 SEM of two independent experiments in which supernatant from capture-fusion experiments was applied to PMA/IFN-c-stimulated THP-
1, which were then fused with Huh7.5 in a further round of capture-fusion, or na€ıve Huh7.5 cells. HCV RNA was quantified up to 5 days after
fusion. (F) HCV RNA 5 days after fusion in capture-fusion experiments, with or without TVR 1.0 lM using sera from donors infected with diverse
HCV genotypes. Each point represents mean HCV RNA 6 SEM from at least four biological replicates from a representative patient sample.
Fig. 4. Sensitivity of patient-derived HCV to antiviral drugs can be assayed in the capture-fusion model. HCV derived from serum from 9 G1
and 5 G3 donors was treated with varying concentrations of TVR or AVR in capture-fusion assays and HCV RNA measured after 5 days. G1
patient-derived HCV was more sensitive to TVR than G3 (A and B), but less sensitive to AVR (C and D). Comparison of individual IC50 values
showed TVR IC50 was 0.042 6 0.003 for G1 samples versus 0.117 6 0.015 lM for G3; P 5 0.001 (E). Conversely, AVR IC50 was 0.139 6
0.013 for G1 samples versus 0.044 6 0.007 lM for G3; P 50 .004 (F). Graphs show mean 6 standard error of the mean.
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breakthrough sera were obtained from 2 patients with
G1 HCV who initially responded to TVR, pegylated
IFN (Peg-IFN) and RBV, but experienced virological
breakthrough by treatment week 12. Sequencing of the
first 200 amino acids of viral NS3 to 1% frequency
by pyrosequencing found wild-type (WT) virus at
baseline and TVR resistance-associated mutations
V36M/R155K at breakthrough in the majority of
sequences. TVR sensitivity pre- and postbreakthrough
assessed in the capture-fusion assay demonstrated a
loss of sensitivity in the resistant strains (Fig. 5A). Pre-
and post-treatment serum was obtained from 1 further
patient with G1 HCV with a poor clinical response to
TVR, Peg-IFN, and RBV (circa 1 log10 reduction in
viral load at week 4). No TVR resistance-associated
mutations were identified pretreatment (sequencing to
1% frequency), although V36M/R155K mutations
were present at treatment failure. This strain
demonstrated poor TVR sensitivity in the capture-
fusion assay both before and after exposure (Fig. 5B).
Pretreatment sera from 2 further patients with G1
HCV and a poor clinical response to TVR, Peg-IFN,
and RBV also demonstrated poor TVR sensitivity in
the capture-fusion assay (data not shown). This sug-
gests that phenotypic sensitivity to TVR may be more
predictive of response than genotypic sensitivity.
IFN sensitivity may be a determinant of acquisition
of resistance to direct-acting antiviral drugs. Whether
host or viral factors dominate IFN sensitivity is
unclear. Archived pretreatment sera from 4 patients
who responded to Peg-IFN and RBV (HCV RNA
undetectable at treatment week 4) and 4 patients with
a null response (<2 log10 drop in viral load at treat-
ment week 12) were used to examine IFN sensitivity
Fig. 5. Phenotypic and genotypic drug resistance correlates with drug sensitivity in the capture-fusion assay. Pretreatment and postbreak-
through sera from 2 patients who failed treatment with TVR, Peg-IFN, and RBV demonstrated loss of TVR sensitivity in the capture-fusion assay
after acquisition of genotypic and clinical TVR resistance (A). Pre- and post-treatment serum from a patient with little clinical response to TVR,
Peg-IFN, and RBV showed poor TVR sensitivity both pretreatment and after treatment failure (B). Using archived pretreatment sera from patients
who did or did not respond to Peg-IFN and RBV treatment, HCV strains from patients who responded to treatment (C) were more sensitive to IFN
in the capture-fusion assay than viral strains from patients who did not respond (D). Graphs show mean 6 standard error of the mean.
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in the capture-fusion assay. Pretreatment HCV from
patients who responded to IFN was more sensitive to
IFN in the capture-fusion assay than virus from patients
with a null response (Fig. 5C,D). Patient viral loads
and viral replication achieved in the assay did not differ
significantly between the groups (data not shown).
In contrast to G1, the predominant mode of treat-
ment failure in G3 HCV infection is relapse. Relapse
rates are higher in patients who receive suboptimal
RBV dosing.29,30 Archived pretreatment sera from 10
G3 patients with cirrhosis treated with Peg-IFN and
RBV, 4 with sustained virological response (SVR), and
6 who relapsed were used to study pretreatment IFN
and RBV sensitivity. No difference in IFN sensitivity
was observed, but pretreatment HCV from patients
with SVR was more sensitive to RBV in the assay than
virus from relapsers (Fig. 6).
Sensitivity to TVR in the Capture-Fusion Assay
Correlates With Clinical Response. Although TVR
was poorly effective in G3 HCV, a subgroup of
patients (30%) did respond.26 To establish whether
the capture-fusion assay could identify TVR-sensitive
G3 HCV, pretreatment, blinded sera were obtained
from 8 patients with G3 HCV who had received TVR
monotherapy in a clinical trial.26 TVR sensitivity of
each sample in the capture-fusion assay correlated with
clinical response, whereas a biochemical phenotyping
assay did not12 (Fig. 7). Three samples with the great-
est TVR sensitivity in the capture-fusion assay corre-
sponded to patients who responded clinically to TVR.
These results indicate that the assay may predict
patient responses to TVR.
Discussion
We have developed a capture-fusion technique that
allows drug sensitivity of over 80% of HCV viral
strains to be assessed. We found that resistance to
TVR can be reliably determined, clinical sensitivity to
cyclophilin and protease inhibitors can be identified,
and there is a strong correlation between TVR sensitiv-
ity in our assay and clinical response in patients with
G3 HCV, unlike conventional phenotyping assays.
Cell-fusion techniques have been employed to investi-
gate extrahepatic HCV replication,31 but this is the
first report using cell fusion to facilitate replication of
patient-derived HCV strains.
Emerging therapies for chronic HCV infection
involve combinations of DAAs. Different combina-
tions have differential effects on different viral strains,
for example, faldeprevir with a non-nucleoside NS5B
inhibitor cures most patients with G1b HCV, but only
43% of patients with G1a.2 Accurate phenotyping of
infecting virus before antiviral therapy may be valuable
in determining appropriate drug combinations in
future therapeutic regimens. Although the number of
drug combinations tested in our assay is relatively
small, we have no reason to expect that the assay will
not identify viral sensitivity to a wide range of differ-
ent therapies.
We investigated compounds with clinical trial data
that differ in different genotypes. We found a close
correlation between activity in patients and our assay,
suggesting that the capture-fusion model may be useful
in assessing sensitivity to DAAs. For the protease
inhibitor, TVR, our assay accurately identifies viruses
with known resistant variants, and, of interest, we
identified a single patient with WT protease sequence
and a poor therapeutic response to TVR whose virus
was phenotypically resistant to TVR. These data sug-
gest that novel resistant variants to TVR may exist and
lie outside the classical resistance-associated regions.
Further work will be required to delineate this region
and identify the frequency of these variants.
The clinical response to Peg-IFN and RBV therapy for
HCV is dominated by host (interleukin [IL]28B)32,33
and viral genotype. In an assessment of viral IFN sensi-
tivity in 8 patients with diverse responses, we noted
reduced sensitivity in patients who showed no clinical
response. The archival samples analyzed could not be
correlated with IL28B genotype, and insufficient samples
were available to assess RBV sensitivity. Further studies
will be needed to investigate the complex interactions
between host IL28B genotype, viral IFN sensitivity, and
clinical outcome. We noted a reduced response to RBV
in patients with G3 HCV who relapsed, when compared
to patients who achieved SVR, suggesting that RBV sen-
sitivity may be an important determinant of response in
this genotype. Further studies, including viral sequencing
and phenotyping in chimeric replicons, will be required
to confirm this observation and are underway.
It has long been recognized that monocytes from
patients with HCV contain viral fragments, but it is
unclear whether these cells contain replicating virus.
We find that fusing monocytes from patients with
HCV to replication-permissive hepatocytes allows viral
replication in chimeric cells, indicating that monocytes
contain viable HCV. The role of sequestered virus in
viral persistence and the emerging immune response
remains to be determined.
Interestingly, given the antiviral action of IFN-c, we
found that IFN-c prestimulation of THP-1 was
required, in addition to PMA, to achieve viral replica-
tion after fusion of HCV-exposed THP-1 with
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Huh7.5. Others have observed Fc receptor up-
regulation after PMA/IFN-c treatment of monocyte
cell lines, with enhanced uptake of HCV immune
complexes.22 Certainly, uptake of HCV into THP-1
cells appears independent of the classical HCV entry
receptors, CD81, SR-B1, claudin, and occludin.
Fig. 6. Pre-treatment RBV sensitivity in the capture-fusion assay correlates with treatment response in G3 patients with cirrhosis treated with
IFN/RBV. Using archived pretreatment sera from 10 G3 patients with cirrhosis who relapsed or achieved SVR after Peg-IFN and RBV treatment,
no difference in IFN sensitivity was observed according to treatment outcome (A, B, and E). HCV strains from patients who achieved SVR were
more sensitive to RBV in the capture-fusion assay than viral strains from patients who relapsed (C, D, and F). Graphs show mean 6 standard
error of the mean.
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Significant replication of HCV does not occur in
THP-1 cells, suggesting that fusion with Huh7.5 may
provide access to permissive factors absent in THP-1.
These may include the phosphoinositide kinases, PI3K
or PI4K, given that the PI3K/PI4K inhibitor, wort-
mannin, reduced replication after fusion. Delivery of
HCV to Huh7.5 cells by fusion bypassed MxA induc-
tion, despite retention of IFN-signaling pathways. This
suggests that one mechanism underlying the capture-
fusion process is delivery of virus to hepatocytes with-
out an intracellular innate immune response. However,
other factors are likely to play a role and elucidating
the mechanisms underlying HCV replication after
monocyte-hepatocyte fusion requires further work.
The assay described depends upon detection of low-
level HCV RNA by PCR. Alternate techniques to
detect HCV proteins directly (e.g., western blotting
and IF) were attempted, but the level of viral protein
was too low to allow detection (western blotting) or
was masked by high levels of nonspecific background
staining in fused cells (IF). PCR is a well-validated
technique to detect viral replication, and the robust
responses observed in the assay support the value of
this approach.
In summary, we have developed a capture-fusion
assay that permits replication of patient-derived HCV
of all viral genotypes in vitro and enables testing of
sensitivity to antiviral drugs. Genotype-specific
responses to novel antiviral drugs and detection of
resistant viral strains have been demonstrated. IFN-
responsive or poorly responsive viral strains can be dis-
tinguished, and the assay can identify the subgroup of
patients with G3 HCV who respond to TVR. The
capture-fusion assay represents a promising new tech-
nique that may help identify the most appropriate
treatment strategy for patients with chronic HCV.
Acknowledgment: The authors gratefully acknowl-
edge the assistance of J. McLauchlan (MRC Virology
Institute, Glasgow) and J. McKeating (University of
Birmingham) in supply of reagents and critical reading
of the manuscript. The authors thank A. Johnstone
(Queen Mary University of London) for advice on
construction of dose-response curves and calculation of
50% inhibitory concentrations. The authors are
extremely grateful to G. Picchio (Janssen Virology) for
supplying telaprevir and generously providing previ-
ously unpublished biochemical phenotyping results
and to T. Haque and M. Macartney (Royal Free Lon-
don NHS Foundation Trust, London) for clinical sam-
ples and sequencing data. The authors are grateful to
N. Naoumov (Novartis Pharma, Switzerland) for sup-
plying alisporivir for research use. The authors also
thank J. Schulz, L. Payaniandy, D. Payaniandy, R.
Marley, P. Kennedy, P. Kooner, and Y. Kallis (Barts
Health NHS Trust, London) for sample collection and
supporting patient recruitment to the study. K. Agar-
wal and I. Carey (King’s College Hospital NHS Foun-
dation Trust, London) and H. Gamal (Cairo) kindly
assisted by supplying clinical samples.
References
1. Heim MH. 25 years of interferon-based treatment of chronic hepatitis
C: an epoch coming to an end. Nat Rev Immunol 2013;13:535-542.
Fig. 7. Correlation between pretreatment TVR sensitivity and response to TVR in 8 patients with G3 HCV. Clinical response to TVR monotherapy
is shown on the y-axes and could be predicted by the capture-fusion assay (A), but not by a biochemical phenotyping assay in which the viral
NS3 was subcloned and enzymatic activity assessed in the presence and absence of TVR using a fluorescence resonance energy transfer cleav-
age assay12 (B).
HEPATOLOGY, Vol. 61, No. 4, 2015 CUNNINGHAM ET AL. 1203
2. Zeuzem S, Soriano V, Asselah T, Bronowicki JP, Lohse AW, Mullhaupt
B, et al. Faldaprevir and deleobuvir for HCV genotype 1 infection. N
Engl J Med 2013;369:630-639.
3. Lok AS, Gardiner DF, Lawitz E, Martorell C, Everson GT, Ghalib R,
et al. Preliminary study of two antiviral agents for hepatitis C genotype
1. N Engl J Med 2012;366:216-224.
4. Kowdley KV, Lawitz E, Poordad F, Cohen DE, Nelson DR, Zeuzem S,
et al. Phase 2b trial of interferon-free therapy for hepatitis C virus
genotype 1. N Engl J Med 2014;370:222-232.
5. Lawitz E, Poordad F, Kowdley KV, Cohen DE, Podsadecki T, Siggelkow S,
et al. A phase 2a trial of 12-week interferon-free therapy with two direct-
acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C
patients with chronic hepatitis C genotype 1. J Hepatol 2013;59:18-23.
6. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T,
Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis
C infection. N Engl J Med 2013;368:1878-1887.
7. Lohmann V, Korner F, Koch J, Herian U, Theilmann L,
Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in
a hepatoma cell line. Science 1999;285:110-113.
8. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z,
et al. Production of infectious hepatitis C virus in tissue culture from a
cloned viral genome. Nat Med 2005;11:791-796.
9. Saeed M, Scheel TK, Gottwein JM, Marukian S, Dustin LB, Bukh J,
Rice CM. Efficient replication of genotype 3a and 4a hepatitis C virus
replicons in human hepatoma cells. Antimicrob Agents Chemother
2012;56:5365-5373.
10. Peng B, Yu M, Xu S, Lee YJ, Tian Y, Yang H, et al. Development of
robust hepatitis C virus genotype 4 subgenomic replicons. Gastroenter-
ology 2013;144:59-61.e6.
11. Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients
with hepatitis C virus infection. Gastroenterology 2010;138:447-462.
12. De Meyer S, Ghys A, Foster GR, Beumont M, Van Baelen B, Lin TI,
et al. Analysis of genotype 2 and 3 hepatitis C virus variants in patients
treated with telaprevir demonstrates a consistent resistance profile across
genotypes. J Viral Hepat 2013;20:395-403.
13. Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson D, Crawfod D, et al. Sap-
phire I: Phase 3 placebo-controlled study of interferon-free, 12-week regi-
men of ABT-450/R/ABT-267, ABT-333 and ribavirin in 631 treatment-
naive adults with hepatitis C virus genotype 1. J Hepatol 2014;60:S25.
14. Mangia A, Marcellin P, Kwo P, Foster GR, Buti M, Brau N, et al. All
oral fixed-dose combination sofosbuvir/ledipasvir with or without riba-
virin for 12 or 24 weeks in treatment-naive genotype 1 HCV-infected
patients: the phase 3 ION-1 study. J Hepatol 2014;60:S523.
15. Castillo I, Rodriguez-Inigo E, Bartolome J, de Lucas S, Ortiz-Movilla
N, Lopez-Alcorocho JM, et al. Hepatitis C virus replicates in peripheral
blood mononuclear cells of patients with occult hepatitis C virus infec-
tion. Gut 2005;54:682-685.
16. Coquillard G, Patterson BK. Determination of hepatitis C virus-
infected, monocyte lineage reservoirs in individuals with or without
HIV coinfection. J Infect Dis 2009;200:947-954.
17. Ducoulombier D, Roque-Afonso AM, Di Liberto G, Penin F, Kara R,
Richard Y, et al. Frequent compartmentalization of hepatitis C virus
variants in circulating B cells and monocytes. HEPATOLOGY 2004;
39:817-825.
18. Pham TN, King D, Macparland SA, McGrath JS, Reddy SB, Bursey
FR, Michalak TI. Hepatitis C virus replicates in the same immune cell
subsets in chronic hepatitis C and occult infection. Gastroenterology
2008;134:812-822.
19. Lanford RE, Chavez D, Chisari FV, Sureau C. Lack of detection of
negative-strand hepatitis C virus RNA in peripheral blood mononuclear
cells and other extrahepatic tissues by the highly strand-specific rTth
reverse transcriptase PCR. J Virol 1995;69:8079-8083.
20. Mellor J, Haydon G, Blair C, Livingstone W, Simmonds P. Low level
or absent in vivo replication of hepatitis C virus and hepatitis G virus/
GB virus C in peripheral blood mononuclear cells. J Gen Virol 1998;
79:705-714.
21. Tsuchiya S, Yamabe M, Yamaguchi Y, Kobayashi Y, Konno T, Tada K.
Establishment and characterization of a human acute monocytic leuke-
mia cell line (THP-1). Int J Cancer 1980;26:171-176.
22. Marino R, Deibis L, De Sanctis JB, Bianco NE, Toro F. Interaction of
immune complexes isolated from hepatitis C virus-infected individuals
with human cell lines. Med Microbiol Immunol 2005;194:73-80.
23. Ploss A, Evans MJ, Gaysinskaya VA, Panis M, You H, de Jong YP,
Rice CM. Human occludin is a hepatitis C virus entry factor required
for infection of mouse cells. Nature 2009;457:882-886.
24. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy
KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hep-
atitis C virus infection. N Engl J Med 2011;364:2405-2416.
25. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al.
Telaprevir for retreatment of HCV infection. N Engl J Med 2011;364:
2417-2428.
26. Foster GR, Hezode C, Bronowicki JP, Carosi G, Weiland O, Verlinden
L, et al. Telaprevir alone or with peginterferon and ribavirin reduces
HCV RNA in patients with chronic genotype 2 but not genotype 3
infections. Gastroenterology 2011;141:881-889.
27. Flisiak R, Feinman SV, Jablkowski M, Horban A, Kryczka W,
Pawlowska M, et al. The cyclophilin inhibitor Debio 025 combined
with PEG IFNalpha2a significantly reduces viral load in treatment-
naive hepatitis C patients. HEPATOLOGY 2009;49:1460-1468.
28. Benhamou Y, Moussalli J, Ratziu V, Lebray P, De Backer K, De Meyer S,
et al. Telaprevir activity in treatment-naive patients infected hepatitis C
virus genotype 4: a randomized trial. J Infect Dis 2013;208:1000-1007.
29. Hezode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, et al.
Telaprevir and peginterferon with or without ribavirin for chronic
HCV infection. N Engl J Med 2009;360:1839-1850.
30. Reddy KR, Nelson DR, Zeuzem S. Ribavirin: current role in the opti-
mal clinical management of chronic hepatitis C. J Hepatol 2009;50:
402-411.
31. Frentzen A, Huging K, Bitzegeio J, Friesland M, Haid S, Gentzsch J,
et al. Completion of hepatitis C virus replication cycle in heterokaryons
excludes dominant restrictions in human non-liver and mouse liver cell
lines. PLoS Pathog 2011;7:e1002029.
32. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ,
et al. Genetic variation in IL28B predicts hepatitis C treatment-
induced viral clearance. Nature 2009;461:399-401.
33. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K,
Sakamoto N, et al. Genome-wide association of IL28B with response
to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis
C. Nat Genet 2009;41:1105-1109.
Supporting Information
Additional Supporting Information may be found at
onlinelibrary.wiley.com/doi/10.1002/hep.27570/suppinfo
1204 CUNNINGHAM ET AL. HEPATOLOGY, April 2015
R
es
ul
ts
B
ac
kg
ro
un
d 
an
d 
A
im
s
S
B
 9
20
0 
is
 a
 n
ov
el
, f
irs
t-i
n-
cl
as
s 
an
ti-
H
C
V
 d
ru
g,
 w
hi
ch
 a
ct
s 
by
 e
nh
an
ci
ng
 th
e 
fu
nc
tio
n 
of
 h
os
t c
yt
os
ol
ic
 s
en
so
r p
ro
te
in
s 
R
IG
-I 
an
d 
N
O
D
2 
th
at
 d
et
ec
t R
N
A
 v
iru
se
s.
 
S
B
 9
20
0 
ha
s 
sh
ow
n 
po
te
nt
 a
ct
iv
ity
 a
ga
in
st
 H
C
V
 G
1a
 a
nd
 G
1b
 re
pl
ic
on
s 
in
 v
itr
o 
an
d 
is
 s
yn
er
gi
st
ic
 w
ith
 o
th
er
 a
nt
i-H
C
V
 d
ru
gs
 s
uc
h 
as
 te
la
pr
ev
ir
(N
S
3 
pr
ot
ea
se
 in
hi
bi
to
r)
, 
N
M
28
3 
(N
S
5B
 in
hi
bi
to
r)
, i
nt
er
fe
ro
n 
an
d 
rib
av
iri
n.
 S
in
ce
 S
B
 9
20
0 
ac
tiv
at
es
 “h
os
t” 
ta
rg
et
s 
in
st
ea
d 
of
 v
ira
l t
ar
ge
ts
, i
t h
as
 th
e 
po
te
nt
ia
l f
or
 p
an
-g
en
ot
yp
ic
 a
nt
iv
ira
l a
ct
iv
ity
 
an
d 
a 
hi
gh
er
 b
ar
rie
r t
o 
vi
ra
l r
es
is
ta
nc
e.
T
o 
ex
pl
or
e 
th
e 
ge
no
ty
pi
c 
ra
ng
e 
of
 S
B
 9
20
0,
 s
en
si
tiv
ity
 o
f p
at
ie
nt
-d
er
iv
ed
 H
C
V
 o
f 
di
ffe
re
nt
 g
en
ot
yp
es
 w
as
 te
st
ed
 in
 th
e 
re
ce
nt
ly
 d
ev
el
op
ed
 c
ap
tu
re
-fu
si
on
 a
ss
ay
, a
 
no
ve
l H
C
V
 r
ep
lic
at
io
n 
m
od
el
 th
at
 is
 h
ig
hl
y 
pr
ed
ic
tiv
e 
of
 c
lin
ic
al
 o
ut
co
m
e 
of
 p
ot
en
tia
l 
an
tiv
ira
ls
.
M
et
ho
ds
P
re
-s
tim
ul
at
ed
 T
H
P
-1
 c
el
ls
 w
er
e 
in
fe
ct
ed
 w
ith
 s
er
um
 fr
om
 d
on
or
s 
ch
ro
ni
ca
lly
 
in
fe
ct
ed
 w
ith
 th
e 
co
m
m
on
 H
C
V
 g
en
ot
yp
es
 G
1 
or
 G
3,
 o
r f
ro
m
 p
at
ie
nt
s 
in
fe
ct
ed
 
w
ith
 th
e 
le
ss
 p
re
va
le
nt
 G
2,
 G
4 
or
 G
6 
H
C
V
.
T
he
 h
yb
rid
 c
el
ls
 w
er
e 
tre
at
ed
 o
nc
e 
w
ith
 a
 ra
ng
e 
of
 c
on
ce
nt
ra
tio
ns
 o
f S
B
 9
20
0.
 
Fo
r c
om
pa
ris
on
, f
us
ed
 c
el
ls
 in
fe
ct
ed
 w
ith
 G
1 
an
d 
G
3 
se
ra
 w
er
e 
tre
at
ed
 w
ith
 
T
el
ap
re
vi
r o
r A
lis
po
riv
ir.
 
T
he
 c
el
ls
 w
er
e 
cu
ltu
re
d 
fo
r 5
 d
ay
s,
 b
ef
or
e 
qu
an
tif
ic
at
io
n 
of
 H
C
V
 R
N
A
 b
y 
P
C
R
.
D
os
e-
re
sp
on
se
 c
ur
ve
s 
w
er
e 
us
ed
 to
 c
al
cu
la
te
 IC
50
va
lu
es
 fo
r e
ac
h 
ex
pe
rim
en
t.
T
H
P
-1
 c
el
l
H
C
V
H
C
V
 c
ap
tu
re
 b
y 
T
H
P
-1
s
H
uh
7.
5 
ce
ll
P
E
G
 fu
si
on
 o
f i
nf
ec
te
d 
T
H
P
-1
 w
ith
 
H
uh
7.
5 
ce
lls
T
re
at
m
en
t w
ith
 S
B
 
92
00
, t
el
ap
re
vi
r o
r 
al
is
po
riv
ir
G
ro
w
th
 o
f f
us
ed
 c
el
ls
 
fo
r 5
 d
ay
s
C
on
cl
us
io
ns
T
he
se
 re
su
lts
 d
em
on
st
ra
te
 a
nt
iv
ira
l a
ct
iv
ity
 o
f S
B
 9
20
0 
ag
ai
ns
t a
 d
iv
er
se
 
ra
ng
e 
of
 H
C
V
 g
en
ot
yp
es
 in
 v
itr
o.
 O
f n
ot
e,
 th
is
 c
om
po
un
d 
sh
ow
s 
ve
ry
 p
ot
en
t 
ac
tiv
ity
 a
ga
in
st
 p
at
ie
nt
-d
er
iv
ed
 G
3 
is
ol
at
es
. T
he
se
 re
su
lts
 s
up
po
rt 
th
e 
po
te
nt
ia
l u
se
 o
f S
B
 9
20
0 
as
 a
 p
an
-g
en
ot
yp
ic
 h
os
t-t
ar
ge
tin
g 
an
ti-
H
C
V
 a
ge
nt
 
th
at
 c
an
 b
e 
us
ed
 w
ith
 d
iff
er
en
t c
la
ss
es
 o
f d
ire
ct
-a
ct
in
g 
an
tiv
ira
ls
 in
 
co
m
bi
na
tio
n 
th
er
ap
y.
S
B
 9
20
0 
in
hi
bi
te
d 
th
e 
re
pl
ic
at
io
n 
of
 G
2,
 G
4 
an
d 
G
6 
H
C
V
 
in
 fu
se
d 
ce
lls
S
er
a 
fro
m
 a
 s
m
al
l n
um
be
r o
f p
at
ie
nt
s 
ch
ro
ni
ca
lly
 in
fe
ct
ed
 w
ith
 G
2,
 G
4 
or
 G
6 
H
C
V
 a
ls
o 
de
m
on
st
ra
te
d 
se
ns
iti
vi
ty
 to
 S
B
 9
20
0 
in
 th
e 
ca
pt
ur
e-
fu
si
on
 m
od
el
. 
P
an
-g
en
ot
yp
ic
 a
nt
i-H
C
V
 a
ct
iv
ity
 o
f S
B
 9
20
0 
as
se
ss
ed
 in
 th
e 
‘c
ap
tu
re
-f
us
io
n’
 r
ep
lic
at
io
n 
as
sa
y
M
or
ve
n 
E
. C
un
ni
ng
ha
m
1 ,
 J
os
ep
h 
D
av
id
so
n-
W
rig
ht
1 ,
 M
ar
c 
C
hi
lto
n1
, M
el
er
i J
on
es
1 ,
 R
aj
en
dr
a 
K
. P
an
de
y2
, A
nj
an
ey
ul
u 
S
he
ri2
, 
S
ee
th
ar
am
ai
ye
r P
ad
m
an
ab
ha
n2
, R
ad
ha
kr
is
hn
an
 P
. I
ye
r2
, G
ra
ha
m
 R
. F
os
te
r1
1.
 T
he
 L
iv
er
 U
ni
t, 
B
liz
ar
d 
In
st
itu
te
, B
ar
ts
 a
nd
 T
he
 L
on
do
n 
S
ch
oo
l o
f M
ed
ic
in
e 
an
d 
D
en
tis
try
, Q
ue
en
 M
ar
y 
U
ni
ve
rs
ity
 o
f L
on
do
n,
U
K
2.
 S
pr
in
g 
B
an
k 
P
ha
rm
ac
eu
tic
al
s,
 M
ill
fo
rd
, M
A
, U
ni
te
d 
S
ta
te
s
S
en
si
tiv
ity
 o
f b
ot
h 
G
1 
an
d 
G
3 
H
C
V
 to
 S
B
 9
20
0 
co
m
pa
re
s 
fa
vo
ur
ab
ly
 to
 T
el
ap
re
vi
r 
an
d 
A
lis
po
ri
vi
r
Fo
r c
om
pa
ris
on
, f
us
ed
 T
H
P
-1
/H
uh
7.
5 
ce
lls
 in
fe
ct
ed
 w
ith
 s
er
a 
fro
m
 d
on
or
s 
w
ith
 
G
1 
or
 G
3 
H
C
V
 w
er
e 
tre
at
ed
 w
ith
 a
 ra
ng
e 
of
 c
on
ce
nt
ra
tio
ns
 o
f a
lte
rn
at
e 
an
ti-
H
C
V
 
dr
ug
s,
 T
el
ap
re
vi
r o
r A
lis
po
riv
ir.
 
G
3 
is
ol
at
es
 w
er
e 
si
gn
ifi
ca
nt
ly
 m
or
e 
se
ns
iti
ve
 to
 S
B
 9
20
0 
th
an
 to
 T
el
ap
re
vi
r (
S
B
 
92
00
 IC
50
0.
05
 ±
0.
01
 µ
M
, T
el
ap
re
vi
r I
C
50
0.
12
 ±
0.
03
 µ
M
, p
= 
0.
01
). 
In
 G
1 
is
ol
at
es
, a
nt
i-v
ira
l p
ot
en
cy
 o
f S
B
 9
20
0 
w
as
 c
om
pa
ra
bl
e 
to
 th
at
 o
f 
A
lis
po
riv
ir 
in
 th
is
 re
pl
ic
at
io
n 
m
od
el
 (S
B
 9
20
0 
IC
50
0.
22
 ±
0.
08
 µ
M
, A
lis
po
riv
ir 
IC
50
0.
14
 ±
0.
03
 µ
M
; p
= 
0.
66
). 
A
 s
im
ila
r p
at
te
rn
 w
as
 s
ee
n 
in
 G
3 
is
ol
at
es
 (S
B
 9
20
0 
IC
50
0.
05
 ±
0.
01
 µ
M
, A
lis
po
riv
ir 
IC
50
0.
04
 ±
0.
02
 µ
M
; p
= 
0.
88
).
S
B
 9
20
0 
in
hi
bi
te
d 
th
e 
re
pl
ic
at
io
n 
of
 G
1 
an
d 
G
3 
H
C
V
 
st
ra
in
s 
in
 th
e 
fu
se
d 
ce
lls
R
ep
lic
at
io
n 
of
 H
C
V
 fr
om
 s
er
a 
of
 p
at
ie
nt
s 
in
fe
ct
ed
 w
ith
 G
1 
H
C
V
 a
nd
 G
3 
H
C
V
 
w
as
 in
hi
bi
te
d 
by
 S
B
 9
20
0 
in
 a
 d
os
e-
de
pe
nd
en
t m
an
ne
r. 
G
3 
is
ol
at
es
 s
ho
w
ed
 s
ig
ni
fic
an
tly
 g
re
at
er
 s
en
si
tiv
ity
 to
 S
B
 9
20
0 
th
an
 G
1a
/b
 
st
ra
in
s 
(IC
50
0.
04
9 
±
0.
01
3 
ve
rs
us
 0
.2
2 
±
0.
07
6,
 p
= 
0.
04
8)
. 
S
en
si
tiv
ity
 o
f p
at
ie
nt
-d
er
iv
ed
 G
1 
or
 G
3 
H
C
V
 to
 S
B
 9
20
0,
 A
lis
po
riv
ir 
or
 T
el
ap
re
vi
r i
n 
th
e 
ca
pt
ur
e-
fu
si
on
 a
ss
ay
. X
-a
xe
s 
sh
ow
 c
on
ce
nt
ra
tio
n 
of
 e
ac
h 
dr
ug
, y
-a
xe
s 
sh
ow
 d
eg
re
e 
of
 
in
hi
bi
tio
n 
of
 re
pl
ic
at
io
n.
 V
al
ue
s 
ar
e 
m
ea
n 
±
s.
e.
m
.
A
ck
no
w
le
dg
em
en
ts
Th
is
 r
ep
or
t p
re
se
nt
s 
in
de
pe
nd
en
t r
es
ea
rc
h 
co
m
m
is
si
on
ed
 b
y 
th
e 
N
at
io
na
l I
ns
tit
ut
e 
fo
r 
H
ea
lth
 R
es
ea
rc
h 
(N
IH
R
). 
Th
e 
vi
ew
s 
ex
pr
es
se
d 
in
 th
is
 p
ub
lic
at
io
n 
ar
e 
th
os
e 
of
 th
e 
au
th
or
(s
) a
nd
 n
ot
 n
ec
es
sa
ril
y 
th
os
e 
of
 th
e 
N
H
S
, t
he
 N
IH
R
 o
r t
he
 D
ep
ar
tm
en
t o
f H
ea
lth
Fo
r f
ur
th
er
 in
fo
rm
at
io
n,
 p
le
as
e 
co
nt
ac
t: 
m
.e
.c
un
ni
ng
ha
m
@
qm
ul
.a
c.
uk
; 
ki
ye
r@
sp
ri
ng
ba
nk
ph
ar
m
.c
om
05010
0
15
0
0.
01
0.
1
10
1.
0
N
o 
D
ru
g S
B
92
00
 D
o
se
 (
M
)
HCV RNA
(% of untreated cells)
G
en
ot
yp
e 
1a
 (
N
 =
 4
)
05010
0
15
0
N
o 
dr
ug
0.
01
0.
1
1.
0
10
S
B
92
00
 D
os
e 
(M
)
HCV RNA
(% of untreated cells)
G
en
ot
yp
e 
3 
(N
 =
 7
)
G
1
G
3
0.
0
0.
1
0.
2
0.
3
0.
4
0.
5
H
C
V
 G
en
ot
yp
e
IC
50
 (

M)
C
om
pa
ris
on
 o
f i
nd
iv
id
ua
l S
B
 9
20
0 
IC
50
va
lu
es
 b
et
w
ee
n 
G
1 
(N
 =
 5
) a
nd
 G
3 
(N
 =
 
7)
 in
fe
ct
ed
 d
on
or
s.
 V
al
ue
s 
ar
e 
m
ea
n 
±
s.
e.
m
. a
nd
 p
va
lu
e 
w
as
 c
al
cu
la
te
d 
us
in
g 
M
an
n 
W
hi
tn
ey
 U
 te
st
.
05010
0
15
0
20
0
N
o 
dr
ug
0.
01
0.
1
1.
0
10
S
B
92
00
 D
os
e 
(M
)
HCV RNA
(% of untreated cells)
G
2b
IC
50
0.
01
5μ
M
02040608010
0
12
0
N
o 
dr
ug
0.
01
0.
1
1.
0
10
S
B
92
00
 D
os
e 
(M
)
HCV RNA
(% of untreated cells)
G
2
IC
50
0.
00
6μ
M
05010
0
15
0
20
0
N
o 
dr
ug
0.
01
0.
1
1.
0
10
S
B
92
00
 D
os
e 
(M
)
HCV RNA
(% of untreated cells)
05010
0
15
0
20
0
N
o 
dr
ug
0.
01
0.
1
1.
0
10
S
B
92
00
 D
os
e 
(M
)
HCV RNA
(% of untreated cells)
G
4
IC
50
0.
01
1μ
M
05010
0
15
0
N
o 
dr
ug
0.
01
0.
1
1.
0
10
S
B
92
00
 D
os
e 
(M
)
HCV RNA
(% of untreated cells)
G
4
IC
50
0.
34
μM
05010
0
15
0
N
o 
dr
ug
0.
01
0.
1
1.
0
10
S
B
92
00
 D
os
e 
(M
)
HCV RNA
(% of untreated cells)
05010
0
15
0
20
0
N
o 
dr
ug
0.
01
0.
1
1.
0
10
S
B
92
00
 D
os
e 
(M
)
HCV RNA
(% of untreated cells)
G
6k
IC
50
0.
06
5 
μM
G
4
IC
50
0.
10
μM
G
6
IC
50
0.
00
9 
μM
0 0.
01
0.1
1.0
10
0 0.
05
0.1
0.5
1.0
0 0.
05
0.1
0.5
1.0
02040608010
0
12
0
S
B
 9
20
0 
(N
 =
 5
)
Te
la
pr
ev
ir 
(N
 =
 9
)
A
lis
po
riv
ir 
(N
 =
 6
)
D
ru
g 
co
nc
en
tr
at
io
n 
(M
)
HCV RNA
(% of untreated cells)
G
en
ot
yp
e 
1
0 0.
01
0.1
1.0
10
0 0.
05
0.1
0.5
1.0
0 0.
05
0.1
0.5
1.0
02040608010
0
12
0
S
B
 9
20
0 
(N
 =
 7
)
Te
la
pr
ev
ir 
(N
 =
 5
)
A
lis
po
riv
ir 
(N
 =
 5
)
D
ru
g 
co
nc
en
tr
at
io
n 
(M
)
HCV RNA
(% of untreated cells)
G
en
ot
yp
e 
3
05010
0
15
0
N
o 
dr
ug
0.
01
0.
1
1.
0
10
S
B
 9
20
0 
D
os
e 
(M
)
HCV RNA
(% of untreated cells)
G
en
ot
yp
e 
1b
 (
N
 =
 1
)
R
e
s
u
lt
s
B
a
c
k
g
ro
u
n
d
 a
n
d
 a
im
s
M
o
n
o
c
y
te
s
 f
ro
m
 p
a
ti
e
n
ts
 w
it
h
 H
C
V
 c
o
n
ta
in
 v
ir
u
s
 a
n
d
 w
e
 h
a
v
e
 s
h
o
w
n
 t
h
a
t 
th
is
 
v
ir
u
s
 r
e
p
lic
a
te
s
 w
h
e
n
 m
o
n
o
c
y
te
s
 a
re
 f
u
s
e
d
 t
o
 t
h
e
 h
e
p
a
to
m
a
 c
e
ll 
lin
e
 H
u
h
7
.5
. 
W
e
 h
a
v
e
 p
re
v
io
u
s
ly
 d
e
v
e
lo
p
e
d
 a
 r
e
p
lic
a
ti
o
n
 s
y
s
te
m
 in
 w
h
ic
h
 p
a
ti
e
n
t-
d
e
ri
v
e
d
 H
C
V
 
is
 “
c
a
p
tu
re
d
” 
b
y
 t
h
e
 m
o
n
o
c
y
ti
c
 c
e
ll 
lin
e
 T
H
P
-1
 a
n
d
 v
ir
a
l r
e
p
lic
a
ti
o
n
 a
s
s
e
s
s
e
d
 a
ft
e
r 
fu
s
io
n
 o
f 
th
e
s
e
 c
e
lls
 t
o
 H
u
h
7
.5
 c
e
lls
. 
In
te
rf
e
ro
n
-γ
(I
F
N
-γ
) 
a
n
d
 P
M
A
 h
a
v
e
 p
re
v
io
u
s
ly
 b
e
e
n
 d
e
m
o
n
s
tr
a
te
d
 t
o
 e
n
h
a
n
c
e
 
a
s
s
o
c
ia
ti
o
n
 o
f 
H
C
V
 i
m
m
u
n
e
 c
o
m
p
le
x
e
s
 w
it
h
 o
th
e
r 
m
o
n
o
c
y
ti
c
 c
e
ll 
lin
e
s
1
. 
H
e
re
 w
e
 e
x
p
lo
re
d
 t
h
e
 r
e
c
e
p
to
rs
 in
v
o
lv
e
d
 in
 m
o
n
o
c
y
te
 c
a
p
tu
re
/e
n
tr
y
 o
f 
p
a
ti
e
n
t-
d
e
ri
v
e
d
 H
C
V
, 
s
p
e
c
if
ic
a
lly
 t
h
o
s
e
 in
v
o
lv
e
d
 in
 h
e
p
a
to
c
y
te
 H
C
V
 e
n
tr
y
 a
s
 w
e
ll 
a
s
 F
c
γ
re
c
e
p
to
rs
 (
F
c
γ
R
).
M
e
th
o
d
s
U
n
s
ti
m
u
la
te
d
 T
H
P
-1
 o
r 
c
e
lls
 p
re
-s
ti
m
u
la
te
d
 w
it
h
 P
M
A
 a
n
d
 I
F
N
-γ
 w
e
re
 i
n
c
u
b
a
te
d
 
w
it
h
 s
e
ra
 f
ro
m
 p
a
ti
e
n
ts
 w
it
h
 c
h
ro
n
ic
 H
C
V
 a
n
d
 H
C
V
 R
N
A
 q
u
a
n
ti
fi
e
d
 b
y
 q
P
C
R
. 
m
R
N
A
 e
x
p
re
s
s
io
n
 o
f 
c
la
s
s
ic
a
l H
C
V
 e
n
tr
y
 r
e
c
e
p
to
rs
 a
n
d
 F
c
γ
R
 w
a
s
 c
o
m
p
a
re
d
 in
 
s
ti
m
u
la
te
d
 a
n
d
 u
n
s
ti
m
u
la
te
d
 c
e
lls
 a
n
d
 s
u
rf
a
c
e
 r
e
c
e
p
to
r 
e
x
p
re
s
s
io
n
 a
n
a
ly
s
e
d
 b
y
 
F
A
C
S
. 
S
ti
m
u
la
te
d
 T
H
P
-1
 w
e
re
 i
n
c
u
b
a
te
d
 w
it
h
 b
lo
c
k
in
g
 a
n
ti
b
o
d
ie
s
 t
o
 c
a
n
d
id
a
te
 e
n
tr
y
 
re
c
e
p
to
rs
 p
ri
o
r 
to
 i
n
c
u
b
a
ti
o
n
 w
it
h
 p
a
ti
e
n
t 
s
e
ra
 a
n
d
 P
E
G
-m
e
d
ia
te
d
 f
u
s
io
n
 w
it
h
 
H
u
h
7
.5
 c
e
lls
. 
H
C
V
 R
N
A
 w
a
s
 q
u
a
n
ti
fi
e
d
 im
m
e
d
ia
te
ly
 a
n
d
 u
p
 t
o
 7
 d
a
y
s
 a
ft
e
r 
fu
s
io
n
.
R
e
s
u
lt
s
 a
re
 m
e
a
n
 ±
s
.d
. 
a
n
d
 p
v
a
lu
e
s
 w
e
re
 c
a
lc
u
la
te
d
 u
s
in
g
 t
h
e
 M
a
n
n
-W
h
it
n
e
y
 U
 
te
s
t.
C
o
n
c
lu
s
io
n
s
U
p
ta
k
e
 o
f 
p
a
ti
e
n
t-
d
e
ri
v
e
d
 H
C
V
 i
n
to
 T
H
P
-1
 m
o
n
o
c
y
te
s
 i s
 m
e
d
ia
te
d
 p
ri
m
a
ri
ly
 
th
ro
u
g
h
 C
D
6
4
. 
B
lo
c
k
in
g
 C
D
6
4
 d
id
 n
o
t 
c
o
m
p
le
te
ly
 a
b
ro
g
a
te
 H
C
V
 u
p
ta
k
e
 s
u
g
g
e
s
ti
n
g
 t
h
a
t 
o
th
e
r,
 a
s
 y
e
t 
u
n
d
e
fi
n
e
d
 r
e
c
e
p
to
rs
 m
a
y
 a
ls
o
 b
e
 i
n
v
o
lv
e
d
 b
u
t 
th
e
s
e
 a
re
 d
is
ti
n
c
t 
fr
o
m
 c
la
s
s
ic
a
l H
C
V
 e
n
tr
y
 r
e
c
e
p
to
rs
 in
c
lu
d
in
g
 C
D
8
1
. 
A
lt
h
o
u
g
h
 w
e
 f
o
u
n
d
 n
o
 e
v
id
e
n
c
e
 o
f 
H
C
V
 r
e
p
lic
a
ti
o
n
 in
 T
H
P
-1
 c
e
lls
, 
re
p
lic
a
ti
o
n
 
o
c
c
u
rr
e
d
 a
ft
e
r 
fu
s
io
n
 w
it
h
 H
u
h
7
.5
 c
e
lls
 s
u
g
g
e
s
ti
n
g
 t
h
a
t 
H
C
V
 i
n
te
rn
a
lis
e
d
 in
to
 
T
H
P
-1
 v
ia
 C
D
6
4
 i
s
 r
e
p
lic
a
ti
o
n
-c
o
m
p
e
te
n
t.
 T
h
is
 m
a
y
 h
a
v
e
 im
p
lic
a
ti
o
n
s
 f
o
r 
v
ir
a
l 
p
e
rs
is
te
n
c
e
 a
n
d
 r
e
la
p
s
e
 a
ft
e
r 
a
n
ti
v
ir
a
l t
h
e
ra
p
y
.
P
re
tr
e
a
tm
e
n
t 
o
f 
T
H
P
-1
 w
it
h
 P
M
A
/I
F
N
-γ
e
n
h
a
n
c
e
s
 
a
s
s
o
c
ia
ti
o
n
 o
f 
p
a
ti
e
n
t-
d
e
ri
v
e
d
 H
C
V
P
a
ti
e
n
t-
d
e
ri
v
e
d
 H
C
V
 a
s
s
o
c
ia
te
d
 p
o
o
rl
y
 w
it
h
 u
n
s
ti
m
u
la
te
d
 T
H
P
-1
 c
e
lls
, 
b
u
t 
th
is
 w
a
s
 
e
n
h
a
n
c
e
d
 b
y
 2
4
 h
o
u
rs
 p
re
-s
ti
m
u
la
ti
o
n
 w
it
h
 P
M
A
 a
n
d
 I
F
N
γ
 (
1
2
1
 ±
6
2
 v
e
rs
u
s
 3
8
0
 ±
2
5
2
 
H
C
V
 c
o
p
ie
s
/μ
g
 t
o
ta
l 
R
N
A
, 
p
=
 0
.0
2
6
)
T
h
e
 L
iv
e
r 
U
n
it
, 
B
liz
a
rd
 I
n
s
ti
tu
te
, 
B
a
rt
s
 a
n
d
 T
h
e
 L
o
n
d
o
n
 S
c
h
o
o
l 
o
f 
M
e
d
ic
in
e
 a
n
d
 D
e
n
ti
s
tr
y
,
Q
u
e
e
n
 M
a
ry
 U
n
iv
e
rs
it
y
 o
f 
L
o
n
d
o
n
, 
U
K
C
D
6
4
 (
F
c
γ
R
I)
 i
s
 a
 n
o
v
e
l 
re
c
e
p
to
r 
fo
r 
H
C
V
 e
n
tr
y
 i
n
to
 m
o
n
o
c
y
te
s
M
o
rv
e
n
 E
. 
C
u
n
n
in
g
h
a
m
, 
J
o
s
e
p
h
 D
a
v
id
s
o
n
-W
ri
g
h
t,
 M
e
le
ri
 J
o
n
e
s
, 
J
o
s
h
u
a
 L
. 
W
o
n
g
, 
J
e
n
n
if
e
r 
A
. 
W
a
te
rs
, 
G
ra
h
a
m
 R
. 
F
o
s
te
r
R
e
p
li
c
a
ti
o
n
 o
f 
p
a
ti
e
n
t-
d
e
ri
v
e
d
 H
C
V
 a
ft
e
r 
T
H
P
-
1
/H
u
h
7
.5
 c
e
ll
 f
u
s
io
n
 w
a
s
 r
e
d
u
c
e
d
 b
y
 b
lo
c
k
in
g
 C
D
6
4
 
P
re
-i
n
c
u
b
a
ti
o
n
 w
it
h
 C
D
6
4
 b
lo
c
k
in
g
 a
n
ti
b
o
d
ie
s
 r
e
d
u
c
e
d
 t
h
e
 a
m
o
u
n
t 
o
f 
H
C
V
 
d
e
te
c
ta
b
le
 im
m
e
d
ia
te
ly
 a
ft
e
r 
fu
s
io
n
 o
f 
in
fe
c
te
d
 T
H
P
-1
 w
it
h
 H
u
h
7
.5
 c
e
lls
, 
a
n
d
 
a
ls
o
 r
e
d
u
c
e
d
 H
C
V
 r
e
p
lic
a
ti
o
n
 in
 t
h
e
 f
u
s
e
d
 c
e
lls
 (
1
9
 ±
1
2
 v
e
rs
u
s
 1
1
6
 ±
1
0
0
 H
C
V
 
c
o
p
ie
s
/μ
g
 t
o
ta
l 
R
N
A
 7
 d
a
y
s
 a
ft
e
r 
fu
s
io
n
, 
p
 =
 0
.0
0
5
).
 
B
lo
c
k
in
g
 a
n
ti
b
o
d
ie
s
 t
o
 C
D
8
1
, 
S
R
-B
1
 o
r 
C
D
3
2
 h
a
d
 n
o
 e
ff
e
c
t.
P
M
A
/I
F
N
-γ
tr
e
a
tm
e
n
t 
o
f 
T
H
P
-1
 c
e
ll
s
 i
n
c
re
a
s
e
s
 C
D
6
4
 
e
x
p
re
s
s
io
n
 a
t 
th
e
 c
e
ll
 s
u
rf
a
c
e
C
e
ll 
s
u
rf
a
c
e
 e
x
p
re
s
s
io
n
 o
f 
C
D
8
1
, 
S
R
-B
1
 o
r 
C
D
3
2
 w
a
s
 n
o
t 
a
ff
e
c
te
d
 b
y
 P
M
A
/I
F
N
-
γ
e
x
p
o
s
u
re
.
R
e
fe
re
n
c
e
1
.
M
a
ri
n
o
 R
, 
D
e
ib
is
L
, 
D
e
 S
a
n
c
ti
s
J
B
, 
B
ia
n
c
o
N
E
, 
T
o
ro
 F
. 
In
te
ra
c
ti
o
n
 o
f 
im
m
u
n
e
 
c
o
m
p
le
x
e
s
 i
s
o
la
te
d
 f
ro
m
 h
e
p
a
ti
ti
s
 C
 v
ir
u
s
-i
n
fe
c
te
d
 i
n
d
iv
id
u
a
ls
 w
it
h
 h
u
m
a
n
 c
e
ll 
lin
e
s
.
M
e
d
 M
ic
ro
b
io
l
Im
m
u
n
o
l
1
9
4
, 
7
3
-8
0
 (
2
0
0
5
)
1
A
c
k
n
o
w
le
d
g
e
m
e
n
ts
T
h
is
 r
e
p
o
rt
/a
rt
ic
le
 p
re
s
e
n
ts
 in
d
e
p
e
n
d
e
n
t 
re
s
e
a
rc
h
 c
o
m
m
is
s
io
n
e
d
 b
y
 t
h
e
 N
a
ti
o
n
a
l 
In
s
ti
tu
te
 
fo
r 
H
e
a
lt
h
 R
e
s
e
a
rc
h
 (
N
IH
R
).
 T
h
e
 v
ie
w
s
 e
x
p
re
s
s
e
d
 i
n
 t
h
is
 p
u
b
lic
a
ti
o
n
 a
re
 t
h
o
s
e
 o
f 
th
e
 
a
u
th
o
r(
s
) 
a
n
d
 n
o
t 
n
e
c
e
s
s
a
ri
ly
 t
h
o
s
e
 o
f 
th
e
 N
H
S
, 
th
e
 N
IH
R
 o
r 
th
e
 D
e
p
a
rt
m
e
n
t 
o
f 
H
e
a
lt
h
.
F
o
r 
fu
rt
h
e
r 
in
fo
rm
a
ti
o
n
 p
le
a
s
e
 c
o
n
ta
c
t 
m
.e
.c
u
n
n
in
g
h
a
m
@
q
m
u
l.
a
c
.u
k
P
M
A
/I
F
N
-γ
tr
e
a
tm
e
n
t 
o
f 
T
H
P
-1
 c
e
ll
s
 i
n
c
re
a
s
e
s
 C
D
6
4
 
g
e
n
e
 e
x
p
re
s
s
io
n
In
c
u
b
a
ti
o
n
 o
f 
T
H
P
-1
 c
e
lls
 w
it
h
 P
M
A
 a
n
d
 I
F
N
-γ
le
d
 t
o
 i
n
c
re
a
s
e
d
 e
x
p
re
s
s
io
n
 o
f 
C
D
6
4
 m
R
N
A
, 
b
u
t 
n
o
t 
th
a
t 
o
f 
C
D
3
2
, 
C
D
8
1
, 
S
R
-B
1
 o
r 
L
D
L
-R
. 
O
th
e
r 
c
a
n
d
id
a
te
 
re
c
e
p
to
rs
 (
c
la
u
d
in
-1
, 
o
c
c
lu
d
in
 a
n
d
 C
D
1
6
) 
w
e
re
 n
o
t 
e
x
p
re
s
s
e
d
 b
y
 T
H
P
-1
 c
e
lls
 
b
e
fo
re
 o
r 
a
ft
e
r 
s
ti
m
u
la
ti
o
n
. 
P
a
ti
e
n
t-
d
e
ri
v
e
d
 H
C
V
 i
s
 i
n
te
rn
a
li
s
e
d
 i
n
to
 p
re
-s
ti
m
u
la
te
d
 
T
H
P
-1
 c
e
ll
s
T
ry
p
s
in
 t
re
a
tm
e
n
t 
o
f 
s
ti
m
u
la
te
d
 T
H
P
-1
 a
ft
e
r 
e
x
p
o
s
u
re
 t
o
 s
e
ru
m
 f
ro
m
 d
o
n
o
rs
 c
h
ro
n
ic
a
lly
 
in
fe
c
te
d
 w
it
h
 H
C
V
 c
o
n
fi
rm
e
d
 in
te
rn
a
lis
a
ti
o
n
 o
f 
p
a
ti
e
n
t-
d
e
ri
v
e
d
 v
ir
u
s
. 
In
te
rn
a
lis
a
ti
o
n
 
o
c
c
u
rr
e
d
 p
re
d
o
m
in
a
n
tl
y
 b
e
tw
e
e
n
 1
 a
n
d
 4
 h
o
u
rs
 a
ft
e
r 
in
fe
c
ti
o
n
.
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S
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im
e
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h
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expression relative to GAPDH
L
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L
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0
.111
0
2
6
2
4
0
T
im
e
 (
h
o
u
rs
)
Fold change in mRNA
expression relative to GAPDH
C
D
3
2
T
H
P
-1
 e
xp
re
s
s
io
n
 o
f 
F
c
γ
R
 m
R
N
A
, 
a
n
d
 m
R
N
A
 o
f 
re
c
e
p
to
rs
 
a
s
s
o
c
ia
te
d
 w
ith
 H
C
V
 e
n
tr
y 
in
to
 h
e
p
a
to
c
yt
e
s
. 
G
e
n
e
 e
xp
re
s
s
io
n
 
w
a
s
 m
e
a
s
u
re
d
 b
e
fo
re
 a
n
d
 2
, 
6
 a
n
d
 2
4
 h
o
u
rs
 a
ft
e
r 
s
tim
u
la
tio
n
 w
ith
 
P
M
A
 a
n
d
 IF
N
-γ
. 
m
R
N
A
 is
 e
xp
re
s
s
e
d
 r
e
la
tiv
e
 t
o
 G
A
P
D
H
 a
n
d
 
u
n
s
tim
u
la
te
d
 c
e
ll
s
, 
o
n
 a
 l
o
g
a
ri
th
m
ic
 s
c
a
le
. 
**
p
<
 0
.0
1
; 
*p
<
 0
.0
5
. 
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o
u
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D
6
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a
U
n
s
tim
u
la
te
d
 
T
H
P
-1
b
P
M
A
/I
F
N
-
γ
T
H
P
-1
 c
e
ll
s
 w
e
re
 in
c
u
b
a
te
d
 in
 t
h
e
 
p
re
s
e
n
c
e
 o
r 
a
b
s
e
n
c
e
 o
f 
P
M
A
 a
n
d
 
IF
N
-γ
fo
r 
2
4
 h
o
u
rs
 b
e
fo
re
 
q
u
a
n
tif
ic
a
tio
n
 o
f 
C
D
6
4
 e
xp
re
s
s
io
n
 
b
y 
fl
o
w
 c
yt
o
m
e
tr
y.
 S
h
a
d
e
d
 
h
is
to
g
ra
m
s
 s
h
o
w
 r
e
c
e
p
to
r 
e
xp
re
s
s
io
n
, 
c
le
a
r 
h
is
to
g
ra
m
s
 s
h
o
w
 
is
o
ty
p
e
 c
o
n
tr
o
ls
.
U
n
s
ti
m
u
la
te
d
S
ti
m
u
la
te
d
1
0
1
0
0
1
0
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T
H
P
-1
 c
e
ll
s
HCV RNA
(copies/
µ
g total RNA)
p
=
 0
.0
2
6
T
H
P
-1
 c
e
ll
s
 w
e
re
 c
u
lt
u
re
d
 f
o
r 
2
4
 
h
o
u
rs
 w
ith
 P
M
A
 2
0
0
 n
g
/m
L
 a
n
d
 
IF
N
γ
1
0
 n
g
/m
L
 (
s
tim
u
la
te
d
),
 o
r 
w
ith
o
u
t 
c
yt
o
k
in
e
s
 (
u
n
s
tim
u
la
te
d
),
 
b
e
fo
re
 in
fe
c
tio
n
 w
ith
 p
a
tie
n
t-
d
e
ri
ve
d
 
H
C
V
. 
H
C
V
 R
N
A
 w
a
s
 m
e
a
s
u
re
d
 2
4
 
h
o
u
rs
 a
ft
e
r 
in
fe
c
tio
n
. 
G
ra
p
h
 is
 
p
lo
tt
e
d
 o
n
 a
 l
o
g
a
ri
th
m
ic
 s
c
a
le
 a
n
d
 
s
h
o
w
s
 m
e
a
n
 ±
s
.e
.m
. 
a
n
d
 is
 
re
p
re
s
e
n
ta
tiv
e
 o
f 
2
 in
d
e
p
e
n
d
e
n
t 
e
xp
e
ri
m
e
n
ts
.
1
4
2
4
 
1
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1
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0
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0
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N
o
 t
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p
s
in
T
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p
s
in
T
im
e
 a
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e
r 
in
fe
c
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o
n
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h
o
u
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)
HCV RNA
(copies/
µ
g total RNA)
T
re
a
tm
e
n
t o
f 
p
re
-s
tim
u
la
te
d
 
T
H
P
-1
 c
e
ll
s
 w
ith
 t
ry
p
s
in
 a
t 
va
ri
o
u
s
 t
im
e
s
 a
ft
e
r 
in
c
u
b
a
tio
n
 
w
ith
 p
a
tie
n
t 
s
e
ra
 s
u
g
g
e
s
ts
 
p
a
tie
n
t-
d
e
ri
ve
d
 H
C
V
 is
 
in
te
rn
a
lis
e
d
 in
to
 T
H
P
-1
 c
e
ll
s
 
b
y 
4
 h
o
u
rs
 a
ft
e
r 
in
fe
c
tio
n
. 
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p
=
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.0
2
9
 f
o
r 
th
e
 c
o
m
p
a
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s
o
n
 
b
e
tw
e
e
n
 t
ry
p
s
in
-t
re
a
te
d
 c
e
lls
 
a
t 
1
 h
o
u
r 
a
n
d
 2
4
 h
o
u
rs
 a
ft
e
r 
in
fe
c
tio
n
 w
ith
 p
a
tie
n
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d
e
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d
 
H
C
V
.
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HCV RNA
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µ
g total RNA)
p
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.0
0
5
P
M
A
/I
F
N
-γ
tr
e
a
te
d
 T
H
P
-1
 c
e
ll
s
 w
e
re
 p
re
-
in
c
u
b
a
te
d
 w
ith
 b
lo
c
k
in
g
 a
n
tib
o
d
ie
s
 t
o
 
C
D
8
1
, 
S
R
-B
1
, 
C
D
3
2
 o
r 
C
D
6
4
 b
e
fo
re
 
in
fe
c
tio
n
 w
ith
 p
a
tie
n
t-
d
e
ri
ve
d
 H
C
V
 a
n
d
 
fu
s
io
n
 w
ith
 H
u
h
7
.5
 c
e
lls
. 
B
lo
c
k
in
g
 o
f 
C
D
6
4
, 
b
u
t 
n
o
t 
C
D
3
2
, C
D
8
1
 o
r 
S
R
-B
1
, 
re
d
u
c
e
d
 H
C
V
 R
N
A
 d
e
te
c
ta
b
le
 
im
m
e
d
ia
te
ly
 a
ft
e
r 
fu
s
io
n
.
P
M
A
/I
F
N
-γ
tr
e
a
te
d
 T
H
P
-1
 c
e
ll
s
 w
e
re
 
in
fe
c
te
d
 w
ith
 p
a
tie
n
t-
d
e
ri
ve
d
 H
C
V
, 
w
ith
 o
r 
w
ith
o
u
t 
C
D
6
4
 b
lo
c
k
in
g
 p
ri
o
r 
to
 in
fe
c
tio
n
, 
th
e
n
 f
u
s
e
d
 w
ith
 H
u
h
7
.5
 c
e
lls
. 
T
h
e
 f
u
s
e
d
 
c
e
ll
s
 w
e
re
 m
a
in
ta
in
e
d
 in
 c
u
lt
u
re
 f
o
r 
u
p
 t
o
 
7
 d
a
ys
 a
ft
e
r 
fu
s
io
n
. 
B
lo
c
k
in
g
 C
D
6
4
 
re
d
u
c
e
d
 H
C
V
 r
e
p
lic
a
tio
n
 a
ft
e
r 
fu
s
io
n
.
R
es
ul
ts
B
ac
kg
ro
un
d 
an
d 
ai
m
s
T
el
ap
re
vi
r e
nh
an
ce
s 
tre
at
m
en
t r
es
po
ns
e 
in
 g
en
ot
yp
e 
1 
(G
1)
 H
C
V
, b
ut
 c
ur
e 
ra
te
s 
re
m
ai
n 
lo
w
 a
m
on
gs
t p
at
ie
nt
s 
w
ith
 p
rio
r t
re
at
m
en
t n
ul
l r
es
po
ns
e.
G
en
ot
yp
e 
3 
(G
3)
 H
C
V
 is
 in
se
ns
iti
ve
 to
 te
la
pr
ev
ir,
 b
ut
 a
 s
ub
se
t o
f G
3 
pa
tie
nt
s 
(~
30
%
) m
ay
 re
sp
on
d1
.
W
e 
ha
ve
 d
ev
el
op
ed
 a
 n
ov
el
 c
ap
tu
re
-f
us
io
n 
as
sa
y 
to
 s
tu
dy
 p
at
ie
nt
-d
er
iv
ed
 H
C
V
.
H
er
e 
w
e 
de
m
on
st
ra
te
 th
at
 th
is
 a
ss
ay
 c
an
 id
en
tif
y 
pr
e-
tre
at
m
en
t t
el
ap
re
vi
r 
se
ns
iti
vi
ty
 in
 p
at
ie
nt
 s
 w
ith
 G
1 
an
d 
G
3 
H
C
V
.
M
et
ho
ds
P
re
-tr
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en
t a
nd
 p
os
t-b
re
ak
th
ro
ug
h 
sa
m
pl
es
 w
er
e 
ob
ta
in
ed
 fr
om
 th
re
e 
G
1 
pa
tie
nt
s 
(p
re
vi
ou
s 
‘n
ul
l r
es
po
nd
er
s’
) w
ho
 fa
ile
d 
re
tre
at
m
en
t w
ith
 te
la
pr
ev
ir,
 
pe
gI
FN
 a
nd
 ri
ba
vi
rin
.
P
re
-tr
ea
tm
en
t s
er
um
 s
am
pl
es
 w
er
e 
ob
ta
in
ed
 fr
om
 e
ig
ht
 G
3 
pa
tie
nt
s 
tre
at
ed
 w
ith
 
te
la
pr
ev
ir 
m
on
ot
he
ra
py
1 ,
 b
lin
de
d 
to
 v
iro
lo
gi
ca
l r
es
po
ns
e.
 
P
re
-s
tim
ul
at
ed
 T
H
P
-1
 c
el
ls
 w
er
e 
in
fe
ct
ed
 w
ith
 d
on
or
 s
er
um
 a
nd
 fu
se
d 
w
ith
 
H
uH
7.
5 
ce
lls
 u
si
ng
 p
ol
ye
th
yl
en
e 
gl
yc
ol
.
T
he
 fu
se
d 
ce
lls
 w
er
e 
tre
at
ed
 w
ith
 te
la
pr
ev
ir 
at
 a
 ra
ng
e 
of
 c
on
ce
nt
ra
tio
ns
 fo
r 5
 
da
ys
.
A
fte
r R
N
A
 e
xt
ra
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io
n,
 o
f H
C
V
 R
N
A
 w
as
 q
ua
nt
ifi
ed
 b
y 
re
al
-ti
m
e 
qP
C
R
.
T
H
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 c
el
l H
C
V
H
C
V
 c
ap
tu
re
 b
y 
T
H
P
-1
s
H
uH
7.
5 
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ll
P
E
G
 fu
si
on
 o
f i
nf
ec
te
d 
T
H
P
-1
 w
ith
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uH
7.
5 
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lls
G
ro
w
th
 o
f f
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ed
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Presence of viable HCV RNA in monocytes at the end of 
treatment predicts relapse in genotype 3 HCV infection
Morven E. Cunningham, Alia Javaid, Jenny Waters and Graham R. Foster
Centre for Digestive Diseases, Blizard Institute, Barts and The London School of Medicine and Dentistry
1. Background and aims
• Genotype 3 HCV is generally regarded as “easy to treat” based on 
clinical trial results showing response rates of up to 80%
• Response rates as low as 45% have been observed in real-world 
studies, particularly in patients with advanced fibrosis or cirrhosis
• Most patients who fail treatment for G3 HCV initially respond to 
antiviral therapy, but relapse after the end of treatment
• Data from our group indicates that relapse occurs rapidly after 
cessation of therapy, indicating viral persistence in a sanctuary site
• HCV RNA has been demonstrated in peripheral blood mononuclear 
cells (PBMCs) from patients with chronic HCV, but whether viral 
replication occurs in these cells remains controversial.
• We have recently developed a novel cell fusion technique to assay 
replication of patient-derived HCV 
• This study uses our fusion assay to test the hypothesis that viable 
HCV in monocytes at the end of treatment predicts relapse in patients 
with genotype 3 HCV.
3. Results
18 sequential patients at the end of 24 weeks of pegylated interferon and 
ribavirin therapy for genotype 3 HCV were recruited into the study. Baseline 
characteristics and outcome of treatment were as shown.
Patients who relapsed were slightly older (mean age 52.3 ± 8.0 versus 39.6 ±
8.7 years, P = 0.02) and had slightly higher fibrosis scores (mean 3.8 ± 1.9 
versus 1.8 ± 1.2, P = 0.04) than patients with SVR. Baseline viral load did not 
differ.
HCV RNA was quantified in unfused monocytes (Day 0), and in monocytes 5 
days after fusion with Huh-7.5 cells
2. Methods
• PBMCs were isolated from whole blood taken from patients at the end of treatment 
for chronic genotype 3 HCV (A).
• CD14 (+) monocytes were isolated from total PBMCs by magnetic cell separation 
(B-C).
• CD14 (+) monocytes were fused with the human hepatoma cell line Huh-7.5, using 
polyethylene glycol (PEG) (D).
• The fused cells were grown in culture for up to 5 days, in the presence or absence 
of antiviral agents
• After RNA extraction, HCV RNA was quantified by PCR.
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4. Conclusions
• These data demonstrate that the presence of replication-competent HCV in 
monocytes at the end of treatment may predict relapse in patients with G3 HCV.
• Monocytes may act as a sanctuary site for HCV virions during interferon-based 
treatment, facilitating relapse after withdrawal of therapy.
• It may be possible to tailor the duration of therapy for patients with genotype 3 
HCV infection, based on clearance of viable HCV from monocytes. 
• Alternatively, novel direct-acting antiviral agents could be used as add-on therapy 
for patients with persistent viable HCV RNA in monocytes after 24 weeks of 
pegylated interferon and ribavirin therapy
• The value of either approach in reducing rates of relapse needs to be investigated 
in clinical trials.
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Characteristic N = 18
Gender (M:F) 6:12
Age, years (mean ± SD) 43.8 ± 10.3
Viral load (median, range) 2.24 x105
(0.12 x105 – 1.45 x107) 
Fibrosis score (median, range) 3 (0 – 6)
Ethnicity: Caucasian
Bengali
Pakistani
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The amount of HCV RNA 
detectable in monocytes from most 
patients who relapsed increased 
after fusion, indicating viral 
replication in the fused cells. The 
opposite trend was seen in fused 
monocytes from patients with SVR.
Overall, the percentage change in 
HCV RNA detectable 5 days after 
cell fusion was significantly greater 
in relapsers than patients with SVR.
Day 0 Day 5
0
20
40
60
80
100
Days post-fusion
H
C
V
 R
N
A
(c
o
p
ie
s
/u
g
 t
o
ta
l 
R
N
A
)
w
w
w
.p
o
s
te
rs
e
s
s
io
n
.c
o
m
w w w . p o s t e r s e s s i o n . c o m
www.postersession.com
Early experience with telaprevir for patients with 
advanced fibrosis or cirrhosis
Morven E. Cunningham, Josephine Schulz, Louise Payaniandy, Yiannis Kallis, Patrick Kennedy, Paul Kooner, 
Richard Marley and Graham R. Foster
The Royal London Hospital, Barts Health NHS Trust
1. Background
• The direct-acting HCV protease inhibitor telaprevir has recently 
been licensed for treatment of chronic genotype 1 HCV 
infection, and promises significant improvements in sustained 
virological response (SVR) for these patients.
• The patients who may benefit most from novel HCV therapies, 
namely those with advanced fibrosis or cirrhosis who have 
previously failed to respond to pegylated interferon (pegIFN) and 
ribavirin treatment, are relatively poorly represented in the 
telaprevir clinical trials.
• Results recently presented by the French early access 
programme (CUPIC) suggest that telaprevir has excellent 
antiviral efficacy but a high incidence of adverse events in 
cirrhotic patients with previous relapse or partial response to 
pegylated interferon and ribavirin (non-responders were not 
included).
• Efficacy, safety and tolerability were assessed in patients with 
genotype 1 HCV and advanced fibrosis/cirrhosis who have 
received telaprevir-containing treatment at the Royal London 
Hospital, including those with previous null response to 
pegylated interferon/ribavirin therapy
4. Antiviral efficacy
Treatment efficacy is shown as the percentage of patients with undetectable 
HCV RNA who had reached the relevant timepoint.
2 patients (both prior null responders) had detectable HCV RNA at week 4. 
One patient stopped therapy, the other continued as HCV RNA was <1000 
(41IU/mL). This patient had negative HCV RNA at week 8, but was positive at 
week 12 and stopped therapy. One patient withdrew prior to week 4 and one 
patient has not yet reached week 4.
One further patient withdrew from all therapy between weeks 4 and 12. 2 
patients stopped telaprevir at week 10, but continued pegIFN and ribavirin and 
HCV RNA was undetectable at week 12.
2. Methods
Laboratory results and case notes were reviewed for all patients treated with pegylated 
interferon, ribavirin and telaprevir at Barts Health NHS Trust between September 2011 
and June 2012.
For further information please contact m.e.cunningham@qmul.ac.uk
This report/article presents independent research commissioned by the National 
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4. Conclusions
•Telaprevir in combination with pegIFN and ribavirin appears efficacious in patients 
with advanced fibrosis or cirrhosis, who have previously failed treatment with pegIFN
and ribavirin alone, including prior null responders.
•The incidence of significant side effects in this subgroup of patients is high and 
necessitates frequent follow-up with medical support.
•Side effects, particularly rash, may limit duration of telaprevir treatment. Whether this 
impacts on SVR remains to be seen.
3. Patient Demographics
Twelve patients with genotype 1 HCV commenced treatment with pegylated interferon 
α-2a, ribavirin and telaprevir between September 2011 and June 2012.
The majority of patients were male, with a relatively high viral load.
All patients had advanced fibrosis/cirrhosis either proven by biopsy (Ishak score 4-6), 
or with clinical, radiological and biochemical features suggestive of cirrhosis. 
Most patients were treatment-experienced.
Demographic N = 12
Gender (M:F) 8:4
Age, years (median, range) 58.5 (35 – 66)
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Treatment 
naïve (2)
Relapse (6)
Null 
responder 
(4)
Non-biopsy 
proven 
cirrhosis (3)
4/6 (2)
5/6 (2)
6/6 (5)
Genotype 
1 (1)
Genotype 
1b (5)
Genotype 
1a (6)
Treatment 
history
Fibr
osis
Genotype/subt
ype
Week 4 Week 12 Week 24
0
20
40
60
80
100
All patients
Relapsers
Null responders
%
 w
it
h
 u
n
d
e
te
c
ta
b
le
H
C
V
 R
N
A
8/10 6/6 2/4 7/8 5/5 2/3 4/4 2/2 2/2
n/number 
reaching 
timepoint
5. Safety and tolerability
2 patients (17%) experienced serious adverse events during telaprevir treatment
• One patient required admission for blood tranfusion
• One patient required admission for treatment of leukocytoclastic 
vasculitis as well as blood transfusion
The second patient died at week 21 of treatment, with decompensated cirrhosis 
and E. coli sepsis.
2 patients (17%) stopped telaprevir therapy at week 10 due to adverse events; one 
due to leukocytoclastic vasculitis and the other due to moderate rash. Both 
continued pegIFN and ribavirin.
2 patients (17%) stopped all therapy at weeks 2 and 4 due to poor tolerability.
Other adverse effects are summarised below.
Adverse effect Number affected (%)
Fatigue 12 (100)
Pruritis 4 (33)
Depression 4 (33)
Rash 3 (25)
Anal pain 3 (25)
Nausea 3 (25)
Gastrointestinal disturbance 3 (25)
Oral candidiasis 2 (17)
Anaemia (Hb<10 g/dL) 6 (50)
Transient hyperbilirubinaemia 3 (25)
